Molecular strategies to reduce unnecessary repeat prostate biopsies of men with elevated serum PSA by Pang, Karl H
 Molecular strategies to reduce unnecessary 
repeat prostate biopsies of men with elevated 
serum PSA  
 
By Karl H. Pang 
 
MRCS (The Royal College of Surgeons of England, UK) 
MBChB (The University of Glasgow, UK) 
MSc in Clinical Research (The University of Sheffield, UK) 
Intercalated BSc in Immunobiology (King’s College London, UK) 
 
 
A thesis submitted for the award of a Doctorate in Philosophy 
 
 
University of Sheffield 
The Department of Oncology and Metabolism and  
Academic Urology Unit 
 
January 2018 
 
	
	
2	
 
 
 
I hereby declare that no part of this thesis has previously 
been submitted for any degree or qualification at this, or 
any other University or institute of learning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
3	
Table of Contents 
 
TABLE	OF	CONTENTS	 3	
ABSTRACT	 9	
FOREWORD	 10	
ACKNOWLEDGMENTS	 11	
LIST	OF	ABBREVIATIONS	 12	
GRANT	FUNDING	FOR	SUPPORT	OF	THIS	WORK	 16	
LIST	OF	ACHIEVEMENTS	ARISING	FROM	THE	WORK	UNDERTAKEN	IN	THIS	THESIS	 17	
Peer-reviewed publications	 17	
Abstract publications	 17	
Other publications	 18	
Oral presentations	 18	
Poster presentations	 19	
Prizes	 19	
LIST	OF	TABLES	 20	
LIST	OF	FIGURES	 21	
CHAPTER	1:	INTRODUCTION	 23	
1.1 Cancer background	 24	
1.1.1 Pathogenesis of cancer	 24	
1.1.2 Hallmarks of cancer	 25	
1.1.2.1 Sustaining proliferative signalling	 27	
1.1.2.2 Evading growth suppressors	 27	
1.1.2.3 Activating invasion and metastasis	 27	
1.1.2.4 Enabling replicative immortality	 28	
1.1.2.5 Inducing angiogenesis	 28	
1.1.2.6 Resisting cell death	 28	
1.1.3	Emerging	hallmarks	and	characteristics	 29	
1.1.3.1 Reprogramming energy metabolism	 29	
1.1.3.2 Evading immune destruction	 29	
1.1.4	Sustaining	core	and	emerging	hallmarks	 29	
	
	
4	
1.2 The prostate gland	 30	
1.2.1	Anatomy	and	histology	of	the	prostate	 30	
1.2.1.1 Surface anatomy	 30	
1.2.1.2 Histology	 32	
1.2.1.3 Vascular, lymphatic and nerve supply	 32	
1.2.1.4 Structures surrounding the prostate	 33	
1.2.2 Functions of the prostate	 33	
1.3 Prostate cancer	 34	
1.3.1	Epidemiology	of	prostate	cancer	 34	
1.3.1.1 Worldwide	 34	
1.3.1.2 United Kingdom	 34	
1.3.3	Signs	and	symptoms	of	prostate	cancer	 39	
1.3.4	Histopathology	of	prostate	cancer	 41	
1.3.5	Prostate	cancer	classification	 41	
1.3.5.1 Prostate cancer grading	 41	
1.3.5.2 Prostate cancer staging	 43	
1.3.6 Prostate cancer screening	 45	
1.3.7	Diagnosis	of	prostate	cancer	 45	
1.3.7.1 Prostate-specific antigen	 45	
1.3.7.2 Prostate-specific antigen density and kinetics	 46	
1.3.7.3 Prostate Cancer Gene 3	 48	
1.3.7.3.1 A function of PCA3	 49	
1.3.7.3.2 Clinical barriers to use of the PCA3 assay	 50	
1.3.7.4 Other biomarkers	 51	
1.3.7.5 Prostate biopsy	 52	
1.3.7.5.1 Transrectal Ultrasound-guided biopsy	 53	
1.3.7.5.2 Transperineal biopsy	 54	
1.3.7.5.3 Prostate biopsy complications	 54	
1.3.7.6 Imaging	 55	
1.3.8	Management	of	prostate	cancer	 55	
1.3.8.1 Localised prostate cancer	 58	
1.3.8.1.1 Watchful waiting	 58	
1.3.8.1.2 Active surveillance	 58	
1.3.8.1.3 Radical prostatectomy	 59	
1.3.8.1.4 Radiotherapy	 59	
1.3.8.1.5 Options other than surgery or radiotherapy	 60	
1.3.8.2 Locally advanced and metastatic prostate cancer	 61	
1.3.8.2.1 Androgen deprivation therapy	 61	
1.3.8.2.2 Castration-resistant prostate cancer	 62	
1.3.8.2.3 Metastatic prostate cancer	 62	
1.4 Prostate cancer and androgen regulation	 62	
1.4.1	Paracrine/autocrine	synthesis	 64	
1.4.2 Androgen receptor mutation	 65	
1.5 Genetic mechanisms of prostate cancer	 66	
1.5.1 Cancer pathways	 68	
1.5.1.1 Phosphoinositide 3-kinase pathway	 68	
1.5.1.2 Ras/Raf/mitogen-activated protein kinase pathway	 68	
1.5.1.3 Tumour Protein 53	 69	
1.5.1.4 Retinoblastoma protein	 69	
1.5.1.5 v-myc myelocytomatosis viral oncogene homolog	 69	
1.5.2	Prostate	cancer	specific	pathways	 69	
1.5.2.1 Androgen-signalling	 69	
1.5.2.2 E26 transformation-specific (ETS) gene fusions	 70	
1.5.2.3 Speckle-type POZ protein (SPOP) mutations	 71	
	
	
5	
1.5.2.4 Somatic Copy Number Aberrations and gene expression	 71	
1.5.2.5 Cytokine signalling	 71	
1.6 Epigenetics of prostate cancer	 72	
1.6.1 DNA methylation	 72	
1.6.2	Histone	and	chromatin	modifications	 73	
1.6.3 Non-coding and MicroRNAs	 74	
1.6.4	MicroRNA	and	prostate	cancer	 76	
1.6.4.1 MicroRNA and cellular pathways	 78	
1.6.4.2 MicroRNA and androgen-signalling	 78	
1.6.4.3 MicroRNA as biomarkers	 79	
1.6.4.4 RNA methylation	 81	
1.7 Aims	 84	
1.8 Significance	 86	
CHAPTER	2:	MATERIALS	AND	METHODS	 87	
2.1 ProtecT and ProMPT studies	 88	
2.1.1	Patient	recruitment,	consent	and	ethical	approval	 88	
2.2. General laboratory equipment and reagents	 91	
2.2.1 Laboratory equipment	 91	
2.2.2	Plastic	and	disposable	equipment	 92	
2.2.3	General	laboratory	chemicals	and	reagents	 92	
2.3 General materials and methods	 93	
2.3.1	Cell	Lines	and	cell	cultures	 93	
2.3.2 Urinary sample preparation	 94	
2.3.3 Prostate tissue collection	 94	
2.3.3.1 Prostate tissue fixation and embedding	 94	
2.3.3.2 FFPE sectioning	 95	
2.4 Specific materials and methods	 95	
2.4.1 RNA Extraction	 95	
2.4.1.1 Cell lines and urinary pellets	 96	
2.4.1.2 Prostate biopsy FFPE	 99	
2.4.2 Reverse transcription	 100	
2.4.3 Real-time PCR	 102	
2.5 Immunoprecipitation and sequencing of m6A	 103	
2.5.1 Immunoprecipitation of m6A	 104	
2.5.1.1 mRNA purification and RNA fragmentation	 104	
2.5.1.2 Immunoprecipitation	 105	
2.5.1.3 Elution	 106	
2.5.1.4 RNA purification	 106	
2.5.1.5 Immunoprecipitation quality control	 107	
2.5.2	Library	preparation	and	sequencing	 107	
2.6 Statistical Analysis	 110	
CHAPTER	3:	A	RETROSPECTIVE	ANALYSIS	OF	REPEAT	PROSTATE	BIOPSY	OUTCOMES
	 111	
	
	
6	
4.1 Background	 112	
4.2 Methods	 113	
4.2.1	Design	and	patient	population	 113	
4.2.2 Data collection and analysis	 113	
4.2.3 Statistical analysis	 113	
4.3 Results	 114	
4.3.1	Patient	population	within	the	Sheffield	cohort	 114	
4.3.2	Outcomes	of	repeat	prostate	biopsy	 114	
4.3.3	Prostate	cancer	identified	by	prostate	biopsy	 118	
4.3.4	The	risks	of	being	diagnosed	with	cancer	on	repeat	biopsy	 118	
4.3.5	Comparison	between	men	with	and	without	cancer	 123	
4.3.6	Uni-	and	Multivariable	analysis	of	predictors	 123	
4.3.7	Review	of	the	international	data	 123	
4.4.1	Diagnostic	rate	of	prostate	cancer	on	repeat	biopsies	 128	
4.4.2 Grades of prostate cancer	 129	
4.4.3	Predictors	of	prostate	cancer	 130	
4.4.4 Limitations	 131	
4.4.5 Generalisability	 131	
4.5 Conclusions	 131	
CHAPTER	4:	THE	IDENTIFICATION	AND	ROLE	OF	 132	
PCA3-SHRNA2	IN	PROSTATE	CANCER	 132	
3.1 Background	 133	
3.2 Methods	 133	
3.2.1	Identification	of	hairpin	RNA	structures	 133	
3.2.2	Cell	lines	and	androgen	regulation	of	RNA	 134	
3.2.3	Expression	of	PCA3-shRNA	in	urinary	samples	 134	
3.2.4	RNA	extraction	and	quantification	(cell	lines	and	urine)	 135	
3.2.5	Cloning	primary	transcripts	using	3’RACE	 135	
3.2.6	mRNA	target	analysis	and	knock-up	 136	
3.3 Results	 136	
3.3.1 Identification of PCA3-shRNA	 136	
3.3.2	Determination	of	the	genomic	origin	of	PCA3-shRNA	 137	
3.3.3 Expression of PCA3-shRNA	 143	
3.3.3.1 Cell lines	 143	
3.3.3.2 Urinary samples	 145	
3.3.4	The	ability	of	PCA3-shRNA2	to	identify	disease	(urine)	 152	
3.3.5	Androgen	regulation	of	PCA3-shRNA2	 154	
3.3.6	Functional	role	of	PCA3-shRNA2	 155	
3.3.6.1 Localization of PCA3-shRNA2	 155	
3.3.6.2 Identifying potential mRNA targets	 155	
3.3.6.3 The selection and expression of mRNA targets in cell lines	 161	
3.3.6.4 Expression of target mRNAs in urinary samples	 165	
3.4 Discussion	 168	
3.4.1	Identification	of	PCA3-shRNA2	and	expression	in	urinary	samples	 168	
3.4.2	The	biological	role	of	PCA3-shRNA2	 169	
	
	
7	
3.5 Conclusions	 170	
CHAPTER	5:	PCA3-SHRNA2	EXPRESSION	AND	EVENTUAL	DIAGNOSIS	OF	PROSTATE	
CANCER	 171	
5.1 Background	 172	
5.2 Methods	 172	
5.2.1	Expression	of	PCA3-shRNA2	in	FFPE	samples	 172	
5.2.2	RNA	extraction	from	prostate	biopsies	(FFPE)	 173	
5.3 Results	 174	
5.3.1 Patients and FFPE samples	 174	
5.3.2	Expression	of	PCA3-shRNA2	in	prostate	biopsies	(FFPE)	 176	
5.3.3	PCA3-shRNA2	expression	and	eventual	diagnosis	 179	
5.3.4	The	ability	of	PCA3-shRNA2	to	identify	disease	(PBx	FFPE)	 183	
5.4 Discussion	 184	
5.5 Conclusion	 186	
CHAPTER	6:	N6-ADENOSINE	METHYLATION	AND	CANCER	 187	
6.1 Background	 188	
6.2 Methods	 189	
5.2.1 In-silico analysis of m6A	 189	
5.2.1.1 Selection and annotation of RNA transcriptomic datasets	 189	
6.2.1.2 RNA Selection	 189	
6.2.1.3 Statistical analysis	 190	
6.2.2	Immunoprecipitation	and	sequencing	of	m6A	 190	
6.3 Results	 191	
6.3.1	Microarray	datasets	and	sample	population	 191	
6.3.2	The	proportion	of	N6-adenosine	methylated	RNAs	 203	
6.3.3	Fold	changes	of	m6A	susceptible	RNAs	 203	
6.3.4	Fold	changes	of	the	most	differentially	expressed	RNAs	 215	
6.3.5	Functional	annotation	of	m6A	susceptible	RNAs	 220	
6.3.5.1 Individual cancers	 220	
6.3.5.2 Between cancers	 230	
6.3.6 Immunoprecipitation of m6A	 234	
6.3.6.1 Validation of post-fragmentation RNA size	 234	
6.3.6.2 Immunoprecipitation quality control	 235	
6.3.7	RNA-sequencing	of	m6A-IP	libraries	 237	
6.3.7.1 MeRIP-seq read quality control	 237	
6.3.7.2 MeRIP-seq read mapping	 239	
6.3.7.3 Identification of m6A sites	 239	
6.3.8	Expression	of	m6A	transcripts	in	prostate	cancer	cell	lines	 241	
6.4 Discussion	 246	
6.4.1	In-silico	analysis	of	N6-methyladenosine	 246	
6.4.2	N6-methyladenosine	profiling	in	prostate	cancer	cell	lines	 248	
6.4.3 N6-methyladenosine machinery	 250	
6.5 Conclusion	 251	
	
	
8	
CHAPTER	7:	DISCUSSION	 252	
7.1 Repeat prostate biopsy outcomes	 253	
7.2 PCA3-shRNA2 and prostate cancer	 254	
7.3 N6-adenosine methylation and prostate cancer	 255	
7.4 Conclusions	 257	
REFERENCES	 258	
APPENDICES	 288	
ProtecT consent form	 288	
ProMPT consent form	 289	
COPIES	OF	PUBLICATIONS	ARISING	FROM	THESIS	 290	
 
 
 
	
 
 
	
	
	
	
	
	
	
	
	
 
	
 
 
 
	
	
9	
Abstract 
 
Prostate cancer (PCa) is the most common cancer in men. It is a 
heterogeneous disease and currently there are no reliable biomarkers 
available to stratify men for prostate biopsy (PBx) and treatment. Hence, 
there is a risk of over-diagnosing insignificant disease, or under-diagnosing 
significant disease. We aimed to evaluate Prostate Cancer gene 3 (PCA3, 
FDA approved) and N6-methyladenosine (m6A) for diagnostic properties. 
 
PCA3 is a long non-coding RNA (ncRNA) that is unstable, has an unclear 
biological role and is expensive to chemically treat to prevent degradation 
prior to analysis. Long ncRNAs are degraded into shorter forms, we explored 
whether this was the fate for PCA3. We identified a short segment of RNA 
within intron 1 of PCA3 bioinformatically which we termed PCA3 short RNA2 
(PCA3-shRNA2). The expression of this short RNA correlated to that of 
PCA3 in PCa cell lines, urinary samples and PBx tissue. PCA3-shRNA2 was 
overexpressed in urinary samples obtained from men with PCa compared to 
BPH, was regulated by testosterone and had a diagnostic accuracy similar to 
that of PCA3. We identified oncogenic mRNA targets of PCA3-shRNA2 and 
found that COPS2 was underexpressed in cancerous urinary samples.  
 
There are over a hundred RNA modifications described and methylation of 
N6-adenosine base is the most common methylated site. m6A is reversible 
and may be involved in oncogenesis. We profiled m6A in PCa cell lines by 
immunoprecipitation and RNA sequencing and found oncogenic RNAs (e.g. 
PARG) that were differentially expressed in LNCaP-LN3 cells. 
 
We identified a novel RNA within PCA3 that is easy to measure, 
overexpressed in PCa samples and appeared to target oncogenic mRNAs. 
We profiled m6A in PCa cell lines and have identified N6-adenosine 
methylated RNAs associated with PCa development. In conclusion PCA3-
shRNA2 and m6A have evolving roles in cancer and may function well as 
biomarkers. 
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1.1 Cancer background 
The National Cancer Institute defines cancer as an abnormal growth of cells 
which tend to proliferate in an uncontrolled way and in some cases, 
metastasize and invade other tissues. Cancer can arise from different organ 
structures and develops as a result of abnormal genetic and/or epigenetic 
events.  
 
The International Agency for Research on Cancer (WHO, GLOBOCAN 
Project) estimates around 14.1 million new cancer cases, 8.2 million cancer 
deaths and 32.6 million people living with cancer in 2012 worldwide 
(GLOBOCAN, 2012).  
 
Cancer was first described in Egypt in 1600 BC. Edwin Smith Papyrus was 
the ancient Egyptian textbook on trauma surgery which described eight 
cases of breast tumours/ulcers that were removed by cauterization with a 
‘fire drill’.  
 
The ‘Father of Medicine’, Greek physician Hippocrates (460-370 BC) used 
the term carcinos and carcinoma to describe tumours. The Greek word 
translates to ‘crab’ since tumours possess finger-like spreading projections 
and have the crab-like tenacity to grasp and invade tissues. In 28-50 BC, the 
Roman physician, Celsus translated the Greek term into cancer, the Latin 
word for crab. Galen (130-200 AD), another Greek physician, used oncos to 
describe malignant tumours, which is now used to form the name of the 
cancer specialty, ‘oncology’ (Hajdu, 2011).  
 
1.1.1 Pathogenesis of cancer 
Cancer arises from alterations of complex biological mechanisms. It is a 
disease of disruption in cell/tissue growth regulation. Under normal 
circumstances, cell growth is regulated by oncogenes (cell growth promoters) 
and tumour suppressor genes (cell growth inhibitors). Genetic changes as a 
result of inherited genes (5-20% germ-line mutations), or environmental 
factors (90-95% somatic events) such as smoking, radiation and 
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environmental pollutants, lead to an imbalance of oncogenes and tumour 
suppressor genes causing cancer development (oncogenesis or 
tumorigenesis). Disruption can occur at any stage from within the nucleus 
such as, DNA modifications and DNA transcription to RNA, to within the 
cytoplasm such as RNA modifications, microRNA (miRNA) regulations 
(epigenetic events), RNA translation to proteins, and post-translational 
protein modifications (Croce, 2008).  
 
The Catalogue of Somatic Mutations in Cancer (COSMIC) 
(http://cancer.sanger.ac.uk) is the world’s largest and most comprehensive 
database for somatic mutations in human cancer. In 2004, four genes were 
described when COSMIC was launched (Bamford et al., 2004), and now a 
around two million coding point mutations in over one million tumour samples 
across most human genes are described (Forbes et al., 2015). 
 
Hanahan and Weinberg proposed that six hallmarks of cancer form a 
structured principle that allows a model for understanding the complexities of 
oncogenesis. In 2000, the authors identified the six hallmarks as sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis. Underlying these mechanisms are genome 
instability, which induces genetic diversity (Hanahan et al., 2000). Progress 
in the last couple of decades has added two emerging hallmarks- 
reprogramming of energy metabolism and evading immune destruction 
(Hanahan et al., 2011).  
 
1.1.2 Hallmarks of cancer 
The development of cancer and its ability to survive and spread is dependent 
on various important biological processes that become dysregulated. The six 
hallmarks of cancer described by Hanahan and Weinberg are shown in 
Figure 1). This section gives an overview of the features of oncogenesis. 
specific mechanisms related to prostate oncogenesis are discussed in more 
details later on.  
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Figure 1. The hallmarks of cancer. 
It has been described that cancer cells are able to alter homeostatic biological 
mechanisms and possess the six characteristics illustrated in this figure in order to 
survive, proliferate and invade (Hanahan et al., 2011)   
 
 
 
 
 
 
	
 
 
	
	
27	
1.1.2.1 Sustaining proliferative signalling 
One of the most important feature of oncogenesis, is growth. Cancer cells 
have the ability to sustain chronic cell growth and division (proliferation) 
through dysregulating growth promoting signals that instruct entry into and 
progression through the cell division cycle within normal tissues. Key growth 
signalling pathways that are interrupted by cancer includes MAP-kinase 
(Mitogen-activated protein kinase), mTOR-kinase (Mammalian target of 
rapamycin) and PI3K (Phosphoinositide 3-kinase). Cancer cells can either 
produce signalling factors themselves, or stimulate normal cells to release 
proliferative signals (Bhowmick et al., 2004).  
 
1.1.2.2 Evading growth suppressors 
In well-controlled cell cycles, growth suppressors act to inhibit overgrowth. In 
order to maintain continuous growth, cancer cells possess mechanisms to 
bypass suppression via inhibition of two main pathways, RB (Retinoblastoma) 
and TP53 (Tumour protein p53) pathways. The RB protein integrates signals 
from extracellular sources, whilst TP53 receives inputs from abnormal 
intracellular stress. Both regulatory circuits are gatekeepers of cell cycle 
progression (Sherr et al., 2002).  
 
1.1.2.3 Activating invasion and metastasis 
Cancer cells grow locally and have capabilities to invade local structures and 
spread to distant sites through metastasis. This process is termed the 
invasion-metastasis cascade. Cancer cells intravasate into nearby blood and 
lymphatic vessels, transit through the haematogenous and lymphatic 
systems and extravasate into distant tissues forming micrometastases. E-
cadherin is a cell-to-cell adhesion molecule which assembles cell sheets and 
maintain cell quiescence. The invasion-metastasis cascade is associated 
with a decrease expression of E-cadherin, and the uncontrolled epithelial-
mesenchymal transition (EMT) regulatory program. The EMT program can 
be activated transiently and enable cancer cells to invade, resist apoptosis 
and disseminate (Thiery et al., 2009).  
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1.1.2.4 Enabling replicative immortality 
To form macroscopic tumours, cancer cells require unlimited replication. 
Within normal cells, excessive proliferation is limited by two barriers, 
senescence, which is the irreversible entrance into a non-proliferative, viable 
state; and crisis, which involves cell death. Cancer cells bypass senescence 
and crisis, and transit into immortalization exhibiting unlimited replicative 
potential. Telomeres are partly responsible for unlimited proliferation and are 
structures attached to the end of chromosomes protecting chromosomal 
DNAs from end-to-end fusions (Blasco, 2005). Cancer cells maintain 
telomeric DNA lengths to avoid initiating senescence or apoptosis, achieved 
most commonly by increasing the expression of telomerase. 
 
1.1.2.5 Inducing angiogenesis 
Like normal tissue and cells, tumours require nutrients and oxygen, and 
removal of metabolic waste and carbon dioxide. Following vasculogenesis 
and angiogenesis during embryogenesis, the normal vasculature becomes 
quiescent. Angiogenesis only occurs following stress such as, wound healing 
or female menstruation. In tumour growth, there is a persistent ‘angiogenic 
switch’ causing quiescent vasculature to expand (Baeriswyl et al., 2009). The 
defect partly lies upon the angiogenesis inducer, VEGF (Vascular endothelial 
growth factor) and inhibitor, TSP-1 (Thrombospondin-1).  
 
1.1.2.6 Resisting cell death 
Programmed cell death by apoptosis is an important activity involved in 
preventing cancer development. Apoptosis can be triggered by various 
physiological stresses and is regulated in part by pro- (Bax and Bak) and 
anti-apoptotic (Bcl-2) proteins. The apoptotic signals trigger a cascade of 
proteolysis mediated by caspases. Disassembled cells are then consumed 
by phagocytic cells (Adams et al., 2007). Autophagy is an intracellular 
degradation activity that is caspase-independent and is mediated through 
lysosomes (Levine et al., 2008). Cancer cells have the ability to avoid 
apoptotic and autophagic mechanisms and continue to proliferate in an 
uncontrolled manner.  
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1.1.3 Emerging hallmarks and characteristics 
There are two additional hallmarks of cancer that have been described, 
including deregulating cellular metabolism and evading the immune system 
(Hanahan et al., 2011).  
 
1.1.3.1 Reprogramming energy metabolism 
In order to sustain the six core hallmarks described above, cancer cells 
require sufficient energy. Normal cells produce energy through aerobic 
metabolism (using oxygen) and glycolysis (metabolizing glucose). Cancer 
cells have the ability to reprogram energy metabolism and exhibit a 
metabolic switch to provide continuous glycolytic fuelling. There is a state of 
upregulation of glucose transporters and multiple enzymes of the glycolytic 
pathway (DeBerardinis et al., 2008; Hsu et al., 2008). 
 
1.1.3.2 Evading immune destruction 
The immune system serves as a protective mechanism in recognizing and 
eliminating infected, and possibly cancerous cells. In mice studies, tumours 
developed more abundantly in immunodeficient mice compared to 
immunocompetent controls, suggesting that the immune system has a role in 
oncogenesis (Kim et al., 2007). Proposed mechanisms include the ability of 
cancer cells to paralyze infiltrating cytotoxic T-lymphocytes and natural killer 
cells (Yang et al., 2010), or recruiting immunosuppressive cells such as, T-
regulatory cells (Mougiakakos et al. 2010). 
 
1.1.4 Sustaining core and emerging hallmarks  
Two evolving characteristics of cancer facilitate the process of both core and 
emerging hallmarks: genomic instability and mutation, and tumour-promoting 
inflammation.  
 
1) Genomic instability and mutation 
Alterations in the genomes of cancer cells results in heritable phenotypes 
such as, inactivation of tumour suppressors and evading apoptosis. The 
mutation of genes is achieved through increased sensitivity to mutagenic 
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factors or through defects in the genomic maintenance machinery. The 
proteins that are involved in detecting DNA damage, repairing DNA, and 
inactivating mutagenic molecules are defective (Negrini et al., 2010). The 
result is abnormal and uncontrolled gene expression of factors that promote 
oncogenesis and factors that inhibit tumour suppression through the six core 
and two merging cancer hallmarks. 
 
2) Tumour-promoting inflammation 
It is thought that evading the immune system is an emerging hallmark, and 
this theory is consolidated by the fact that tumours are infiltrated by both 
innate and adaptive cells on histopathological examination of tumour 
specimens. As cancer cells interact with immune cells evading clearance, 
they enhance the release of inflammatory mediators which gives rise to the 
unanticipated effect of enhancing tumour progression. This is achieved by 
the release of inflammatory mediators that facilitate growth, angiogenesis, 
and invasion and metastasis (Grivennikov et al., 2010). 
 
1.2 The prostate gland 
 
1.2.1 Anatomy and histology of the prostate  
1.2.1.1 Surface anatomy 
The prostate gland is a pyramid-shaped structure with its apex directing 
downwards and its base directing upwards towards the bladder. The gland 
lies below the urinary bladder and it situated in front of the rectum. The 
prostate weighs ~20g and is ~3cm long, 4cm wide and 2cm thick (Figure 2) 
in young men. The prostate gland is anatomically split into zones, the 
transition zone (5-10% of prostate volume) surrounds the urethra, the 
peripheral zone (70% of prostate volume) includes the peripheral sections of 
the gland, and the central zone (25% of prostate volume) is located between 
the transition and peripheral zones. The ejaculatory ducts run through the 
central zone (Wein et al., 2015).  
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The prostatic urethra runs through the prostate and divides the gland into left 
and right lateral lobes. The posterior aspects of the lateral lobes and the 
median sulcus are palpable by digital rectal examination (DRE). The paired 
ejaculatory duct enters the prostate and opens into the middle of the 
prostatic urethra at the seminal colliculus (verumontanum).  
 
The prostate is encapsulated by a dense capsule and is fixed to the pubic 
bone by two puboprostatic ligaments. The endopelvic fascia covers the 
prostate ventrally and extends to both sides and covers the levator ani 
muscle. The Denovilliers’ fascia separates the prostate dorsally from the 
rectum (Wein et al., 2015). 
 
 
	
Figure 2. Anatomy of the prostate. 
The prostate gland is situated below the bladder and produces substances which 
contribute to semen. The prostatic urethra and ejaculatory duct (from seminal 
vesicles) run through the prostatic transition zone and transports urine and ejaculate 
(Based on graphics created by Cancer Research UK, 
http://www.cancerresearchuk.org/about-cancer/prostate-cancer/about).  
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1.2.1.2 Histology 
The prostate is formed of tubuloalveolar glands, and have pseudostratified 
columnar epithelium. The columnar cells contain secretory granules. Basal 
cells are located between the columnar cells and are the fundamental cells 
for epithelial regeneration. Each gland is embedded in fibromuscular stroma 
(70% of the prostate mass) containing connective tissue and smooth muscle. 
During ejaculation, the smooth muscles contract and expulse glandular 
content (McNeal, 1981).  
 
1.2.1.3 Vascular, lymphatic and nerve supply 
The blood supply originates from the internal iliac vessels. The inferior 
vesical artery divides into urethral and capsular branches, and the urethral 
branches enter the basal prostate and bladder neck at 4 and 8 o’clock 
positions, supplying the transition zone. The capsular branches join the 
cavernous nerves laterally and run to the pelvic floor giving rise to smaller 
arteries that perforate the capsule. Additional arterial supply comes from the 
middle rectal artery, internal pudendal artery and obturator artery. 
 
The venous vessels drain via the vesicoprostatic plexus (deep venous 
complex) to the internal iliac veins. The vesicoprostatic plexus lies under the 
puboprostatic ligaments and pubic bone, where the blood from the deep 
penile vein joins the plexus. 
 
The lymphatic drainage of the prostate drains to the obturator and internal 
iliac nodes. In addition, there is lymphatic communication with the external 
iliac, presacral and para-aortic lymph nodes. 
 
The autonomic innervation reaches the prostate via the lateral cavernous 
nerves. Parasympathetic (S2-4) signals stimulate the glandular activity and 
the sympathetic (L1-2) nerves controls smooth muscle contraction through 
alpha-receptors (Wein et al., 2015). 
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1.2.1.4 Structures surrounding the prostate 
The paired seminal vesicles are located behind the bladder and its ducts 
open into the ductus deferens and form the ejaculatory duct.  The seminal 
vesicles consist of duct-like glandular tissue, about 15cm long with a muscle-
containing wall. The seminal vesicle produces an alkaline (pH 7.4) secretion 
of gelatinous consistency which contains fructose and forms half of the 
semen volume. Sperm and testosterone is produced in the testicles and 
matured sperms are stored in the epididymis. The vas deferens is a tube that 
transports semen and sperm from the epididymis to the ejaculatory duct 
during ejaculation (Figure 2).  
 
1.2.2 Functions of the prostate 
The epithelial cells of the prostate secrete a glycoprotein enzyme called 
prostate-specific antigen (PSA). It is a member of the kallikrein-related 
peptidase family, hence it is also termed kallikrein-3 (KLK3). PSA is 
produced to liquefy semen in the ejaculate to allow transportation of sperm 
facilitating fertilization (Balk et al., 2003). The prostate secretes fluid that 
forms ~20% of the semen volume. The prostatic fluid is thin, acidic (pH 6.4) 
and contains spermine, spermidine, prostaglandins, zinc, citric acid, 
immunoglobulins, phosphatases and proteases. Constituents help to liquefy 
semen and provide nutrition and optimal conditions for sperms to travel and 
fertilize the ovum (Wein et al., 2015). 
 
The prostate functions as a valve preventing urine flow during ejaculation. 
Micturition is controlled by parasympathetic activity, leading to bladder neck 
relaxation. Ejaculation is controlled by the sympathetic nerves, and is the 
result of contraction of the smooth muscle stroma.   
 
To function adequately, the prostate needs androgens. Testosterone is 
produced mainly by the testicles, its metabolite, dihydrotestosterone (DHT) 
predominantly regulates the prostate.   
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1.3 Prostate cancer  
Prostate cancer is the most common cancer in men and occurs in the 
peripheral zone of the prostate gland.  This chapter describes the 
epidemiology, clinical presentation, investigation and management of PCa. 
 
1.3.1 Epidemiology of prostate cancer 
1.3.1.1 Worldwide 
Approximately 1.1 million men were diagnosed with the disease worldwide in 
2012, which accounts for around 15% of cancer diagnoses in men. Around 
70% of these cases occur in more developed regions (GLOBOCAN, 2012). 
The incidence of PCa varies worldwide, by around 25% (Figure 3). The 
highest rates are seen in Australia, New Zealand, Northern America and in 
Western/Northern Europe due to the increasing practice of PCa testing and 
subsequent diagnosis on prostate biopsy (PBx) in these developed regions. 
Incidence rates are relatively high in some less developed areas including 
the Caribbean, Southern Africa and South America. The lowest rates are 
seen in Eastern/South-central Asia (Arnold et al., 2013). Prostate cancer is 
the fifth leading cause of cancer-death in men with an estimated 307,000 
deaths worldwide in 2012. This accounts for approximately 6.6% of total 
male deaths. Due to the fact that PSA testing has a greater effect on 
incidence than on mortality, there is less variation in mortality rates 
worldwide compared to incidence. The number of deaths from PCa is larger 
in less developed regions (Figure 3). Mortality rates are generally high in 
predominantly black populations, very low in Asia and intermediate in the 
Americas and Oceania (GLOBOCAN, 2012). There is an expected rise in the 
disease’s economic burden associated with the increases in life expectancy 
and incidence of PCa. It is estimated that the costs of PCa in Europe exceed 
€8.43 billion, and this amounted to €106.7-179 million for all PCa patients 
diagnosed in 2006 (Luengo-Fernandez et al., 2013). 
 
1.3.1.2 United Kingdom 
According to Cancer Research UK, there were around 46,690 new 
diagnoses of PCa in 2014, which accounts for ~13% of all new cancers in 
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the UK. Over the past decade, PCa incidence rates have increased by 
around 5% and is expected to rise by 12% between 2014 and 2035 (Figure 
4a). This is largely related to increasing PSA testing. Prostate cancer is the 
most common cancer in UK men and is the second most common cause of 
cancer death in UK men after lung cancer. In 2014, around 11,300 men died 
from PCa (CRUK, 2016). Over the last decade, the number of deaths have 
decreased by around 13% and is expected to decrease by 16% between 
2014 and 2035 (Figure 4b). 
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Figure 3. Estimated age-standardised rates (world) per 100,000. 
The incidence and mortality rates vary within different parts of the world secondary 
to PSA testing, genetics, individual risks factors and ethnicity. The incidence of PCa 
in the UK is within the top 25% globally (Adapted from GLOBOCAN 2012, 
http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp). 
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a) 
 
b) 
 
 
Figure 4. Age-standardised incidence and mortality rate (per 100,000 UK 
men) of prostate cancer.  
a) The anticipated further rise in incidence is largely related to increase awareness 
of PCa and PSA testing; b) The anticipated further decrease in mortality rate is 
largely related to increasing PSA testing, early diagnosis and subsequent treatment 
of PCa (Adapted from the UK national cancer intelligence network, 2013, 
http://www.ncin.org.uk/publications/). 
 
	
	
38	
1.3.2 Risk factors and aetiology of prostate cancer 
The aetiology of PCa is unclear, but the three well-defined risk factors are 
increasing age, ethnic origin (Kheirandish et al., 2011) and heredity 
(Hemminki, 2012). There is evidence for a genetic component to PCa based 
on two factors, namely family history and ethnic background (Hemminki, 
2012; Jansson et al., 2012). In addition, genome-wide association studies 
(GWAS), including a meta-analysis of around 87,000 individuals have 
identified 100 common susceptibility loci contributing to PCa (Al Olama et al., 
2014).  
 
The risk is doubled if one first-degree relative has PCa. Approximately 9% 
have true hereditary PCa, defined as three or more affected relatives, or at 
least two relatives who have been diagnosed with early-onset (before age 55) 
PCa (Hemminki, 2012). Patients with hereditary PCa do not differ in other 
ways compared with spontaneous disease, apart from that they have an 
onset of disease, six-seven years earlier.  
 
Other factors found to be associated with PCa include diet, alcohol 
consumption, chronic inflammation and occupational exposure (Nelson et al., 
2003; Leitzmann et al., 2012). However, there is currently insufficient 
evidence to recommend lifestyle changes in order to decrease the risk of 
developing PCa (Richman et al., 2011). Research into selenium, Vitamin E 
(SELECT trial) (Lippman et al., 2009), and lycopene (meta-analysis of eight 
randomised-controlled trials, RCT) (Ilic et al., 2012) all did not show any 
negative correlations with PCa risk.  
 
Metabolic syndrome is weakly associated with PCa risk and among single 
variables of the syndrome (meta-analysis) including body mass index, 
dyslipidaemia/glycaemia, high triglycerides, low high-density lipoprotein-
cholesterol, only hypertension and waist circumference (>102cm) were 
associated with a greater risk of PCa by 15% and 56% respectively (Esposito 
et al., 2013).  
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The role of medications in PCa has also been investigated. In three parallel 
prospective studies, the use of testosterone in 1,023 hypogonadal men did 
not show an increased risk of PCa (Haider et al., 2015). The use of Aspirin 
(meta-analysis) and non-steroidal anti-inflammatory medications reveal 
conflicting data (Bhindi et al., 2014; Huang et al., 2014). 5-alpha reductase 
inhibitors (5-ARI) such as Finasteride and Dutasteride have been studied in 
the Reduction by Dutasteride of Prostate Cancer (REDUCE) RCT and 
although it appears that this class of medications have a potential benefit in 
preventing or delaying PCa development, this must be weighed against side 
effects and the potential risk of low-grade disease progressing to high-grade 
PCa. However, none of the 5-ARIs have been approved for this indication 
(Thompson et al., 2003; Andriole et al., 2010). The investigation into statins 
also did not reveal any preventive effect on PCa risk (Esposito et al., 2013; 
Freedland et al., 2013). 
 
1.3.3 Signs and symptoms of prostate cancer 
Most PCas are situated in the peripheral zone of the prostate gland and may 
be palpable on DRE when the volume is >0.2ml. Prostate cancer is detected 
in ~18% by DRE alone irrespective of PSA level. Abnormal DRE findings 
warrant a PSA test and PBx. Early PCa usually give rise to no symptoms. 
Approximately 30% of men present with no symptoms (Miller et al., 2003). 
Symptoms appear when cancer invades the urethra, or obstruct the urinary 
flow (Figure 5). Symptoms of haematuria or lower urinary tract symptoms 
(LUTS), including difficulty initiating, hesitancy, poor stream and terminal 
dribbling may occur (Kupelian et al., 2006). In severe obstruction, the risk of 
urinary retention with or without kidney injury can occur. In advanced or 
metastatic disease, patients may complain of back pain (bony metastasis), 
fatigue or lethargy. When the cancer affects the spinal nerves causing cauda 
equina syndrome (CES), urgent assessment and management in the form of 
steroids, MRI (Magnetic resonance imaging) and radiotherapy/surgical 
decompression are needed. Symptoms/signs of CES include, back pain, 
lower limb weakness/numbness, perineal (saddle) anaesthesia and 
urinary/faecal disturbance (Dy et al., 2008).  
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Figure 5. Signs and symptoms of prostate cancer. 
If cancer is not obstructing urine outflow, there may be no symptoms. Obstructive 
symptoms include lower urinary tract symptoms (poor stream, dribbling) and in 
complete obstruction, urinary retention may occur. In bone metastasis, men may 
present with bony pain and present with signs and symptoms of cauda equina 
syndrome (Based on graphics created by Cancer Research UK, 
http://www.cancerresearchuk.org/about-cancer/prostate-cancer/symptoms). 
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1.3.4 Histopathology of prostate cancer 
The most common histopathological form of PCa is acinar adenocarcinoma 
(~95%), which is a malignant tumour formed from glandular structures in 
epithelial tissue. Non-acinar carcinoma variants accounts for around 5-10% 
of primary PCa. These histological variants include sarcomatoid carcinoma, 
urothelial carcinoma, squamous cell carcinoma, adenosquamous carcinoma, 
ductal adenocarcinoma, basal cell carcinoma and neuroendocrine tumours, 
including small-cell carcinoma and clear cell adenocarcinoma (Humphrey, 
2012; Humphrey et al., 2016).  
 
There are histopathological types that have malignant potential, and patients 
with these pathologies need to be followed-up closely to identify progression. 
The two main pathologies associated with PCa are high-grade prostatic 
intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation 
(ASAP), the latter being less significant (Humphrey et al., 2016).  
 
1.3.5 Prostate cancer classification 
Prostate cancer is graded histopathologically and staged by means of clinical 
examination (DRE findings), tissue biopsy and imaging. In 2004, the World 
Health Organization (WHO) produced a classification system for tumours of 
the urinary system and male genital organs. This grading system was 
revised and updated in 2016 (Humphrey et al., 2016). The aim of the 
classification is to aid risk stratification and management protocols.   
 
1.3.5.1 Prostate cancer grading 
Gleason grading is based on the combination of two grading scores. On 
examination of specimens, the first (primary) and second (secondary) 
Gleason score is the most common and second (secondary) most common 
cell type/pattern seen respectively. The International Society of Urological 
Pathology (ISUP) 2014 Gleason grading conference of PCa introduced an 
updated grading system from the ISUP 2005 (Epstein et al., 2016). A score 
between 1-5 is given, 1, being well differentiated, and 5, being poorly 
differentiated (Figure 6). The total score is then further grouped into grades 
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1-5 (Table 1). Gleason scores <6 is regarded as grade 1, Gleason 9-10 as 
grade 5, and Gleason 7 (3+4) as grade 2, and Gleason 7 (4+3) as grade 3. 
The ISUP 2014, has therefore further codify the clinically highly significant 
differences between Gleason 7, 3+4 and 4+3 PCa (4+3 being more 
aggressive/high-risk).  
	
	
	
 
Figure 6. Gleason grading schematic diagram. 
Gleason score range between 1 and 5 based on how differentiated cells are under 
histopathological examination. Two scores are added together to give a final score. 
Gleason scores 7-10 are considered as high-grade disease (Humphrey et al., 2016). 
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Gleason Score Grade Group 
2-6 1 
7 (3+4) 2 
7 (4+3) 3 
8 (4+4, 3+5, 
5+3) 
4 
9-10 5 
 
Table 1. International Society of Urological Pathology 2014 grade groups. 
The new ISUP grading system now comprises of Gleason scores <6-10 
subcategorized into 5 grade groups. Gleason 2-6 being in group 1 and Gleason 9-
10 being in group 5 (Mottet et al., 2017). 
 
1.3.5.2 Prostate cancer staging 
The widely-used tumour (T), nodal (N), metastasis (M) staging system is 
used for staging PCa. The T-stage describes the primary tumour and the 
degree of invasion of the disease locally, T1-2 being confined to the prostate 
capsule, and T3-4 being invasion through the capsule to structures including 
the seminal vesicles, rectum and pelvic wall. Tumour detected on 
transurethral resection of prostate (TURP) or transrectal ultrasound-guided 
prostate biopsy (TRUS-PBx) are T1 disease and disease that are palpable 
on DRE are labelled as T2 disease (Table 2). The N-stage highlights the 
spread of PCa in relation to the regional lymph nodes drained by the prostate 
gland (N1). These include nodes of the pelvis, below the bifurcation of the 
common iliac arteries. Pelvis MRI can assess the prostate as well as 
identifying any enlarged/abnormal regional lymph nodes. Finally, the M-stage 
describes any spread to non-regional lymph nodes (M1a- non-pelvic nodes) 
or distant structures such as the bones (M1b) or distant organs commonly 
the liver, brain and lungs (M1c) (Table 2). Whole body MRI can evaluate 
distant organ metastasis and non-regional lymph nodes. In addition, single-
photon emission CT (SPECT) is useful in assessing bony metastasis. In 
summary staging requires a combination of DRE, PBx and imaging in the 
form of computerized tomography (CT) scan, MRI and isotope bone scan. 
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Tumour (T) Stage 
TX 
T0 
T1 
   T1a 
   T1b 
   T1c 
T2 
   T2a 
   T2b 
   T2c 
T3 
   T3a 
   T3b 
T4 
 
Primary tumour cannot be assessed 
No evidence of tumour 
Tumour not palpable or visible by imaging 
Tumour in <5% of resected tissue 
Tumour in >5% resected tissue 
Identified by needle biopsy 
Tumour confined within the prostate (palpable on DRE) 
Involves one half of one lobe or less 
Involves more than half of one lobe 
Involves both lobes 
Tumour extends through prostatic capsule 
Extracapsular extension (uni- or bilateral) 
Invades seminal vesicle(s) 
Fixed or invades adjacent structures other than seminal 
vesicles- external sphincter, rectum, levator muscles, pelvic 
wall 
Node (N) Regional 
NX 
N0 
N1 
 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Regional lymph node metastasis 
Metastasis (M) 
MX 
M0 
M1 
   M1a 
   M1b 
   M1c 
 
Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis 
Non-regional lymph node(s) 
Bone(s) 
Other sites(s) 
 
Table 2. Tumour Node Metastasis (TNM) classification of prostate cancer. 
The tumour (T) stage describes the degree of prostate invasion. The node (N) and 
metastasis (M) stage describe the presence of nodal or distant organ involvement. 
The TNM staging system was developed by the American Joint Committee on 
Cancer (AJCC) and the Union for International Cancer Control (UICC) (Adapted 
from the European Association of Urology 2017 guidelines (Mottet et al., 2017).  
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1.3.6 Prostate cancer screening 
The systematic examination and investigation of asymptomatic men is 
termed population screening. The aim is to reduce overall mortality with the 
secondary aim of maintaining quality of life (QoL). Mortality rates from PCa 
vary from country to country. A recent report on reduced mortality rate seen 
in the USA is probably related to aggressive PCa screening (through PSA 
testing) and aggressive treatment (Etzioni et al., 2013). Prostate cancer 
screening is a controversial topic with conflicting data arising from large 
RCTs (Andriole et al., 2009; Schröder et al., 2009; Hugosson et al., 2010). 
Screening for PCa in the NHS is not practiced, as overall benefits may not be 
superior to the risks of over diagnosis and over-treatment. A Cochrane 
review published in 2013 reported that screening was associated with an 
increased diagnosis of PCa, more localised PCa than advanced PCa. From 
results of five RCTs (341,000 randomised men), no PCa-specific survival 
benefit was observed and from results of four RCTs, no overall survival 
benefit was observed (Ilic et al., 2013). Within the UK, at risk individuals (age 
over 50 years, family history, African-Americans, raised PSA) may be offered 
PSA testing (Mottet et al., 2017) and individual patients can ask their GPs for 
a PSA test. 
 
1.3.7 Diagnosis of prostate cancer 
Definitive diagnosis of PCa is based on histopathological examination of 
specimens obtained from PBx, TURP or prostatectomy for benign prostate 
hyperplasia (BPH). Tissue sampling/diagnosis is usually proceeded by 
suspicion detected on DRE, PSA testing and an MRI scan. 
	
1.3.7.1 Prostate-specific antigen 
Prostate-specific antigen, also known as kallikrein-3 (KLK3), is a glycoprotein 
enzyme encoded in humans by the KLK3 gene. PSA is present in the blood 
in multiple forms known as isoforms, and some of these forms are more 
cancer-specific. PSA testing was introduced in the late 1980’s to aid PCa 
diagnosis (Stamey et al., 1987). Whilst PSA is relatively organ-specific, 
elevations in serum PSA levels are not cancer-specific. PSA is secreted by 
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the prostatic glandular epithelium into the prostatic ducts. As such, no or low 
levels of PSA should reach the blood stream. Any physiological or 
pathological process that affects the prostate/blood barrier will allow PSA to 
reach the blood stream. Examples of these include  BPH, prostatitis and 
malignancy (Nadler et al., 1995). The threshold for an abnormal PSA level 
has been 4.0ng/ml and the associated estimated sensitivity and specificity 
are 21-44% and 91-92% respectively. Using a cut-off of 3.0 ng/ml increases 
the sensitivity and decreases the specificity to 32% and 85% respectively 
(Wolf et al.) (Holmström et al., 2009). The positive predictive value for a PSA 
level >4.0 ng/ml is ~30% (Catalona et al., 1994), and the negative predictive 
value for a PSA value <4.0 ng/ml estimated by The Prostate Cancer 
Prevention Trial (PCPT) is 85% (Thompson et al., 2004). Moreover, many 
men may have PCa despite having a low PSA level (Dong et al., 2008). 
Since there is doubt in the diagnostic accuracy of PSA levels, patients with 
suspected PCa undergo a PBx.  
 
1.3.7.2 Prostate-specific antigen density and kinetics 
To improve the specificity for prostate cancer, various modifications of the 
PSA assay have been suggested.  
 
1) PSA density 
The PSA density is the PSA serum level divided by the prostate volume 
determined by TRUS-PBx. The higher the density, the more likely it is that 
the cancer is clinically significant. Lower densities are seen in men with large 
glands through BPH. 
 
2) PSA velocity and doubling time 
PSA velocity (PSAV) is the increase in PSA over time (ng/ml/year) and PSA 
doubling time (PSA-DT) is the exponential increase in PSA measured 
against previous values. Both may have a role in prognosis in treated PCa, 
but limited diagnostic use (Mottet et al., 2017).  
 
 
	
	
47	
3) Free/total PSA ratio 
Free/total (f/t) PSA ratio may be used to differentiate BPH from PCa. It 
stratifies the PCa risk with 4-10ng/ml total PSA and negative DRE. In a 
reported study, 56% of men with f/t PSA <0.10 were found to have PCa on 
PBx, in contrast only 8% of men with f/t PSA >0.25ng/ml were found to have 
PCa (Catalona et al., 1998). 
 
4) Other forms of PSA testing, PHI, 4K and IsoPSA 
A few tests measuring a range of KLK in serum and plasma are now 
commercially available, including the FDA-approved Prostate Health Index 
(PHI) test and the four kallikrein score (4K). Both the PHI and the 4K score 
are used with the intention to reduce the number of unnecessary PBx (Loeb 
et al., 2014; Bryant et al., 2015).  
 
The PHI test combines free and total PSA and the (-2)pro-PSA isoform 
(p2PSA) and is calculated using the following formula, ((−2)pro-PSA/fPSA) × 
PSA1/2. Isoforms of PSA have similar biological roles but differ in sequence 
and structural form. PHI was approved by the FDA in 2012 and studies have 
shown that PHI can improve the detection of high-risk PCa and is associated 
with PCa aggressiveness (Lazzeri et al., 2013).  
 
The 4K score measures free, intact and total PSA and kallikrein-like 
peptidase 2 (hK2). In addition, the 4K score also takes into account clinical 
information such as age and history of previous PBx results. A meta-analysis 
showed that the 4K score is associated with an improvement of 8-10% in 
predicting biopsy-confirmed PCa with an estimate of avoiding 48-56% of 
current PBx (Voigt et al., 2014). However, unlike PHI, the 4K score is not yet 
FDA-approved, and currently more prospective data is needed to compare 
PHI and the 4K score.  
 
The PHI and 4K score measure only a few known isoforms of PSA that give 
meaningful information if they are present at a given time. IsoPSA is a 
structure-based (rather than concentration-based) test that incorporates the 
entire spectrum of PSA structural changes. IsoPSA has been shown in a 
	
	
48	
prospective study to be more superior than standard PSA at predicting PCa 
(versus benign) and high-grade PCa (versus low-grade and benign). Once 
validated, IsoPSA may be another potential assay that would help to better 
select at risk men for PBx (Klein et al., 2017).  
 
1.3.7.3 Prostate Cancer Gene 3 
To aid the detection of PCa, several biomarker screens have been 
performed using normal and malignant prostate samples. On such screen 
identified the Prostate cancer gene 3 PCA3 non-coding RNA (Bussemakers 
et al., 1999). 
 
PCA3 ncRNA has been shown to be useful when used in conjunction with 
PSA (PCA3 score, PCA3/PSA mRNA ratio x 1000) to predict PCa on repeat 
PBx (rPBx). The PCA3 test was approved by the FDA in 2012. PCA3 is a 
long ncRNA that was discovered in 1999 (Bussemakers et al., 1999) and has 
been found to be overexpressed in >95% (53 out of 56 radical prostatectomy 
specimens) of primary PCa tissue. The PCA3 gene is located on 
chromosome 9q21-22 and was originally described as being formed by 4 
exons (1, 2c, 3, 4) with alterative polyadenylation at 3 different positions in 
exon 4. Subsequently, 4 new transcription start sites (Exon 1), 2 new 
differentially spliced exons (2a and 2b), and 4 new polyadenylation sites in 
exon 4 have been identified (Clarke et al., 2009). The presence of large 
number of stop codons in all 3 reading frames and the lack of an extensive 
open reading frame (ORF) suggest that PCA3 is a ncRNA. The PCA3 gene 
is found to be embedded in intron 6 of the BCH motif-containing molecule at 
the carboxyl terminal region 1 gene (BMCC1, also known as PRUNE2) 
(Figure 7), but transcribed in the antisense orientation (Bussemakers et al., 
1999; Clarke et al., 2009). 
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Figure 7. Location of PCA3. 
PCA3 (Blue) is embedded in intron 6 of BMCC1 (Grey) in chromosome 9 and is 
transcribed in the antisense direction (Red arrow). PCA3 has 6 exons and 4 
transcription start sites. The ncRNA is prostate cancer specific and is 
overexpressed in >95% of primary prostate cancer tissue (Bussemakers et al., 1999; 
Clarke et al., 2009). 
 
A quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
analysis of PCA3 showed low levels of expression in normal prostate and 
BPH tissue, no expression in other tissues, and a median upregulation of 
PCA3 in PCa cells by ~66 folds relative to non-malignant tissue (de Kok et 
al., 2002; Hessels et al., 2003). Unlike PSA, this test is organ- and PCa-
specific (Crawford et al.; Nadler et al., 1995), it can be detected in urinary 
samples (PROGENSA assays), more readily after DRE (Groskopf et al., 
2006), and has a sensitivity of 67% and a specificity of 83% (Hessels et al., 
2003). A European prospective multicentre study (Haese et al., 2008) and 
the REDUCE RCT (Aubin et al., 2010) demonstrated that the PCA3 score is 
higher in men with a positive biopsy than in men with a negative biopsy. A 
PCA3-Score threshold of 35 provides an optimal balance between sensitivity 
(47–58%) and specificity (72%) for detecting PCa. A score of 35 would avoid 
67% of PBx, missing 21% of high-grade tumours. However, lowering the 
score to 20 would miss only 9% of high-grade tumours, but at the expense of 
avoiding less PBx (44%) (Haese et al., 2008). Overall, PCA3 is a valuable 
biomarker used in conjunction with PSA to guide the need for rPBx in the 
detection of PCa (Tinzl et al., 2004; van Gils et al., 2007; Roobol et al., 2010). 
 
1.3.7.3.1 A function of PCA3 
The function of PCA3 is not entirely clear. However, PCGEM1 (Prostate-
specific transcript 1, chromosome 2q32) is also a ncRNA and like PCA3, it is 
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prostate-specific and is overexpressed in PCa (Srikantan et al., 2000). 
PCGEM1 has been found to promote cell proliferation and inhibit apoptosis 
(Petrovics et al., 2004; Fu et al., 2006), these functional roles may also apply 
to PCA3. BMCC1/PRUNE2 has also been found to be overexpressed in PCa 
tissues and thought to have a role in cellular proliferation, apoptosis, and 
cellular transformation (Clarke et al., 2009). Knowing that the PCA3 gene is 
embedded in the BMCC1 gene, it may have roles similar to BMCC1. In 
addition, it has been shown that PCA3 has a dominant-negative oncogenic 
role in regulating tumour suppressor gene BMCC1, through RNA editing 
mediated by a complex containing adenosine deaminase acting on RNA 
(ADAR) family members (Salameh et al., 2015).  
 
Although PCA3 is overexpressed in PCa tissue, its role in predicting the 
presence of PCa on rPBx in men with elevated PSA level and a previous 
negative biopsy is not entirely clear. Although studies have shown that PCA3 
scores can predict the probability of a positive rPBx result, the optimum cut-
off value is unknown (Haese et al., 2008; Aubin et al., 2010; Kirby et al., 
2012).  
 
1.3.7.3.2 Clinical barriers to use of the PCA3 assay 
Although PCA3 helps in the diagnosis of PCa, there are logistic and 
implementation problems associated with this test. Firstly, the target for 
detection is a long RNA (gene size is 25kb, PCR target assay size is 380bp) 
(Bussemakers et al., 1999). These molecules are unstable and prone to 
digestion by endogenous RNases. As such, handling the sample prior to the 
assay requires laborious stringency, which limits its adoption and ensures a 
high cost. Secondly, the function of PCA3 is unclear, producing a biological 
gap in knowledge that hampers the scientific community’s acceptance of this 
assay. Finally, the test has a lower sensitivity than PSA for PCa, including 
potentially aggressive disease (Roobol et al., 2010). Although, PCA3 is able 
to detect both low- and high-grade disease, like PSA, its sensitivity and 
specificity vary according to different cut-off scores. In addition, the 
relationship between PCA3-scores and parameters (i.e. tumour volume and 
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Gleason Score) of PCa aggressiveness is unclear. Although some studies 
have established a positive correlation between PCA3-scores and more 
serious disease (>T2, Gleason >6), others have not (Roobol et al., 2010).  
Little is known about the function of many long ncRNAs, and until recently 
their importance biologically was unclear. The recent Gencode human 
genome sequence assembly identified 10,000 long ncRNAs with features 
similar to PCA3 (Derrien et al., 2012). Many are located within or adjacent to 
other RNAs (PCA3 is located within BMCC1) (Clarke et al., 2009) and many 
are processed to smaller more active species (Röther et al., 2011).  
 
1.3.7.4 Other biomarkers 
Biomarkers are measurable markers detected in urine, blood/plasma or 
tissue specimens, and function to help diagnose disease, predict 
progression/prognosis and to monitor for recurrence following treatment. The 
evolution of PSA led to earlier diagnosis and treatment of PCa, however, as 
discussed, PSA is often associated with false-negative results. This has 
focused research on markers to detect PCa, and to differentiate indolent 
disease from aggressive disease. RNA profiling using microarray-based 
techniques is used to trace changes in gene expression during oncogenesis.  
 
Two current promising RNA biomarkers are the PCA3 ncRNA and 
transmembrane protease, serine 2 (TMPRSS2) fusion transcripts.  
 
In men with an initial negative PBx who have a persistent risk, such as 
elevated PSA or abnormal DRE, there are additional tests available to aid 
rPBx decisions. The urinary PCA3 test discussed earlier is one additional 
test that can be used. Other tests that are available are the serum 4K, PHI 
and IsoPSA tests (Chapter 1.3.7.2), or a tissue-based epigenetic test 
(ConfirmMDx). The ConfirmMDx test quantifies the methylation level of 
promoter regions of three genes (RASSF1, GSTP1 and APC) in benign 
prostatic tissue. A multicentre study showed a negative predictive value of 88% 
when methylation was absent in all three markers, suggesting that rPBx 
could be avoided in these men (Stewart et al., 2013; Partin et al., 2014). 
	
	
52	
Given the limited currently available data, no recommendation can be made 
regarding its routine application.  
 
Gene rearrangements have been described in multiple cancers. The 
TMPRSS2-ERG fusion gene comprises the androgen-responsive genes 
TMPRSS2 and erythroblast transformation-specific (ETS)-related genes 
(ERG), and was observed in ~40-80% of PCa in 2005 (Tomlins et al., 2005). 
Both genes are located on chromosome 21, and the TMPRSS2-ERG score 
is calculated using the formula, (TMPRSS2-ERG mRNA/PSA RNA copies) x 
100,000. A recent meta-analysis showed that TMPRSS2-ERG 
overexpression is associated with tumour stage, but not with disease 
recurrence or mortality in men treated with radical prostatectomy (Pettersson 
et al., 2012). 
 
The Mi-Prostate Score (MiPS) combines the prognostic significance of urine 
TMPRSS2-ERG and urine PCA3 with serum PSA to generate a PCa risk 
assessment score. Although not yet FDA-approved, the MiPS has been 
shown to be more superior to PSA alone in predicting biopsy-confirmed PCa 
and high-grade disease (Tomlins et al., 2016). 
 
Biological markers, including urine PCA3, transmembrane protease, serine 
2- ETS-related gene (TMPRSS2-ERG) fusion, or PSA isoforms such as the 
PHI index appear promising as does genomics on the tissue sample itself 
(Jerónimo et al., 2011; Berg et al., 2014; Cantiello et al., 2016). However, 
further study data will be needed before such markers can be used in 
standard clinical practice.  
 
1.3.7.5 Prostate biopsy 
A PBx is considered if the PSA level is raised and/or abnormal findings on 
DRE is detected. Limited PSA elevation alone does not necessitate 
immediate PBx, and warrants repeating. This is because as discussed 
before, PSA is not cancer-specific and may be raised under numerous 
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conditions.  There are two main routes for biopsy– either through the rectum 
or through the perineum. 
 
1.3.7.5.1 Transrectal Ultrasound-guided biopsy 
A transrectal ultrasound-guided prostate biopsy (TRUS-PBx) is currently a 
standard biopsy modality of choice (NICE, 2014b; Mottet et al., 2017). It is 
performed under local anaesthetics with prophylactic antibiotics cover. The 
ultrasound probe is inserted into the rectum and 6 or more cores of tissue 
are taken with a needle from each lobe of the prostate. 
 
Over 100,000 TRUS-PBxs are performed annually in the UK and 
approximately 70% of UK men are found not to have PCa (Lane et al., 2010). 
The low detection rate maybe due to small tumours, tumours located 
peripherally or anteriorly that are difficult to sample, or no tumours in the first 
place (PBx following a raised PSA that is not cancer related). Men with an 
initial negative biopsy and persistently raised PSA are subject to rPBx. The 
PCa detection rates on rPBx is around 10 to 30% (Keetch et al., 1994; 
Djavan et al., 2001). Unnecessary PBx increases healthcare costs, patients’ 
anxiety and puts patients at risk of PBx complications including infection and 
bleeding (Rosario et al., 2012; Loeb et al., 2013b). The percentage of men 
hospitalized for complications after biopsy is 4.1%, and this figure seems to 
be increasing (Nam et al., 2010). In addition, there is a risk of over-
diagnosing insignificant tumours and delaying the detection of significant 
disease. Each rPBx could cost ~£310 if they are transrectal or £650 if they 
are transperineal (NICE, 2014a). European guidelines suggest that one set 
of rPBx is warranted where there is an abnormal DRE, persistently elevated 
PSA value and a histopathological finding suggestive of malignancy (HGPIN) 
on initial biopsy. There are no further recommendations on subsequent 
repeat biopsies (Mottet et al., 2017). The decision as to how best to proceed 
is based predominantly on retrospective international data and the man’s 
original experience of biopsy (Wade et al., 2013). Although there are new 
biomarkers found such as PCA3 to help better select men for initial and rPBx, 
	
	
54	
these are not used globally secondary to its high cost, and its unclear 
biological role in PCa (Kirby et al., 2012).  
 
1.3.7.5.2 Transperineal biopsy  
Other approaches include the transperineal approach, which is performed 
under general anaesthetics and requires accessing the prostate gland 
through the perineum. Cancer detection rates are comparable to TRUS-PBx 
(Takenaka et al., 2007). 
 
Saturation biopsy involves taken >20 cores and the PCa detection rate is 
between 30 and 43% (Walz et al., 2006). The increased number of cores 
taken is to maximise detection rate on rPBx following a negative initial PBx. 
Saturation biopsy can be performed with the transperineal approach 
(Transperineal template biopsy, TPM-Bx), which detects an additional 38% 
of cancer, however, there is a ~10% risk of urinary retention (Moran et al., 
2006). 
 
Multiparametric MRI (mpMRI) are increasingly performed prior to PBx to 
improve the detection of clinically significant PCa and to allow MRI-targeted 
biopsy in case of positive mpMRI (Schoots et al., 2015). MRI-targeted PBx 
can be performed through USS/mpMRI fusion software. However, there are 
contradictory data as to whether there is a difference in PCa detection rate 
between MRI-targeted and systematic PBx and systematic PBx alone 
(Panebianco et al., 2015; Tonttila et al., 2016). 
 
1.3.7.5.3 Prostate biopsy complications 
Prostate biopsy complications are listed in Table 3. Although antibiotic cover 
reduces the risk of severe infection, this is on the incline as a result of 
antibiotic resistance (Loeb et al., 2013b). 
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Complications Percentage (%) 
Haematospermia 
Haematuria >1day 
Rectal bleeding <2days 
Prostatitis 
Fever >38.50C 
Epididymitis 
Rectal bleeding >2days 
Urinary retention 
Other complications requiring hospitalization 
37.4 
14.5 
2.2 
1.0 
0.8 
0.7 
0.7 
0.2 
0.3 
 
Table 3. Complication rates per biopsy session. 
Adapted from the European Association of Urology 2016 guidelines. Complication 
rates are reported irrespective of the number of cores taken. The most common 
complication is haematospermia (37.4%) and haematuria lasting over 1 day (14.5%). 
Other complication rates are <1% (Mottet et al., 2017).  
	
1.3.7.6 Imaging 
For staging (Section 1.3.5.2), following tissue diagnosis of PCa, cross-
sectional abdomino-pelvic imaging using MRI and a bone scan is used to 
detect distant organ/lymph node and bone involvement respectively.  
 
Multiparametric MRI of the pelvis is a dynamic contrast-enhanced MRI 
technique for local detection/staging of PCa. Correlation with radical 
prostatectomy shows that mpMRI has sensitivity rates of 80% for detecting 
Gleason >7 tumours of <0.5ml volume and 100% for detecting >2ml tumours 
(Turkbey et al., 2011; Bratan et al., 2013).  
 
1.3.8 Management of prostate cancer 
The treatment of PCa depends on the patient’s fitness and performance 
status (including co-morbidities) and their cancer (stage, grade and risk of 
the disease) (Table 4). Localised disease can be managed by watchful 
waiting, active monitoring/surveillance, radical radiotherapy or radical surgery 
(NICE, 2014b; Mottet et al., 2017). The optimal treatment option for localised 
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disease is not known and the UK Prostate Testing for Cancer and Treatment 
(ProtecT) RCT aimed to evaluate this (Lane et al., 2010, 2014). Between 
1999 and 2009, ProtecT recruited 82,429 men for PSA testing within nine UK 
cities. A total of 2664 men received a diagnosis of localised PCa and 1643 
were randomised to active monitoring (n=545), radical prostatectomy (n=553) 
or radical radiotherapy (n=545). At a median of 10 years follow-up, disease-
specific mortality was not significantly different amongst treatments, however, 
there were higher rates of disease progression in the active monitoring group 
(Hamdy et al., 2016). Metastatic disease is managed with hormonal therapy 
or chemotherapy. However, a proportion of men who receive hormonal 
therapy become resistant to the treatment and deteriorate rapidly. The 
cancer progresses in an androgen-independent (Castration-resistant PCa, 
CRPC) manner and the mechanisms underlying this are not entirely clear. 
The treatment options for localised and locally advanced/metastatic PCa are 
summarized in Figure 8. 
 
 
Low-risk Intermediate-risk High-risk 
PSA <10ng/ml 
and Gleason <7 
and cT1-2a 
PSA 10-20ng/ml or 
Gleason 7 or cT2b 
PSA >20ng/ml or 
Gleason >7 or cT2c 
Any PSA, any Gleason, 
but cT3-4 or cN+ 
Localised Locally advanced 
 
Table 4. European Association of Urology risk groups for localised and 
locally advanced prostate cancer. 
Risk stratification (low, intermediate and high) is based on PSA, Gleason score and 
staging (imaging). Treatment decisions are based on PCa risk, patient co-
morbidities and patient’s wishes (Mottet et al., 2017). 
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Figure 8. Summary of the treatment options for prostate cancer. 
Treatment depends on the risk of disease and whether the disease is localised, 
locally advanced or metastatic. Options include watchful waiting, active surveillance, 
radical surgery or radiotherapy and hormonal therapy. 
 
WW, watchful waiting; AS, active surveillance; RP, radical prostatectomy; RT, 
radiotherapy; HIFU, high-intensity focused ultrasound; ADT, androgen deprivation 
therapy; MAB, maximal androgen blockade (for castration-resistant disease) 
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1.3.8.1 Localised prostate cancer 
Localised PCa is disease confined to the prostate, tumour stage T1-2. 
Insignificant or indolent disease may not need immediate radical treatment. 
Epstein defined indolent PCa as, Gleason score <6; <3cores positive; <50% 
positive per core (Epstein et al., 1994). 
	
1.3.8.1.1 Watchful waiting 
Many men with incidental finding or screened-detected PCa will not 
necessarily need definitive treatment. These men could be managed 
conservatively to reduce over-treatment of insignificant low-risk disease. 
Watchful waiting (WW) is also termed deferred or symptom-guided treatment, 
which refers to monitoring until the patient develops symptoms. This 
approach is more of a palliative approach that is preferred in men with a life 
expectancy of less than 10 years. The aim is to minimize treatment-related 
adverse effects (Albertsen, 2015). Follow-up is patient-specific and 
assessment is not pre-defined. Many small, localised and low-grade disease 
do not progress, and radical treatment may result in over-treatment. This was 
confirmed by a recent analysis in 19,659 men with 10 years follow-up. Men 
with low co-morbidity index scores had a low-risk of death at 10 years or died 
from competing causes. In addition, men with higher co-morbidity scores, 
tumour aggressiveness had little impact on overall survival (Albertsen et al., 
2011). 
 
1.3.8.1.2 Active surveillance 
For those who do not need or want immediate treatment, active surveillance 
(AS) may be offered.  Treatment is deferred until there are clinical features of 
disease progression. Follow-up is pre-defined and assessments include DRE, 
PSA, rPBx and mpMRI. The aim is to detect progressing disease that would 
initiate prompt curative treatment. The AS approach is preferred in men with 
life expectancy of over 10 years (Thomsen et al., 2014; Welty et al., 2014). 
The current selection criteria for AS is based on two systematic reviews and 
include, Gleason 6, <2-3 positive cores on PBx with <50% cancer 
involvement or each core, a clinical T1c or T2a, PSA <10ng/ml (Thomsen et 
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al., 2014; Loeb et al., 2015). The initiation of active treatment should be 
based on a change in PBx results (Gleason score, number of positive cores), 
T-stage progression, or upon a patient’s request. 
 
1.3.8.1.3 Radical prostatectomy  
Radical prostatectomy (RP) should be offered to a patient with low- and 
intermediate-risk PCa with at least 10 years of life expectancy. The 
procedure involves eradication of disease by removal of the entire prostate, 
both seminal vesicles and pelvic lymph nodes. Due to the abundant nerve 
supply around the prostate, there is a risk of incontinence and impotency. 
The prostate could be removed via the traditional open approach (retropubic 
prostatectomy, RRP), laparoscopic prostatectomy (LP) or robotic-assisted LP 
(RALP). Prostatectomy was traditionally indicated in organ-confined disease 
(T1-T2), however, in recent years, there has been an interest in performing 
RP for locally advanced T3 disease (Ward et al., 2005; Hsu et al., 2007). 
Minimally-invasive approaches may have the benefit of better operating view 
for the surgeon, reduced peri-operative morbidity and hospital stay, however, 
the oncological outcomes and survival may not differ significantly (Novara et 
al., 2012; Ramsay et al., 2012).  
 
1.3.8.1.4 Radiotherapy 
External beam radiotherapy (EBRT) can be used as primary or adjuvant 
treatment, and can be used in conjunction with hormonal therapy to improve 
outcomes (D’Amico et al., 2008; Bolla et al., 2010). EBRT can be offered to 
all risk groups of non-metastatic PCa. Combination therapy with hormonal 
therapy is recommended short-term in intermediate-risk PCa and long-term 
in high-risk localised disease. Men with low-risk disease, without a previous 
TURP and with a prostate volume <50ml may be offered brachytherapy as a 
monotherapy. Low-dose-rate (LDR) brachytherapy uses radioactive seeds 
permanently implanted into the prostate (Davis et al., 2012). Radiotherapy 
complications include gastrointestinal and genitourinary toxicity (Zelefsky et 
al., 2008), erectile dysfunction and an increased risk of being diagnosed with 
secondary malignancies (Abdel-Wahab et al., 2008). However, radiotherapy 
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has a lesser effect on erectile function compared with surgery (Robinson et 
al., 2002). The risk of developing rectal cancer and bladder cancer following 
radiotherapy can be a 1.7-fold (Baxter et al., 2005) and 2.34-fold (Liauw et al., 
2006) increase retrospectively compared to surgery.  
 
1.3.8.1.5 Options other than surgery or radiotherapy 
Other modalities for managing localised PCa include cryosurgery (CSAP), 
high-intensity focused US (HIFU), photodynamic therapy, radiofrequency 
ablation and electroporation. A lot of these treatment modalities are in the 
early phases of evaluation, and there are sufficient data only on CSAP and 
HIFU.  
 
Cryosurgery involves freezing (-400C) of the prostate by the placement of a 
cryoneedle under TRUS guidance. Men who are eligible for CSAP are ones 
who have a life expectancy of >10 years, prostate gland <40ml, PSA 
<20ng/ml and Gleason <7 (Rees et al., 2004; Ramsay et al., 2015).  
 
High-intensity focused ultrasound uses focused US waves to induce tissue 
damage by thermal (650C) effects. This procedure is performed under 
general or spinal anaesthesia and is offered to patients with low- to 
intermediate-risk disease. In a recent systematic review comparing CSAP 
(n=3995) and HIFU (n=4000) with AS, RP and EBRT, there was no evidence 
that mortality at 4 years, or other cancer-specific outcomes differed between 
treatments (Ramsay et al., 2015). 
 
Focal therapy refers to treatment of low-volume (disease occupying 5-10% of 
the prostate volume) unifocal or unilateral disease, usually in the form of 
ablative therapy such as CSAP or HIFU. The main aim of focal therapy is to 
ablate tumours selectively and limiting toxicity by sparing the neurovascular 
bundles, sphincter and urethra (Eggener et al., 2007). Although in the same 
systematic review published by Ramsay et al, there were no significant 
differences in oncological outcome at 3 years amongst a subgroup of focal 
therapy against RP and EBRT, focal therapy remains investigational and 
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should not be offered as a therapeutic alternative outside clinical trials 
(Ramsay et al., 2015).  
 
A recent RCT comparing AS (n=207) and TOOKAD® Soluble-Vascular 
Photodynamic Therapy (VTP, n=206) showed that at a median (IQR) follow-
up of 24 (24-25) months the disease progression rate was lower in the VTP 
group (VTP, 28% and AS, 58%, p<0.0001). Therefore men with localised, 
low-risk PCa can be managed with tissue-preserving focal therapy through 
VTP with good disease-free progression outcomes (compared with AS) and 
reduced need for whole-gland radical treatment (Azzouzi et al., 2017).   
 
1.3.8.2 Locally advanced and metastatic prostate cancer 
	
1.3.8.2.1 Androgen deprivation therapy 
The pathogenesis of PCa is associated with androgens, hence targeting the 
hormonal pathway suppresses disease progression. Androgen deprivation 
can be achieved by either inhibiting the action on androgens at the receptors, 
or suppressing the secretion of testicular androgens.  
 
Androgen deprivation therapy (ADT) is achieved surgically by bilateral 
orchidectomy or pharmacologically with anti-androgens, LHRH antagonists 
or agonists. Surgery results in castration (testosterone <20ng/dl) within 12 
hours, and is a straight-forward procedure that can be performed under local 
anaesthetics (Desmond et al., 1988). Drugs that suppress the secretion of 
testicular androgens include Luteinising-hormone-releasing hormone (LHRH) 
agonists (Leuprolide, Goserelin) and LHRH antagonists (Abarelix, Degarelix), 
and drugs that act on androgen receptors (AR) include anti-androgens 
(steroidal- Cyproterone acetate; non-steroidal- Flutamide, Bicalutamide). 
LHRH agonists are delivered as depot injections on a 1-, 2-, 3- or 6-monthly 
basis, and castration is usually obtained within 2-4 weeks. In contrast LHRH 
antagonists are given on a 1-monthly basis and castration is achieved within 
days (Pagliarulo et al., 2012). In the first instance of managing locally 
advanced disease, either LHRH agonists/antagonists or anti-androgens are 
used as monotherapy. A systematic review of the side effects of ADT has 
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recently been published and common/severe effects include erectile 
dysfunction, hot flushes, non-metastatic bone fractures, metabolic effects 
(lipids, glucose), cardiovascular morbidity and fatigue (Ahmadi et al., 2013). 
 
1.3.8.2.2 Castration-resistant prostate cancer 
During castration, the occurrence of castration-resistant (CRPC) is 
systematic. When CRPC develops (rising PSA or radiological progression 
despite testosterone <50ng/ml), maximal androgen blockade (MAB) is 
achieved by combining LHRH agonist/antagonist and anti-androgens 
together (Pagliarulo et al., 2012). Newer medications that manage CRPC 
include Abiraterone acetate (CYP17 inhibitor- suppresses testosterone 
synthesis), and Enzalutamide (a novel anti-androgen). 
 
1.3.8.2.3 Metastatic prostate cancer 
Primary ADT is the standard of care for patients with metastatic PCa. In 
metastatic CRPC (mCRPC), MAB should be initiated (Pagliarulo et al., 2012). 
There is evidence from RCTs that ADT combined with chemotherapy 
(Docetaxel) provides a more superior overall survival rate. The STAMPEDE 
(Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation 
of Drug Efficacy) RCT randomised 2962 men to four groups of treatment  
and showed that the median overall survival in the ADT alone and ADT + 
Docetaxel group to be 71 and 81 months respectively (James et al., 2016). 
Sweeney et al who randomised 790 men also showed a significant higher 
survival rate in the combination group (57.6 months versus 44 months) 
compared to ADT alone (Sweeney et al., 2015). There is evolving evidence 
that ADT combined with radical prostatectomy or radiotherapy provides an 
overall survival benefit in newly diagnosed metastatic PCa (Culp et al., 2014; 
Gratzke et al., 2014). 
 
1.4 Prostate cancer and androgen regulation 
Androgens play a crucial role in male sexual development and prostate 
physiology. Testosterone is produced by testicular Leydig cells, and 
dihydrotestosterone (DHT) is produced from testosterone in peripheral 
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tissues by 5-alpha reductase (Michaud et al., 2015). Testosterone is 
bounded to sex hormone-binding globulin (SHBG), however, it is the 
unbound, free testosterone that is the active form (Figure 9). It is known that 
androgens have an important role in the pathogenesis and progression of 
PCa (androgen hypothesis). This was first brought to attention when Huggins 
and Hodges observed the benefits of castration in patients with PCa 
(Huggins et al., 1941). Several cell lines studies have shown that PCa cells 
grow in an androgen-dependent manner. Hormonal therapy remains the first 
line treatment for advanced or metastatic disease (discussed earlier 1.3.8.2), 
which targets the hypothalamus-pituitary-adrenal/testicular-prostate axis  
(Heidenreich et al., 2008). However, ADT is not curative and in some men, 
PCa reactivates AR-signalling and resumes proliferation despite low levels 
(<20ng/dl) of testosterone (CRPC). AR-signalling is maintained through 
multiple mechanism including AR mutation, AR amplication, altered co-
regulator profiles, and extra-gonadal androgen production (Karantanos et al., 
2015).  
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Figure 9. The hypothalamus-pituitary axis. 
The hypothalamus releases luteinizing hormone-releasing hormone (LHRH) to 
trigger the pituitary gland to release luteinizing hormone (LH) and 
adrenocorticotrophic hormone (ACTH). LH facilitates the production of testosterone 
in testicular Leydig cells. Testosterone is converted into dihydrotestosterone (DHT) 
via 5-alpha reductase. ACTH acts on adrenal glands to stimulate the release of 
adrenal androgens (Dehydroepiandrosterone, DHEA), and together with DHT, 
prostate growth is enhanced. 
 
1.4.1 Paracrine/autocrine synthesis 
In normal homeostasis, testosterone and DHT are produced to provide 
survival and proliferation of prostatic epithelium by a paracrine loop. During 
PCa progression, an autocrine loop is established and PCa cells produce 
numerous factors/androgens to support their own growth (Logothetis et al., 
2013). The levels of DHT and key enzymes in androgen synthesis, such as 
CYP17A1 (Cytochrome P450 hydroxylase type enzyme) and HSD3B1 are 
higher in CRPC. This suggests increased androgen synthesis in advanced 
PCa, partly due to upregulation of enzymes through autocrine androgen 
synthesis (Chang et al., 2011). There are multiple steps in the synthesis of 
adrenal and testicular androgens, and some hormonal treatments are based 
on inhibiting androgen synthesis through inhibiting enzymes. An example is 
the inhibition of CYP17A1 by Abiraterone acetate (Figure 10). 
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Figure 10. Androgen biosynthesis. 
The biochemical pathways in androgen synthesis is summarized in this figure. 
Current and new medications aim to block receptors or inhibit key enzymes involved 
in androgen synthesis, such as the inhibition of CYP17A1 by Abiraterone acetate 
(Karantanos et al., 2015). 
 
1.4.2 Androgen receptor mutation 
The AR gene is located on the X chromosome at Xq11-Xq12. Androgen 
receptor mutations occur in >10% of patients with CRPC. The mutant 
broadens the ligand-binding specificity of AR, sensitizing it to other steroid 
hormones such as progesterone and oestrogens (Grasso et al., 2012a). 
H874Y mutation enhances the binding of AR co-regulators and increases AR 
transcriptional activity through AR protein conformational change. In addition, 
mutation of W435L promotes androgen-independent AR activation (Schröder, 
2008). Results suggest that AR mutations provide survival benefits to PCa 
cells and promote resistance to anti-androgens (Karantanos et al., 2015). 
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Enzalutamide is a novel antagonist of AR, inhibiting nuclear translocation, 
chromatin binding and interactions with AR co-regulators (Tran et al., 2009).  
 
1.5 Genetic mechanisms of prostate cancer 
Prostate cancer is a heterogeneous disease, although it’s slow growing, a 
proportion of men will have aggressive disease with metastasis and die from 
the disease. The majority of men will have indolent (Epstein criteria) disease 
that will not necessarily progress, and over-treatment of such low-risk 
disease leads to greater risks of morbidity (Epstein et al., 1994). An 
appreciation of the molecular basis of PCa allows us to understand the 
varying behaviour of the disease. 
 
Normal cells divide, turnover and produce proteins in a controlled manner. 
When these processes become unregulated, oncogenesis occurs (Hanahan 
et al., 2011). Regulations may occur at the genetic or epigenetic level. 
Genetic processes are irreversible and include DNA mutation or 
chromosomal translocation, deletion and amplification (Croce, 2009). 
Epigenetic changes do not alter gene sequence or chromosomal structure 
and are commonly reversible (Figure 11). 
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Figure 11. A summary of the events leading to oncogenesis. 
The development of tumours is the result of genetic and/or epigenetic events. 
Genetic and epigenetic alterations/mutations lead to uncontrolled cell proliferation, 
avoidance of apoptosis, increased angiogenesis and tissue invasion.  
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Different types of genetic variations can affect tumorigenesis, including 
germline variations (Choudhury et al., 2012) and somatic alterations. 
Germline changes are transmittable to offspring and are present in every cell, 
in comparison, somatic alterations arise in prostate cells. Genetic alterations 
causing amplification, deletion or translocation of segment of chromosomes 
lead to an imbalance of amplification of oncogenes and deletion of tumour 
suppressor genes. Together with gene fusions, these alterations promote 
oncogenesis. There is a diverse list of genes contributing to key pathways in 
oncogenesis across a wide-spectrum of cancers as well as PCa alone 
(Barbieri et al., 2013, 2014; Boström et al., 2015; Mitchell et al., 2015).  
 
1.5.1 Cancer pathways 
1.5.1.1 Phosphoinositide 3-kinase pathway 
The phosphoinositide-3-kinase (PI3K) pathway is a commonly altered 
signalling pathway in human cancer and is altered in around 25-70% of PCa. 
The alteration of this pathway contributes to cell proliferation, survival and 
invasion. The phosphatase and tensin homolog (PTEN) gene (chromosome 
10q23) is a frequently mutated TS gene and acts to deactivate PI2K-
dependent signalling (Barbieri et al., 2013; Boström et al., 2015). Deletion of 
PTEN occurs in 40% of PCa and studies support the role of PTEN as an 
important tumour suppressor in PCa (Carver et al., 2009). Deletion of PTEN 
is associated with higher grade disease, progression, metastasis and higher 
risk of recurrence in treated disease (McMenamin et al., 1999), (Krohn et al., 
2012), (Choucair et al., 2012). 
 
1.5.1.2 Ras/Raf/mitogen-activated protein kinase pathway 
The mitogen-activated protein kinase (MAPK) pathway has a less 
established role in PCa compared to other common cancers such as lung, 
ovarian and gastrointestinal cancer. However, activation of MAPK signalling 
by Ras and Raf intermediates may enhance transcriptional activity of AR and 
appears to be more enriched in metastatic PCa (Bakin et al., 2003). Other 
rare fusion genes that are associated with the MAPK pathway in PCa include 
KRAS, RAF1 and BRAF (Palanisamy et al., 2010). 
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1.5.1.3 Tumour Protein 53 
Tumour protein p53 acts as a transcription factor activating the transcription 
of genes involved in cell cycle arrest, DNA repair and apoptosis. It is the 
most commonly mutated gene in cancer and deletions at the p53 locus are 
seen in around 25-40% of PCa (Barbieri et al., 2012) (Taylor et al., 2010). 
Interestingly, TP53 defects may be an early onset in PCa, as ~25-30% of 
clinically localised PCa harbour lesions in TP53.  
 
1.5.1.4 Retinoblastoma protein 
Tumour suppressor Retinoblastoma protein (Rb) regulates cell cycling and is 
deleted or mutated in a number of human cancers. The Rb1 gene 
(chromosome 13q14) is commonly inactivated in CRPC (~45%), and has 
been shown to modulate AR-signalling and inhibit progression to castration 
resistance (Aparicio et al., 2011). 
 
1.5.1.5 v-myc myelocytomatosis viral oncogene homolog 
The v-myc myelocytomatosis viral oncogene homolog (MYC) gene located at 
8q24 encodes c-Myc, which is a transcription factor involved in cell cycle 
progression, cell survival and oncogenesis. It is a common oncogene in 
human cancers and is commonly amplified in PCa. The amplication usually 
involves the entire chromosome 8 arm, which may result in amplifying other 
genes within this region (Barbieri et al., 2012; Grasso et al., 2012b). 
 
1.5.2 Prostate cancer specific pathways 
There are generic pathways that are common to a range of human cancers, 
in addition, there are genetic mechanisms that are highly PCa specific. 
 
1.5.2.1 Androgen-signalling 
Focusing on PCa, the discovery of disease regression through suppressing 
androgens (castration) in men with advanced PCa emphasized the 
importance of the androgen-signalling pathway in PCa. Androgen receptor 
(AR) is a ligand-dependent nuclear transcription factor. The presence of 
amplification and mutation of AR in treated metastatic disease and the 
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absence of these AR lesions in primary localised PCa imply that the AR gene 
do not have a role in the pathogenesis of PCa, but have a role in androgen 
resistance during treatment (Taylor et al., 2010; Barbieri et al., 2012). PCa 
that continue to progress despite castration become androgen-independent 
and show features of active AR-signalling (Waltering et al., 2012). 
 
There is also a list of genes encoding proteins that interact and modulate AR 
activity such as transcriptional coactivators (the nuclear receptor coactivator 
2 gene (NCOA2), E1A binding protein p300 gene (EP300), nuclear receptor 
interacting protein 1 gene (NRIP1)), transcriptional corepressors (nuclear 
receptor corepressors 2 gene (NCOR2)) and the forkhead-box family of 
transcription factors (FOXA1). (Taylor et al., 2010; Barbieri et al., 2012; 
Grasso et al., 2012b).  
 
Interactions between AR-signalling and other oncogenic pathways have 
been established. For example, PI3K/Akt signalling pathway inhibits AR-
signalling and by negative feedback, AR inhibition activates Akt signalling. 
This may be a key component of CRPC progression (Carver et al., 2011).  
 
1.5.2.2 E26 transformation-specific (ETS) gene fusions 
The presence of gene fusions between androgen-regulated genes and 
members of the ETS family of transcription factors has an important role in 
prostate oncogenesis. The most common fusion is the transmembrane 
protease, serine 2 (TMPRSS2) gene to the v-ets erythroblastosis virus E26 
oncogene homolog (ERG) gene (Tomlins et al., 2009; Barbieri et al., 2013; 
Boström et al., 2015). Other members of the ETS family that serves as 
partners include ets variant 1, 4, 5 (ETV-1, 4, 5) and Friend leukaemia virus 
integration 1 (FLI1) (Paulo et al., 2012). ETS rearrangements occur in 27-79% 
of radical prostatectomy and PBx samples, and it has been shown that 
transgenic TMPRSS2-ERG mice develop prostatic intraepithelial neoplasia 
(PIN). Tumours consisting of TMPRSS2-ERG also show PTEN loss, 
suggesting cooperation in prostate oncogenesis (King et al., 2009). ETS 
fusions are associated with both aggressive and indolent disease. Some 
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studies report increased Gleason grade and BCR, while some report lower 
Gleason score and increased recurrence-free survival (Tomlins et al., 2009). 
Tumours with ERG rearrangement have increased lesions in PTEN and 
TP53, the high prevalence of ETS fusions and its association with other 
oncogenic proteins led to its evaluation as a therapeutic target. A popular 
interacting enzyme involved in DNA repair, poly (ADP-ribose) polymerase 1 
(PARP1) is under clinical investigation in numerous cancers (Fathers et al., 
2012). Studies have shown inhibiting PARP1 leads to decreased growth of 
ETS fusion-positive lesions. 
 
1.5.2.3 Speckle-type POZ protein (SPOP) mutations 
Mutations in the speckle-type POZ protein (SPOP) gene are the most 
common point mutations seen in primary PCa, representing recurrent 
mutations in 6-13% (Barbieri et al., 2012). SPOP mutations are mutually 
exclusive with TMPRSS2-ERG fusion and TP53 mutations (Barbieri et al., 
2012). Another well-studied protein is the serine peptidase inhibitor, Kazal 
type 1 (SPINK1), when overexpressed, is associated with decreased 
biochemical recurrence-free survival (Tomlins et al., 2008). 
 
1.5.2.4 Somatic Copy Number Aberrations and gene expression  
Somatic copy number aberrations (SCNAs) are the gain or loss of segments 
of DNA, leading to oncogenes amplification or TS genes deletion. SCNAs 
are associated with high-grade disease, advanced tumour stage and other 
factors associated with poor prognosis reflecting the importance of genomic 
instability in prostate tumorigenesis (Robbins et al., 2011; Tapia-Laliena et al., 
2014).  
 
1.5.2.5 Cytokine signalling 
As discussed earlier, inflammation and immunobiology is becoming an 
‘emerging’ cancer hallmark (Hanahan et al., 2011). Cytokine-signalling 
pathways have been shown to be implicated in PCa. The inflammatory 
cytokine Interleukin-6 (IL-6) is overexpressed in PCa and regulates cell 
proliferation, apoptosis and angiogenesis through activation of multiple 
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downstream pathways, such as MAPK (Nguyen et al., 2014). Clinical trials 
testing anti-IL6 antibody have been initiated (Karkera et al., 2011). In addition, 
Inhibitors of cytokine-signalling 3 inhibits apoptosis in AR-negative models 
(Puhr et al., 2009). 
 
1.6 Epigenetics of prostate cancer 
Epigenetic mechanisms are inheritable changes that alter expression without 
changing gene sequence or chromosomal structure. The three main 
components of epigenetics include DNA methylation, chromatin remodelling 
and microRNA (miRNA) regulation (Feinberg et al., 2004; Catto et al., 2011; 
Jerónimo et al., 2011). These mechanisms are reversible unlike genetic 
events.  
 
1.6.1 DNA methylation 
DNA methylation is the best-studied epigenetic change and occurs mostly at 
cytosines followed by a guanine nucleotide (within CpG dinucleotides). An 
addition of a methyl group to the fifth carbon of the cytosine residue ring 
produces 5-methylcytosine (m5C). This process is mediated by DNA 
methyltransferase (DNMT) and uses S-adenosylmethionine (SAM) as the 
methyl donor (Lopez-Serra et al., 2008). DNA hypomethylation is associated 
with oncogenes activation and genetic instability, and DNA hypermethylation 
is thought to promote gene silencing (Sharma et al., 2010).  
 
Cytosine hypomethylation has been shown to be present in metastatic PCa 
affecting chromosome instability and disease progression (Bedford et al., 
1987). Repetitive DNA regions such as LINE1, are hypomethylated in 
approximately 50% of PCa, and more abundant in lymphatic metastases 
(Santourlidis et al., 1999). Genes found to be upregulated following promoter 
hypomethylation in PCa include IGF2, CAGE, CYP1B1, HPSE, PLAU, 
CRIP1, S100P, WNT5A (Jerónimo et al., 2011). Interestingly, PLAU gene 
encodes urokinase plasminogen activator and is associated with castration-
resistance. 
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DNA hypermethylation is the best-known epigenetic mechanism in PCa and 
over 50 hypermethylated genes have been described.  The genes that are 
hypermethylated play key roles in cell cycle control (CCND2, CDKN2A), 
apoptosis (ASC, BCL2), hormone response (AR, ESR2), DNA repair (GSTP1, 
GSTM1), signal induction (EDNRB, RASSF1A, DKK3) and tumour invasion 
(APC, CAV1, CDH1) (Jerónimo et al., 2011). Identification of 
hypermethylation (APC, CCND2, GSTP1, PTGS2, RARB2, RASSF1A) in 
HGPIN and normal prostate tissue, suggests that epigenetic events may 
occur early in the onset of prostate oncogenesis.  
 
1.6.2 Histone and chromatin modifications 
DNA is wrapped around histones to form chromatins and further packed into 
units of nucleosomes forming chromosomes. Histones regulate DNA 
transcription, repair and replication, and are prone to post-translational 
modification (histone ’tail’) for example: acetylation, methylation and 
phosphorylation (Lennartsson et al., 2009). Histone modifications are thought 
to form a code (histone code) and are associated with transcription activation 
or repression, and DNA methylation (Jenuwein et al., 2001; Esteller, 2008).  
 
Mutated genes involved in histone modifications include the lysine (K)-
specific demethylase 6A gene (KDM6A) and the myeloid/lymphoid or mixed-
lineage leukaemia 2 and 3 gene (MLL2, MLL3). These genes encode 
proteins that alter methylation of the histone variant H3, which is involved in 
the regulation of chromatin states and transcriptional control. The 
chromodomain helicase DNA binding protein 1 gene (CHD1) encodes a 
binding protein that remodels chromatin states, and is recurrently deleted in 
PCa at around 10-25%. Primary and metastatic PCa with CHD1 deletion 
have an increase in genomic rearrangements (Barbieri et al., 2013).  
 
Several histone-modifying enzymes including histone deacetylase (HDAC), 
histone methyltransferase (HMT) and histone demethylase (HDM) are 
altered in PCa. The best-studied HMT enzyme is Histone-lysine N-
methyltransferase (EZH2) which catalyses the trimethylation of histone 
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H3K27 and dimethylates H3K9 (Cao et al., 2002). EZH2 upregulation is 
associated with promotor hypermethylation and repression of some genes 
resulting in increased proliferation rate and aggressiveness of PCa (Viré et 
al., 2006).  Overexpression of HDM and HDAC are associated with hormone-
refractory disease. Interestingly, HDAC1 is also overexpressed in PCa 
containing TMPRSS2-ERG fusion (Halkidou et al., 2004). The HDM, lysine-
specific demethylase 1 (LSD1) removes methyl groups from H3K4 and H3K9, 
and overexpression is associated with aggressiveness and CRPC (Metzger 
et al., 2005). 
 
1.6.3 Non-coding and MicroRNAs 
RNAs are transcribed from DNA in the nucleus and are formed of two types, 
ones that are translated into protein (coding-RNAs) and ones that are not 
translated (ncRNAs). Short ncRNAs, named microRNA (miRNA) are around 
19-22 bases in length, and were first documented in 1993 (Miah et al., 2014). 
miRNAs are synthesized (pri-miR) and processed in the nucleus (pre-miR) 
before exportation to the cytoplasm (mature miR). Nearly 2000 miRNAs are 
now reported (see http://www.mirbase.org). The prefix ‘miR’ is followed by a 
number, the latter indicates order of naming/discovery. A capitalized ‘miR’- 
refers to the mature form of miRNA and the uncapitalized ‘mir’ refers to the 
pre/pri-miRNA forms.  The 5’ end of a miRNA contains the ‘seed’ region that 
binds mRNAs with complementary sequences at the 3’ untranslated region 
(3’ UTR) (Bartel, 2009). The miRNA-mRNA pairing recruits a RNA-induced 
silencing complex (RISC) to modulate mRNA expression (Figure 12). Each 
miRNA can interact with multiple mRNAs and each mRNA can be targeted 
by multiple miRNAs. Up to 30% of human genes are regulated by miRNAs. 
MicroRNAs (~40%) are located within coding mRNAs (intronic or exonic) or 
on their own close to CpG islands (~20-40%), and exist solitarily or in 
clusters (~30%). Around 30% of miRNAs are clustered, meaning that a 
single miRNA triggered event can affect several miRNAs within the same 
cluster altering thousands of mRNA/protein targets. (Catto et al., 2011). 
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Figure 12. Illustration of RNA synthesis and regulation of mRNA. 
RNA is transcribed from DNA in the nucleus. mRNAs are exported and translated 
into proteins in the cytoplasm. miRNAs contain the ‘seed’ region at the 5’ end and 
bind complementary sequences at the 3’ UTR end of mRNAs. The pair recruits a 
RNA-induced silencing complex (RISC) which binds target mRNAs resulting in 
degradation (perfect complementation) or altered translation (imperfect 
complementation) of the target mRNAs. 
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1.6.4 MicroRNA and prostate cancer  
Porkka et al reported the first systematic profiling of miRNA expression in 
PCa comparing the aberrant expressions of miRNA in PCa and benign 
prostate cells (Porkka et al., 2007). To date, over 100 reports have 
investigated miRNA expression in PCa using both cell lines and prostate 
specimens.  
 
MicroRNA expression are altered in cancer acting as oncogenes when 
overexpressed, or tumour suppressors when underexpressed (Garzon et al., 
2009). Interestingly miRNAs are also involved with DNA methylation and 
chromatin modification, suggesting interlinks between the three major 
epigenetic events (Guil et al., 2009). Approximately 50 miRNAs (Table 5) 
have been reported in PCa, however, not all have been proven to contribute 
to the disease. In PCa, miRNAs are associated with AR-signalling or 
androgen-independent growth (MiR- 125b, 146a, 221, 222, 331, 488) and 
avoidance of apoptosis (MiR- 21 and 34a and c) (Catto et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
77	
 
Table 5. MicroRNAs expression in prostate cancer. 
A range of miRNAs has been identified and investigated in prostate cancer. 
Common miRNA upregulated and downregulated in prostate cancer, along with 
their target mRNAs and associated downstream pathways are summarized in this 
table. All pathways are associated with oncogenesis (Catto et al., 2011; Fabris et al., 
2016). 
 
AI, androgen-independence. 
 
MiRNA mRNA target Pathway 
Upregulation miR- 
20a 
21 
24 
25 
32 
93 
106b 
125b 
148a 
221 
222 
521 
 
E2F1-3 
PTEN, AKT, androgen pathway 
FAF1 
PTEN 
BCL2 
LATS2 
P21, E2F1 
P53, BAK1 
CAND1 
P27 
P27 
Cockayne syndrome protein A 
 
Apoptosis 
Apoptosis, mTOR, AI 
Apoptosis 
Proliferation 
Apoptosis 
Metastasis  
Apoptosis, cell cycle 
Apoptosis 
Cell cycle 
Cell cycle, AI 
Cell cycle, AI 
DNA repair 
Downregulation miR- 
1 
7 
15a-16 cluster 
34a 
34c 
101 
107 
125b 
143 
145 
146a 
148a 
205 
331-3p 
449a 
1206 
let-7a 
let-7b 
 
Exportin 6, tyrosine kinase 9 
ERBB-2 (EGRF, HER2) 
CCDN1, Wnt3a 
HuR/Bcl2/SIRT1 
E2F3, Bcl2 
EZH2 
Granulin 
BAK1 
MYO6, ERK5 
MYC, MYO6 
ROCK1 
MSK1 
IL-24, -32 
ERBB-2, CDCA5 
HDAC-1 
MCM family 
E2F2, CCND2 
Ras, CycD1 
 
Gene expression 
Signal transduction 
Cell cycle, apoptosis 
Apoptosis  
Apoptosis, proliferation 
Gene expression 
Proliferation 
Apoptosis, AI 
Cell migration, proliferation 
Cell migration, apoptosis 
Proliferation, invasion 
Proliferation, stress response 
Cell growth, invasion, EMT 
Signal transduction, cell cycle 
Gene expression 
DNA replication 
Cell cycle, proliferation 
Cell cycle, apoptosis 
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1.6.4.1 MicroRNA and cellular pathways 
Avoidance of apoptosis can be driven by many miRNAs in PCa. For example, 
the overexpression of miR-20a (also miR25/205) leads to the inhibition of 
transcription factor E2F1, which in turn, results in cell proliferation and 
reduced p53 and caspase-mediated apoptosis (Sylvestre et al., 2007; 
Gandellini et al., 2009). miR-21 targets programmed cell death 4 (PDCD4) 
and PTEN mRNAs to suppress apoptosis (Lu et al., 2008). Reduced levels of 
miR-34 has also been shown to inhibit silent information regulator 1 (SIRT1), 
which inhibits p53 mediated apoptosis. Reduced levels of p53 further inhibits 
miR-34 resulting in an auto-regulatory loop (Yamakuchi et al., 2008).  
 
miR-15 and -16 are downregulated in ~80% of prostate tumours. Loss of 
these two miRNAs induces upregulation of cyclin D1 and increased cell 
proliferation. In addition, reduced miR-15/16 facilitates pro-carcinogenic (cell 
proliferation and migration) Wnt pathway activation (Bonci et al., 2008).  
 
DNA repair is an important activity in suppressing oncogenesis. Stress, 
radiation or any form of mechanism that causes DNA damage leads to a 
complex DNA repair cascade. Upregulation of miR-521 in PCa cells reduces 
cell response to cell damage by targeting Cockayne syndrome protein A 
(CSA). miR-34 exert a similar effect through p53 regulation (Josson et al., 
2008). 
 
1.6.4.2 MicroRNA and androgen-signalling  
Androgen-signalling is one of the most important PCa specific activity. There 
is a complex link between miRNAs and the androgen pathway. miR-125b is 
regulated by androgens via an androgen-responsive element (ARE), and 
upregulation results in androgen-independent growth in LNCaP cells and 
suppression of apoptosis by targeting BAK1 and p53 (Shi et al., 2007, 2011). 
Through miRNA profiling studies, miR-146a has been found to be 
downregulated in hormone-resistant cell lines and transfection with miR-146a 
results in suppression of ROCK1 and subsequently reduced cell proliferation, 
invasion and metastasis (Lin et al., 2008). miR-141 is upregulated in 
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androgen-regulated cells, and its overexpression results in increased PCa 
growth (Waltering et al., 2011). miR-221 and -222 are both upregulated in 
CRPC cells and exhibit androgen-independent growth of prostate cell lines 
(Sun et al., 2009). ERBB-2 tyrosine kinase receptor is overexpressed in PCa 
and is associated with disease progression and androgen-signalling. miR-
331-3p expression is decreased in PCa and transfection of miR-331-3p 
results in reduced ERBB-2 mRNA and downstream PI3KAKT signalling, and 
blockade of the AR-signalling pathway (Epis et al., 2009). 
 
1.6.4.3 MicroRNA as biomarkers 
Evolving information on the roles of microRNAs has established them as 
potential biomarkers and therapeutic targets. They are utilized as urinary 
markers for diagnosing urological cancers and appear to show great 
potential in managing cancers (Miah et al., 2012). Short or microRNAs 
appear to be promising biomarkers as their small size protects them from 
endogenous RNase degradation. They are stable, active and resistant to 
freeze-thawing (Miah et al., 2012). Its ability to individually, or as clusters to 
interact with multiple mRNAs involved in PCa pathways makes them 
attractive as therapeutic targets. In addition, short/miRNAs are detectable in 
urine, blood/serum, ejaculate and prostate tissue, which are ideal patient 
specimens to use for diagnosing or monitoring disease 
progression/recurrence in a clinical setting (Fabris et al., 2016). Current 
techniques available for miRNA detection include quantitative real-time 
polymerase chain reaction (qRT-PCR), microarray and small RNA 
sequencing.  
 
Many studies report numerous upregulated and downregulated miRNAs, with 
conflicting data. This reflects different profiling strategies, differences in 
analytical thresholds, study design (samples and methods) and disease 
heterogeneity. miRNA expression is variable and differs according to the 
phases of development (initiation, progression or metastasis) or treatment 
exposure (ADT, radiotherapy, chemotherapy). This diversity allows in-depth 
evaluation and search for miRNAs as diagnostic and prognostic markers.  
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Many studies have looked into miRNA as diagnostic and prognostic 
biomarkers. Fabris et al conducted a systematic review and highlighted 
plasma miRNAs that were consistently altered in PCa with diagnostic 
properties. These miRNAs include upregulatory, miR-141, 375, 221, 21; and 
downregulatory, miR-181a (Fabris et al., 2016). 
 
Profiling experiments report some consistency in results for miRNAs as 
diagnostic markers. Once PCa is diagnosed and management initiated in the 
form of radical surgery or radiotherapy, or hormonal therapy, disease 
recurrence needs to monitored. This usually requires clinical examination, 
imaging, and some form of biomarker measurement. PSA is expected to fall 
following surgery/hormones, thus patients with detectable PSA after surgery 
are thought to have biochemical recurrence (BCR) and detectable PSA 
following hormonal treatment are thought to have progressed to CRPC (if 
testosterone is <20ng/dl). 
 
miRNAs have been investigated as biomarkers for BCR and progression of 
PCa to CRPC and metastatic PCa. Studies focus on analysing RP and PBx 
specimens and bodily fluids. Some of the miRNAs implicated in BCR include 
miR-96 (Schaefer et al., 2010; Haflidadóttir et al., 2013; Ilic et al., 2016), -21 
(Melbø-Jørgensen et al., 2014; Leite et al., 2015), -221 (Martens-Uzunova et 
al., 2012) and -1193, -4516, -626 (Bell et al., 2015). Larne et al established a 
miR index quote (miQ) that could predict PCa aggressiveness and metastatic 
status, and BCR following RP. The miQ consists of two upregulatory (miR-
96-5p and miR-183-5p) and two downregulatory (miR-145-5p and miR-221-
5p) miRNAs (Larne et al., 2013).  
 
As with BCR, numerous miRNAs have been identified to be associated with 
the onset of CRPC or mCRPC. These include, miR-21 (Ribas et al., 2009), -
141 (Agaoglu et al., 2011), -221, -222 (Sun et al., 2012), -375, 1290 (Huang 
et al., 2015). Interestingly most of these miRNA markers of CRPC are also 
linked to the AR-signalling pathway, such as miR-21, -221 and -222. So far, 
miR-221 appears to be the most promising diagnostic and prognostic 
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biomarker, and is associated with clinico-pathologic factors including the 
Gleason score and clinical recurrence (Spahn et al., 2010; Agaoglu et al., 
2011; Larne et al., 2013).  
 
1.6.4.4 RNA methylation 
DNA methylation is known to be a common and important epigenetic 
modification. The final production of proteins give rise to individual 
phenotypes. Since RNA translation is the final step of gene expression, RNA 
modifications have also been evaluated extensively. More than hundred 
types of post-transcriptional modifications have been identified since the 
1950s. RNA methylation is the most common modification and has been 
known since the 1970s. Methylation can occur at the adenosine (m6A) or 
cytosine (m5C) residues, and at nucleotides (Nm) (N. Liu et al., 2014). The 
interest in N6-methyladenosine (m6A) revived when Jia et al found that m6A 
was reversible through demethylator (eraser) FTO (Fat mass and obesity-
associated protein). The methyl group is donated from SAM (also implicated 
in DNA methylation) and is mediated by methylators (writers) such as N6-
adenosine-methyltransferases METTL3 and METTL14. The m6A machinery 
(Figure 13) is diverse and consists of ‘writers’ (methylators, METTL3), 
‘erasers’ (demethylators, FTO) and ‘readers’ which facilitates and potentiates 
methylation (YTH domain family member, YTHDF3) (Niu et al., 2013; Fu et 
al., 2014).  
 
The first writer identified is METTL3 encoded by the METTL3 gene, and 
knock down of METTL3 leads to apoptosis in human cell lines. METTL14 
also catalyses m6A methylation and form complexes with METTL3 (J. Liu et 
al., 2014). The METTL3-METTL14 complex interacts with Wilm’s tumour 1-
associating protein (WTAP), which is a mRNA splicing regulator involved in 
controlling cell cycles through stabilization of cyclin A2 mRNA (Horiuchi et al., 
2006). Knock down of WTAP results in the largest decrease in m6A in Hela 
cell lines, indicating that WTAP has an important role in methylation, possibly 
through enhancing recruitment of METTL3-METLL14 complex to target 
RNAs (J. Liu et al., 2014).  Silencing of the METTL3-METTL14 complex led 
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to an increase in levels of their target RNAs, suggesting that m6A acts as a 
negative regulator of gene expression (J. Liu et al., 2014).  
 
The first m6A eraser described was the Fat mass and obesity associated 
enzyme (FTO), which removes the methyl group through oxidation (Jia et al., 
2011). The functional consequences of such demethylation are unclear, 
however, the discovery of this first demethylator indicates that m6A is subject 
to sophisticated control. Another m6A eraser is the protein encoded by the 
alkB, alkylation repair homolog 5 (ALKBH5) gene which belongs to the same 
protein family as FTO (Zheng et al., 2013). ALKBH5 knockdown in human 
cell lines results in increased m6A levels and accelerated export of these 
RNAs from the nucleus to the cytoplasm (Zheng et al., 2013). 
 
Embryonic lethal, abnormal vision (ELAVL1) binds UA-rich regions located in 
3’UTR sites of mRNAs (Kundu et al., 2012). RNA-ELALV1 interactions 
regulate the stability of many mRNAs in embryonic stem cells in a m6A-
dependent manner (Y. Wang et al., 2014). YTH-domain family protein, 
YTHDF2 binds more than 3000 cellular RNAs and competes with ribosomes 
for translatable mRNAs. Successful binding results in mRNA localisation to 
mRNA decay sites such as processing bodies (X. Wang et al., 2014). 
Several cytoplasmic mRNA degradation pathways have been established 
(Schoenberg et al., 2012), however, the YTHDF2-mediated mRNA 
degradation is dependent on the methylated state of the target mRNA. 
Therefore, the m6A state of mRNA could regulate its rate of degradation. 
YTHDF1 has been reported to interact with initiation factors to promote 
translation (X. Wang et al., 2014). Recently, eukaryotic initiation factor 3 
(eIF3) has been shown to bind to m6A 5’UTR and promote translation under 
stress (Meyer et al., 2015). HNRNPA2B1 is a nuclear reader of m6A and on 
binding, regulates pre-mRNA processing and splicing (Alarcón et al., 2015). 
 
Knowing that m6A is reversible and is associated with inflammatory and 
malignant (Leukaemia, prostate, breast, colorectal, gastric) processes, it has 
become a target for mass investigation into biological significance and 
clinical relevance (Maity et al., 2015). The m6A distribution has been 
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mapped in liver cell lines, however, its distribution and significance in PCa 
has not been evaluated to date (Dominissini et al., 2012). The methylation of 
N6-adenosine in PCa will be explored in this project. 
	
	
	
	
	
 
Figure 13. The N6-methyladenosine machinery. 
Over one hundred post-transcriptional modifications have been described. RNA 
methylation is the most common RNA modification and the most common 
methylated site is at the adenosine base (m6A). N6-adenosine methylation is 
induced by ‘writers’ including METTL3/14 and WTAP. This process is reversible and 
demethylation is mediated by ‘erasers’ such as FTO and ALKBH5. RNAs that are 
exported into the cytoplasm are modulated by ‘readers’ including ELAVL1, 
YTHDF1-3, eIF3 and HNRNPA2B1, which can affect mRNA processing, 
exportation, storage, translation and RNA degradation.  
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1.7 Aims 
The evolving knowledge on the biological basis of PCa has allowed the 
development of markers to aid PCa diagnosis, stratify men for PBx and 
monitor PCa recurrence (BCR) post-treatment (Post- surgery, radiotherapy 
or hormonal therapy).  
 
Prostate cancer is a heterogeneous disease and some of the current 
problems include, 1) a lack of rPBx protocol for patients with initial negative 
PBx. Automatic rPBx possess procedural complications, and the risk of over-
diagnosing and over-treating indolent PCa. Likewise, under-performing rPBx 
may result in mis-diagnosing aggressive disease; 2) there are no biomarkers 
that could reliably stratify localised disease from advanced (metastatic) 
disease on (r)PBx, or biomarkers that could predict progression of PCa to 
CRPC (when on ADT treatment) or metastatic disease. Hence, urgent 
investigations into new biomarkers with greater sensitivity and specificity are 
needed. This is the ultimate aim of the current project. 
 
International data suggests that the PCa diagnostic rate on rPBx is ~30% 
(Keetch et al., 1994; Djavan et al., 2001). However, rPBx data is not readily 
available from a UK cohort of patient, therefore a retrospective analysis was 
performed to identify the rPBx rate in the Sheffield cohort of patients within 
the national ProtecT RCT and to identify men/specimens for subsequent 
laboratory analyses.  
 
Knowing that ncRNA PCA3 is currently the most prominent FDA approved 
urinary marker to date, we aimed to evaluate this RNA further. PCA3 is a 
long ncRNA and is vulnerable to digestion by urinary RNase, hence prior to 
analysis in the laboratory, urinary samples need to be treated with RNA 
inhibitors which ensures a high cost. In addition, the biological role of PCA3 
is unknown, therefore it’s not widely adopted worldwide, including the UK 
NHS. As discussed earlier, short or miRNAs are more stable and active 
species than long RNAs, in addition, we know that long RNAs are processed 
into shorter forms (Röther et al., 2011). With this in mind, we aimed to 
explore this marker to overcome some of the issues related to it, by 
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identifying a shorter segment within PCA3 and exploring potential biological 
roles of short-PCA3. 
 
As the project progressed, an increasing interest in RNA methylation 
occurred. DNA methylation is a key component of epigenetic pathways in 
cancer. Although RNA methylation has been investigated extensively in the 
past, a specific methylated site, N6-methyladenosine (m6A) has been shown 
to be reversible and implicated in cancer. These recent findings initiated 
further investigation amongst groups interested in cancer epigenetics. Since 
there are no current data on PCa and m6A, this thesis set out to identify the 
distribution of m6A in PCa through an in-silico analysis, followed by 
laboratory evaluation. 
 
In summary, the aim of this thesis was to develop molecular strategies to 
rationalise rPBx in men with elevated PSA. In order to achieve this, the 
following was undertaken: 
  
1) A clinical analysis of rPBx outcomes of men who had an initial 
negative PBx but persistent suspicion of PCa. 
 
2) Identification of a short segment of PCA3 that could potentially replace 
the current PCA3 assay, and evaluation of its diagnostic and 
biological role.  
 
3) Identification of the distribution of m6A in PCa.  
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1.8 Significance  
Prostate cancer is the most common cancer in men and is the second most 
common cause of cancer-related death in the UK. Early diagnosis can 
improve the care of men with this disease, if cases are identified in a prompt 
manner and then managed with the most suitable care pathway (such as 
surveillance for low-risk and radical treatment for high-risk disease). This 
project aimed to improve the detection of PCa and disease progression using 
a small RNA within PCA3 or methylated (specifically, m6A) transcripts that 
are known to be implicated in PCa. With regards to the future, therapeutic 
RNA molecules that target small ncRNAs are in phase 2 and phase 3 clinical 
trials (see http://www.santaris.com/product-pipeline) of hepatitis and sold 
tumours. As such, short RNAs could represent a therapeutic target within 
PCa.	
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CHAPTER 2: Materials and Methods 
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2.1 ProtecT and ProMPT studies 
 
2.1.1 Patient recruitment, consent and ethical approval 
All samples including urine and PBx tissue used in the current study were 
obtained from patients within the ProtecT (Prostate testing for cancer and 
treatment) and ProMPT (Prostate Cancer: Mechanisms of Progression and 
Treatment) studies (Donovan et al., 2003; Lane et al., 2010, 2014; Hamdy et 
al., 2016). Men recruited into the ProtecT study were identified from 
community medical practices across nine cities within the UK. Letters of 
invitation detailing the rationale for the ProtecT study were sent to medical 
practices, and participating practices in turn sent letters inviting men aged 
between 50 and 69 years with no prostatic symptoms and prior PSA testing 
to attend for PSA counselling. Nurse led clinics were held in a primary care 
setting, where participants with an estimated life expectancy of a minimum of 
ten years and without significant cardio-respiratory co-morbidity were given 
detailed information about the implications of PSA testing, treatment 
uncertainties and the need for a RCT. Consent was obtained thereafter for 
PSA testing.  
 
Men with an initial, single PSA value between 3.0 and 19.9ng/ml were 
offered a TRUS-PBx. Men with a positive biopsy and a diagnosis of localised 
PCa were randomised to one of the three treatment arms, 1) active 
surveillance, 2) radical radiotherapy or 3) radical prostatectomy. Shortly after 
the commencement of recruitment, a new study, ProMPT was initiated. This 
study focused on in-vitro and in-vivo analysis of specimens collected from 
ProtecT patients. A detailed rationale for the study was discussed with 
ProtecT patients and a new consent was sought for permission to collect and 
analyse their urine, blood and tissue specimens.  
 
Between 2001 and 2009, 227,000 men were identified at 352 practices and 
invited for PSA counselling within the ProtecT study at a nurse led clinic. A 
total of 111,148 men attended and 10,297 were offered TRUS-PBx. Within 
the Sheffield cohort, 16,656 men were invited for PSA testing, 10,412 
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underwent testing, and 920 had a TRUS-PBx. Prostate cancer was 
diagnosed in 321 men within Sheffield and were subject to randomization 
(Figure 14). The 599 men who had a negative PBx were included in the rPBx 
analysis (Chapter 3).  
 
The ProMPT study began recruitment in 2002 and all centres have stopped 
recruitment except for Oxford at the time of writing. To date, 6414 men have 
consented to participate in ProMPT. Sheffield recruited 1578 men between 
2002 and 2015. ProMPT is a collaborative translational research group 
studying advanced and progressing PCa, focusing on molecular pathology.   
 
Baseline clinical and histopathological data including age at initial PBx, age 
at diagnosis of cancer, number of PSA tests and PBx undergone per patient, 
PSA value/PSA kinetics, PBx characteristics (laterality, number cores, taken, 
number cores positive and length), Gleason score, stage were obtained from 
the ProtecT database, or from laboratory (ICE)/radiological (PACS) computer 
resources at the Royal Hallamshire Hospital, Sheffield Teaching Hospitals 
NHS Trust.  
 
The ProtecT study is registered with clinicaltrials.gov (NCT02044172), and 
as an International Standard Randomised Controlled Trial 
(ISRCTN20141297). The ProtecT trial and the later ProMPT study received 
approval from the Trent Multicentre Research Ethics Committee, MREC 
(HTA 96/20/06; HTA 96/20/99) and the National Research Ethics Service 
(NRES 01/04/061).   
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Figure 14. Flow chart of the study population within the ProtecT/ProMPT study.  
Patients were recruited from nine UK cities (Blue map) between 2001 and 2009. Within Sheffield, a total of 321 men were diagnosed with PCa 
on first biopsy, 599 men had a negative biopsy and were subject to a rPBx.  
 
ProtecT, Prostate testing for cancer and treatment; PSA, prostate-specific antigen; TRUS-PBx, transrectal ultrasound-guided prostate biopsy; 
PCa, prostate cancer. 
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2.2. General laboratory equipment and reagents 
 
2.2.1 Laboratory equipment 
 
Glassware 
Glassware used for this project was washed with RBS detergent (Chemical 
concentrates), tap water and de-ionised water. Washed glassware was dried 
in a hot oven and items that required sterilization were autoclaved for 15 
minutes at 15p.s.i. 
 
-800C freezer      Sanyo 
40C, -200C fridge/freezer     Liebherr 
Ice machine AF100      Scotsman 
Heraeus megafuge 40     ThermoFisher 
Geneflow microcentrifuge     Sigma 
Vortex genie 2      Scientific Industries 
Sub-aqua dual water bath     Grant 
Barnsread nanopure water system   ThermoFisher 
Forma CO2 incubator     ThermoFisher 
GeneAmp PCR 2700 (Thermal cycler)   Applied Biosystems 
HT7900 PCR system     Applied Biosystems 
Qiagen rotor-gene PCR     Qiagen 
Biological safety cabinet     ThermoFisher 
Nanodrop bioanalyzer     Agilent 
P2, 10, 20, 200, 1000 pipettes    Gilson 
Immunoprecipitation magnetic rack   ThermoFisher 
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2.2.2 Plastic and disposable equipment 
 
Plastic pasteur pipettes     Deltalab 
5, 10, 25ml Plastic pipettes    Sigma-Aldrich 
Filter tips for Gilson P10, 20, 200, 1000   Sarstedt 
0.5, 1.5, 2ml eppendorf tubes    Sigma-Aldrich 
1.5, 2ml microcentrifuge tubes    Sigma-Aldrich 
15ml, 50ml centrifuge tubes    Sigma-Aldrich 
BD Microlance 21G, 23G needles    Medisave 
Plastipak 1ml, 3ml syringes    Medisave 
T75, T175 NUNC cell culture flasks with filter cap ThermoFisher 
Nalgene cryogenic 2ml vials    Sigma-Aldrich 
Microamp 0.1, 0.2ml PCR tubes    ThermoFisher 
96 well PCR plates      Starlab 
8 strip PCR caps      Starlab 
384 well PCR plates     Starlab 
384 well PCR plate seals     Starlab 
Semperguard nitrile powder-free gloves   Sempermed 
 
2.2.3 General laboratory chemicals and reagents 
 
Ethanol       ThermoFisher 
Precept       Johnson and Johnson 
FCS (Fetal calf serum)     Seralab 
NEAA (Non-essential amino acid)    Lonza 
Penicillin-Streptomycin     Sigma-Aldrich 
Trypsin       Lonza 
DMSO (Dimethyl-sulfoxide)     Sigma-Aldrich 
Molecular biology water     Sigma-Aldrich 
b-Mercaptoethanol (b-ME)     Sigma-Aldrich 
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2.3 General materials and methods 
	
2.3.1 Cell Lines and cell cultures 
a) Cells (Table 6) were purchased from ATCC and grown in appropriate 
media according to standard methods (https://www.lgcstandards-
atcc.org/Products/Cells_and_Microorganisms/Cell_Lines.aspx?geo_c
ountry=gb) (Leiblich et al., 2006). 
 
 
Table 6. Prostate cell lines. 
The common prostate cell lines used in the current studies are demonstrated. Its 
sensitivity to androgen, origin and sites of metastasis are detailed in this table. 
LNCaP-LN3 is the metastatic sibling of LNCaP (Sobel et al., 2005a). 
 
b) Phosphate Buffered Saline (PBS) 
Oxoid PBS tablets were purchased from Unipath Ltd. One tablet of PBS was 
dissolved in 100ml de-ionised water and autoclaved at 1150C for 10 mins to 
sterilize.  
 
All cell lines were cultured in T75 and T175 flasks with filtered caps in 30-
60ml RPMI L-Glutamine (Lonza) media supplemented with: 10% (50ml) FCS, 
10ml Penicillin (10,000U)-streptomycin (10mg), 10ml NEAA (10mM). LNCaP 
cells, LNCaP-LN3, DU145 or PC3 cells (Sobel et al., 2005a, 2005b) were 
split or harvested when they reached 80-90% confluence. All cell lines were 
incubated at 370C and 5% CO2 and grown in monolayer.  
On harvesting, RPMI medium was removed and cells washed twice with 10-
25ml PBS depending on the size of the flask. A volume of 1.5-3ml of Trypsin 
Cell Line Androgen-sensitive Derivation Metastasis 
LNCaP Yes Lymph nodes Lymph nodes 
LNCaP-LN3 Less than LNCaP Lymph nodes Lymph nodes 
DU145 No Brain Liver, lung 
PC3 No Vertebrae Liver, lung, bone 
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was added and flasks incubated for 5mins at 370C to detach adherent cells. 
Cells were lifted of the base and either redistributed into two new flasks 
containing media (splitting) or washed again with PBS (to inactivate trypsin) 
for cell counting. 
 
For counting, cells were re-suspended in PBS and 10µl was used for the 
microscope-counting chamber (hemocytometer). Cells in two 4x4 (1mm) 
quadrants were counted and the total divided by two, giving X x104 number 
of cells per ml. Cells were washed with PBS after counting and either stored 
at -800C or used immediately for RNA extraction. 
 
2.3.2 Urinary sample preparation 
All urinary samples were obtained from patients within the ProtecT and 
ProMPT studies. Samples were collected in out-patient urology consultant or 
nurse led clinics at Royal Hallamshire Hospital, Sheffield. In order to optimize 
samples for PCA3 analysis, urine was obtained following prostatic massage 
(Hessels et al., 2003). The first 10-20ml of freshly voided urine was collected 
and immediate centrifugation at ~3,300g for 10 mins was undertaken.  The 
supernatant was removed and the cell pellet washed twice in PBS before 
freezing at -80oC until use.  
 
2.3.3 Prostate tissue collection 
All prostate tissue samples were obtained from men within the ProtecT and 
ProMPT studies. Out-patient TRUS-PBx was carried out in the left lateral 
decubitus position under peri-prostatic infiltration of local anaesthetic (1-2% 
Lignocaine) and antibiotic cover by using a 10-core lateral biopsy template. 
Saturation biopsies (20-30 cores) +/- transurethral resection biopsies of the 
transitional zones of the prostate (TURP) were performed in selected men 
with >1 negative rPBx at the discretion of the attending clinician.  
  
2.3.3.1 Prostate tissue fixation and embedding 
Formalin-fixed Paraffin embedded (FFPE) tissues were prepared as follow. 
Fresh PBx cores of tissue were fixed in freshly prepared 4% 
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paraformaldehyde for 3 hours at room temperature. The specimens were 
dehydrated by passing through ascending alcohol concentrations (50% for 
30 mins; 70% 30 mins; 90% 1 hour; absolute for 1 hour), then cleared in 
xylene for 30 mins at 600C in a glass pot. The tissue was then embedded in 
a 1:1 xylene/molten paraplast mixture at 600C for 30 mins, then in fresh 
paraplast at 600C and allowed to solidify by cooling to room temperature. 
Embedded blocks were stored at room temperature in the histopathology 
department, Royal Hallamshire hospital until use. 
 
2.3.3.2 FFPE sectioning  
In order to obtain enriched tissue for analysis, the best block with the most 
abundant tissue visually from each patient was subject to sectioning. A 
microtome was used to cut 4x 10µm section per block, placed in 1.5ml 
eppendorf tubes and stored at -200C (Performed by Maggie Glover). 
 
2.4 Specific materials and methods 
 
2.4.1 RNA Extraction  
Total and/or miRNA were extracted from cell lines, urinary pellets and FFPE 
prostate biopsies from three different commercially purchased RNA 
extraction kits. 
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2.4.1.1 Cell lines and urinary pellets 
 
a) MirVana RNA Isolation Kit (Ambion) 
This kit was used to isolate RNA from cell lines and urinary pellets for the 
PCA3 study. Extraction was performed according to the manufacturer’s 
protocol.  
 
Materials 
- PBS  
- Acid-Phenol:Chloroform (APC) 
- Lysis buffer 
- miRNA homogenate additive 
- Wash solution 
- Elution solution 
 
Approximately 102-107 cells were washed following re-suspension in PBS 
and placed on ice. PBS was removed and 300-600µl lysis solution for 100-
107 cells was added. Solution was vortexed and pipetted vigorously to 
completely lyse the cells and obtain a homogenous lysate. One tenth volume 
of miRNA homogenate additive was added, mixed well and placed on ice for 
10 mins. A volume (300-600µl) of APC that was equal to the lysate volume 
before the addition of homogenate additive was added, and vortexed for 30-
60 sec. The upper aqueous phase was removed (without disturbing the 
lower phase) and transferred to a fresh tube. For small RNA extraction, 1/3 
(1.25 volume for total RNA) volume of room temperature 100% ethanol was 
added to the previously collected aqueous phase. A filter cartridge was 
placed into a collection tube, and the lysate/ethanol mix was pipetted onto 
the filter cartridge. A max. of 700µl was applied to the cartridge at a time and 
centrifuged at RCF 10,000xg (10,000rpm) for 15 sec to pass the mixture 
through the filter. The mixture was applied in successive applications to the 
same filter. The flow-through was discarded, and repeated until all the 
mixture was through the filter. For total RNAs, the filtrate was subject to 
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wash and RNA elution. Extra steps were required to extract small RNAs 
(described below). 
 
Enrichment for small RNAs 
These steps were only applicable to small RNAs. The filtrate was collected 
and if the initial lysate/ethanol mix was >700µl, the flow-through was 
transferred to a fresh tube, and steps repeated until all of the lysate mixture 
was through the filter. The collected filtrate was pooled 2/3 vol. room 
temperature 100% ethanol was added to the filtrate and mixed. The 
filtrate/ethanol was pipetted onto a second filter cartridge. Up to 700µl can be 
applied at a time. For greater volumes, the mixture was applied in 
successive applications to the same filter. The mix was centrifuged for 15 
sec at RCF 10,000xg (10,000rpm). The flow-through was discarded and 
repeated until all of the filtrate/ethanol was through the filter.  
 
Washing and elution 
The steps in washing and eluting was the same for small and total RNAs. 
700µl of wash 1 solution was applied to the cartridge and centrifuged for 5-
10 sec. The flow-through was discarded and the cartridge was placed into 
the same collection tube. The filter was washed twice with 500µl wash 
solution 2/3. The flow-through was discarded each time, and the filter was 
spun for 1 min after the 2nd wash. The cartridge was transferred into a fresh 
collection tube and 100µl of pre-heated (950C) elution solution (or nuclease-
free water) was applied to the center of the filter. The tube was spun for 20-
30 sec at max. speed to recover the RNA. The eluate (containing RNA) was 
collected and stored at -800C or placed on ice and used immediately for 
reverse transcription PCR to cDNA. RNA was analysed using 2100 
bioanalyzer (Agilent) after purification. The concentration was determined by 
measuring the absorbance at 260nm (A260). The ratio of A260 to A280 
provides an indication of RNA purity.  For highly pure RNA a ratio of 1.8-2.1 
is expected. 
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b) Prime 5 PerfectPure RNA cultured cell kit (Scientific Laboratory 
Supplies) 
 
This kit was used to isolate RNA for the N6-methyladenosine analyses as 
suggested by Dominissini et al (Dominissini et al., 2013). Extraction was 
performed according to the manufacturer’s protocol.  
 
Materials 
- Lysis solution + 143mM b-Mercaptoethanol (b-ME)  
- Wash 1 solution 
- DNase solution 
- DNase wash solution 
- Wash 2 solution 
- Elution solution 
 
Lysis solution (800µl for 20-50x 106 cells) was added to the frozen pellets to 
release nucleic acid from the cells. The lysate was passed through 21 and 
23 gauge needles 8-10 times and vortexed vigorously for 2 mins until pellet 
was resuspended. 400µl lysate was pipetted onto a purification column and 
centrifuged for 1 min at 14,500xg. This was repeated until all the lysate was 
passed through. The column was placed into a new tube and 400µl Wash 1 
solution was added and centrifuged for 1 min at 14,500xg. The column was 
placed into a new tube and 50µl DNase solution was added and incubated at 
room temperature for 15 mins to remove genomic DNA. 200µl DNase wash 
solution was added at centrifuged at 14,500xg for 1min and a further 200µl 
DNase wash solution was added and centrifuged at 14,500xg for 2 mins. 
The column was transferred to a new collection tube and 200µl Wash 2 
solution was added and centrifuged at 14,500xg for 1 min. A further 200µl 
Wash 2 solution was added and centrifuged at 14,500xg for 2 mins. The 
column was transferred to a new collection tube and 50µl Elution solution 
was added and centrifuged at 14,500xg for 1 min. RNA was analysed using 
2100 bioanalyzer (Agilent) after purification. 
 
	
	
99	
2.4.1.2 Prostate biopsy FFPE 
 
miRNeasy FFPE Kit (Qiagen) 
This kit was used to extract total and miRNA for the PCA3 rPBx analysis. 
 
Materials 
- Deparaffinization solution (Qiagen) 
- Protein kinase digestion (PKD) buffer 
- Proteinase K 
- DNase booster buffer 
- DNase I stock solution 
- RBC buffer 
- 100% Ethanol 
- RPE buffer 
- RNase-free water 
 
Approximately 300µl Deparaffinization solution was added to the FFPE 
microdissected sections and vortexed for 10 sec to remove the paraffin. 
Samples were incubated at 560C for 3 mins and allowed to cool to room 
temperature. 150µl Buffer PKD was added, tubes vortexed and centrifuged 
at 11,000xg (10,000rpm) for 1 min. 10µl proteinase K was added to the lower 
clear phase and mixed gently to release RNA from the sections. Samples 
were than incubated at 560C for 15 mins and then at 800C for another 15 
mins. The lower, clear phases were transferred into a new 2ml 
microcentrifuge tube and incubated on ice for 3 mins, then centrifuged for 20 
mins at 20,000xg (13,500rpm). The supernatants were transferred into a new 
microcentrifuge tube and 25µl DNase Booster Buffer and 10µl DNase I stock 
solution were added to eliminate all genomic DNA. Samples were mixed 
gently and incubated at room temperature for 15 mins. 320µl Buffer RBC 
was added to adjust binding condition, and mixed. 1120µl ethanol (100%) 
was added and mixed well by pipetting up and down. 700µl of the sample 
was transferred to an RNeasy MinElute spin column placed in a 2ml 
collection tube and centrifuged for 15 sec at 8,000xg (10,000rpm). The flow-
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through was discarded. This step was repeated until the entire sample has 
passed through the spin column. 500µl Buffer RPE was added to the spin 
column and centrifuged for 15 sec at 8,000xg (10,000rpm). The flow-through 
was discarded. 500µl Buffer RPE was added to the spin column and 
centrifuged for 2 mins at 8,000xg (10,000rpm). The flow-through was 
discarded. The spin column was placed in a new collection tube and 
centrifuged at full speed for 5 mins. The collection tube with the flow-through 
was discarded. The spin column was placed in a new 1.5ml collection tube, 
25µl RNase-free water was added and centrifuged for 1 min at full speed to 
elute the RNA. RNA was analysed using 2100 bioanalyzer (Agilent) after 
purification. 
 
2.4.2 Reverse transcription 
A number of different kits were used for reverse transcription (RT) of RNA to 
cDNA. In general, the high-capacity kit RT cDNA kit (Applied Biosystems) 
was used for mRNA, and TaqMan RT microRNA kit (Applied Biosystems) 
was used for miRNA studies.   
 
a) High capacity cDNA reverse transcription kit (Applied Biosystems) 
 
Materials 
- 10x RT buffer 
- 25x 100mM deoxyribonucleotide triphosphates (dNTP) 
- 10x RT random primers 
- MultiScribe reverse transcriptase 
- Molecular biology water (Sigma) 
 
High-capacity cDNA reverse transcription kit (Applied Biosystems) was used 
to reverse transcribe RNA to cDNA. The total input amount of total RNA 
used was up to 2µg of total RNA per 20µl reaction. This input varied 
depending on the type of samples used, for urinary RNA, up to 200ng was 
used. 
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For one sample, 2x RT master mix was prepared (10µl), mixed and placed 
on ice. The mix contained 2µl 10x RT buffer, 0.8 µl 25x dNTP (100mM), 2µl 
10x RT random primers, 1µl MultiScribe reverse transcriptase, 1µl RNase 
inhibitor, 3.2µl Nuclease-free (NF) water. 10µl 2x RT master mix was 
pipetted into an individual 0.5ml eppendorf or into each well of a 96-well 
reaction plate. 10µl RNA (up to 2µg) was added to the 10µl of master mix 
and mixed gently by pipetting up and down (total 20µl volume). Plates were 
sealed with 8-cap strips. The plates/tubes were briefly centrifuged to spin 
down the contents. The plates/tubes were placed in a PCR thermal cycler 
set to run under the following conditions: 250C 10 min, 370C 120 min, 850C 5 
min, 40C finish. 
 
cDNA was stored at -200C or placed on ice and used immediately for 
quantitative PCR (qPCR). 
 
b) TaqMan MicroRNA reverse transcription kit (Applied Biosystems) 
 
Materials 
- 100mM dNTP (with dTTP) 
- MultiScribe Reverse transcriptase, 50U/µl 
- 10x RT buffer 
- RNase inhibitor, 20U/µl 
- NF water 
 
The total RNA input ranged between 1-10ng as recommended by the 
manufacturer. For each reaction, 7µl of master mix (0.15µl dNTP, 1µl 
reverse transcriptase, 1.5µl RT buffer, 0.19µl RNase inhibitor, 4.16µl NF 
water), 3µl 5x RT primer and 5µl RNA (containing 1-10ng) was combined in 
a 0.2ml RT PCR tube or in a well of a 96-well PCR plate. The mix was 
incubated on ice for 5 mins and then incubated in the thermal cycler at 160C 
for 30 mins, 420C 40 mins, 850C 5 mins and 40C finish.  
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cDNA was stored at -200C or placed on ice and used immediately for 
quantitative PCR (qPCR). 
 
2.4.3 Real-time PCR 
Quantitative real-time PCR was performed using two kits. SYBR select 
(Applied Biosystems) was used for cDNA synthesized from mRNA, and 
TaqMan assays/master mix (Applied Biosystems) was used for cDNA 
synthesized from miRNA.  
 
a) SYBR select master mix (Applied Biosystems) 
 
Materials 
- SYBR Select Master mix (2x) 
- NF water 
- Custom designed primers 3mM 
 
A 10µl reaction was made up for each sample containing 5µl SYBR select 
master mix, 1µl forward primer, 1µl reverse primer, 2µl NF water and 1µl 
cDNA. The mixture was made up in a 0.2ml PCR tube or in wells of a 384-
well PCR plate and centrifuged briefly. The plate was sealed with a PCR 
adhesive seal and qPCR was performed on Qiagen rotor-gene (small 
sample tubes) or HT7900 (Applied Biosystems) (384-well plates) PCR 
machines. The cycling mode was as follow: 
 
- Polymerase Activation:  500C 2 mins then 950C 2 mins 
 
- Denature:  950C 15 sec  
- Anneal:  55-600C 15 sec      45 cycles 
- Extend:  720C 1 min 
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b) TaqMan gene expression master mix (Applied Biosystems) 
The custom designed TaqMan assays (primers/probes) were used with the 
TaqMan master mix. 
 
Materials 
- TaqMan gene expression Master mix (2x) 
- NF water 
- Custom designed TaqMan assay (20x) 
 
A 20µl reaction was made up for each sample containing 10µl TaqMan 
master mix, 1µl TaqMan assay and 9µl cDNA/NF water (containing 10-
100ng cDNA). The mixture was made up in wells of a 384-well PCR plate 
and centrifuged briefly. The plate was sealed with a PCR adhesive seal and 
qPCR was performed on HT7900 (Applied Biosystems) (384-well plates) 
PCR machine. The cycling mode was as follow: 
 
- Polymerase Activation:  500C 2 mins then 950C 10 mins 
 
- Denature:  950C 15 sec  
- Anneal/extent: 600C 1 min       45 cycles    
	
2.5 Immunoprecipitation and sequencing of m6A 
RNA extraction, immunoprecipitation (IP), sequencing and bioinformatic 
analyses were performed as per Dominissini et al’s protocol (Dominissini et 
al., 2013), this protocol has been slightly modified by Professor Chuan He’s 
group, Department of Chemistry, University of Chicago, USA (Hsu et al., 
2018).  
 
Total RNA was extracted from each cell line LNCaP and LNCaP-LN3 using 
Prime 5 PerfectPure RNA cultured cell kit (Scientific Laboratory Supplies).  
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2.5.1 Immunoprecipitation of m6A 
 
Materials 
- Tris-hydrochloride pH7.0 and 7.4, 1M (Tris-HCl, Sigma-Aldrich) 
- RNasin Plus RNase inhibitor (Promega) 
- NaCl (Sodium Chloride, Sigma-Aldrich) 
- Igepal CA-630 (Sigma-Aldrich) 
- Anti-m6A rabbit polyclonal antibody (Synaptic Systems) 
- m6A 5’-monophosphate sodium salt (Sigma-Aldrich) 
- Ethanol (Sigma-Aldrich) 
- Dynabeads Protein A for immunoprecipitation (ThermoFisher) 
 
Reagents setup 
 
- IP buffer (5x). 10ml was made with 0.5ml Tris-HCl (1M, pH7.4), 1.5ml 
NaCl (5M), 0.5ml Igepal CA-630 (10% vol/vol stock) and RNase-free 
water. 
 
- Elution buffer (1x). 90µl 5x IP buffer, 150µl m6A salt (20mM), 7µl 
RNasin Plus and 203µl RNase-free water. 
 
2.5.1.1 mRNA purification and RNA fragmentation 
	
mRNA purification  
mRNA purification was performed using the Dynabeads mRNA Purification 
Kit (Ambion) 
 
Materials 
- Dynabeads oligo (dT)25 
- Binding buffer 
- Washing Buffer B 
- 10mM Tris-HCl (pH7.5) 
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A total of 100µg of total RNA from each LNCaP and LNCaP-LN3 cell line 
was used. The RNA was adjusted to 100µl with RNase-free water and 
heated to 65oC for 2 mins to disrupt secondary structures. Dynabeads were 
resuspended and 250µl was transferred to a micro-centrifuge tube and 
placed on a magnetic rack for 30 sec. The supernatant was discarded and 
the Dynabeads were washed in 100µl Binding Buffer. Supernatant was 
discarded and the beads were re-suspended in 100µl Binding Buffer.  
 
Total RNA was added to the Dynabeads/Binding Buffer suspension and 
mixed on a rotator for 10 mins at room temperature to allow mRNA to anneal 
to the oligo (dT)25 on the beads. After 10 mins, the tube was placed on the 
magnet, and the supernatant was removed. The beads were washed twice 
with 100µl Washing Buffer B and then 20µl 10mM Tris-HCl (pH7.5) was 
added to the beads and incubated at 65oC for 2 mins. The tube was placed 
immediately on the magnet and the eluted mRNA was transferred to a new 
RNase-free tube. 
 
mRNA fragmentation 
A total of 1µg of mRNA (polyA+) was made up to 100µl with RNase-free 
water in 0.65ml sonication tubes (diagenode). RNA was fragmented to 
~200nt using a sonication machine (diagenode) as follow: 
 
- 40C 30 sec on        
       30 cycles 
- 40C 30 sec off       
- 40C Hold 
	
2.5.1.2 Immunoprecipitation 
Approximately 5ng (5µl) of untreated fragmented RNA was saved to serve as 
input control in RNA-seq. The remaining 95µl of fragmented RNA (per cell 
line) was made up to 500µl in a IP mix containing 100µl 5x IP buffer, 6µl 
m6A-antibody (0.5mg/ml), 5µl RNasin (100U) and 294µl RNase-free water. 
The RNA/IP mix was incubated with head-over-tail rotation for 2 hours at 4oC. 
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During incubation, 40µl (per reaction) protein A Dynabeads were washed 
twice in 1ml 1x IP buffer on the IP magnetic rack. The IP mix (following 2h of 
incubation) was transferred to the bead-containing tubes and incubated 
further on a rotating wheel for 2 hours at 4oC. After 2 hours, the beads were 
spun down and washed 3x in 1ml 1x IP buffer. 
 
2.5.1.3 Elution  
A total of 50µl elution buffer was added to each sample and incubated for 30 
min on a rotator at 4oC. Beads were spun down and supernatant removed at 
retained (now containing RNA). This elution step was repeated once more. 
All eluates from the same sample were combined (total 100µl) and beads 
were discarded. Each tube containing eluates was supplemented with 1/10th 
3M sodium acetate (pH5.2) and 2.5 volumes of 100% ethanol. The tubes 
were mixed and incubated overnight at 80oC.  
 
2.5.1.4 RNA purification  
RNA purification was performed using the RNA Clean & Concentrator kit 
(ZYMO RESEARCH). 
 
Materials 
- RNA Binding Buffer 
- RNA Prep Buffer 
- RNA Wash Buffer 
 
Each 100µl eluted RNA was mixed with 200µl RNA Binding Buffer (1:2) and 
equal volume (300µl) of 100% ethanol was added. The sample was 
transferred to a Zymo-spin column in a collection tube and centrifuged for 30 
sec at max. speed. The flow-through was discarded and 400µl RNA Prep 
Buffer was added to the column and centrifuged for 30 sec. The flow-through 
was discarded and 700µl RNA Wash Buffer was added and centrifuged for 
30 sec.  The flow-through was discarded and a further 400µl RNA Wash 
buffer was added and centrifuged for 2 mins to ensure complete removal of 
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the Wash Buffer. The column was transferred to a new RNase-free tube and 
14µl RNase-free water was added and centrifuged for 1 min. The eluted 
RNA was stored at -80oC overnight.  
 
2.5.1.5 Immunoprecipitation quality control 
The success of IP was validated by using qRT-PCR to assess the presence 
of methylated transcripts in the m6A-antibody IP samples relative to bead-
only IP (control) samples. Methylated transcripts were chosen from the list 
provided by Dominissini et al (Dominissini et al., 2012).  
 
2.5.2 Library preparation and sequencing 
TruSeq Stranded mRNA library preparation kit Set A (Illumina) was used to 
produce cDNA from input (untreated fragmented) and IP RNA. Libraries 
were subject to next generation sequencing on the Illumina Hiseq 2500 
machine. 
 
Materials (Illumina kit) 
- Fragment, Prime, Finish Mix (FPF) 
- SuperScript II enzyme 
- Act D  
- Second Strand Marking Master mix (SMM) 
- Resuspension buffer 
- A-tailing mix (ATL) 
- Index adaptors 
- Ligation mix (LIG) 
- Stop Ligase Buffer (STL) 
- RNase-free water 
- Ethanol 80% 
- AMPure XP beads (Beckman) 
- PCR Master mix 
- PCR Primers 
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Approximately 7µl IP mRNA and the previously saved 5µl fragmented 
untreated input mRNA was made up to 18µl with FPF mix. The input and IP 
samples were incubated at 94oC for 20 sec to fragment and prime the RNA. 
First strand synthesis was performed by adding 8µl mixture containing 0.8µl 
SuperScript III and 7.2µl Act D to each sample and running the samples 
under the following conditions:  
 
- 250C 10 min  
- 500C 15 min       
- 700C 15 min 
- 40C Hold 
 
Second strand synthesis (20µl	 product) was performed using the SX-8G IP-
Star Compact Automated System (diagenode). In brief, second strand 
synthesis involves incubating and washing (80% Ethanol) the samples under 
various temperatures (automated) with, 
 
1) 25µl second strand synthesis mixture (20µl SMM and 5µl 
Resuspension buffer) 
2) 15µl A-tailing mix (12.5µl ATL and 2.5µl Resuspension buffer) 
3) 7.5µl ligation mix (2.5µl index adaptor, 2.5µl LIG and 2.5µl 
Resuspension buffer) 
4) 5µl STL 
 
Following ligation, the samples were purified using AMPure beads (Beckman) 
and amplified using qPCR as per the Illumina protocol with 25µl PCR master 
mix, 5µl PCR primers, 1µl RNase-free water and 19µl cDNA library. The 
PCR mixture (50µl) was incubated under the following conditions: 
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- 980C 20 sec 
- 980C 10 sec  
- 600C 30 sec 20 cycles 
- 720C 30 sec 
- 720C 30 sec 
- 50C Hold 
 
The PCR product was then purified using AMPure beads (Beckman). The 
50µl PCR product was incubated with 50µl AMPure beads (1:1) at room 
temperature for 15 mins. The mixture was put on the magnet for 5 mins and 
the supernatant was discarded. The beads were washed twice on the 
magnet with 200µl 80% ethanol and left to air dry (~15 mins). The beads 
were resuspended with 22µl RNase-free water and incubated at room 
temperature for 2 mins. The mixture was put on the magnet for 5 mins and 
20µl of the eluate was removed and placed on ice.  
 
Bioinformatic analysis was performed by colleagues from the University of 
Sheffield Bioinformatic hub. The analysis design was performed in 4 steps, 1) 
quality control; 2) mapping with splice aware mapper; 3) peak calling with 
MACS2; 4) peak annotation. Data were analysed as ChIP-seq data instead 
of RNA-seq data as per Dominissini et al’s protocol (Dominissini et al., 2013). 
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2.6 Statistical Analysis 
Statistical analyses were performed using Statistical Package for Social 
Sciences (Version 23.0, 2016, SPSS, Inc., Chicago, IL, USA) software. In 
general, continuous data between groups were compared using Student’s t-
test (two independent groups) or 1-way analysis of variance (ANOVA, 
greater than two independent groups) for parametric data, and Mann-U-
Whitney test for non-parametric data. Categorical data were analysed using 
Chi-Square test or Fisher’s exact test (for small sample size). A p-value 
<0.05 was considered statistically significant. For average calculations, mean 
and standard deviation (SD) were used for parametric data, and median and 
interquartile range (IQR) were used for non-parametric data. Specific 
statistical analysis (for example Kaplan-Meier plots, logistic regression, 
multivariable analysis) are described in relevant result chapters. All graphs 
were plotted using SPSS, GraphPad Prism (Version 6.0, 2014) or Excel 
(Microsoft, version 15, 2016). 
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CHAPTER 3: A Retrospective Analysis of Repeat 
Prostate Biopsy Outcomes 
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4.1 Background 
Transrectal ultrasound-guided prostate biopsy (TRUS-PBx) has historically 
been the gold-standard investigation and tissue diagnosis of PCa. However, 
as discussed in Chapter 1.3.7.5 around 30% or patients who undergo a PBx 
are diagnosed with PCa and around the same percentage, ~30% are 
diagnosed with PCa on repeat PBx (rPBx) (Keetch et al., 1994; Djavan et al., 
2001).  
 
There is limited data regarding the yield and predictors for PCa on initial and 
rPBx in a UK population, where the rate of PSA testing is low compared to 
other comparable countries (Melia et al., 2004). As such, the risks of PCa 
detection on initial and rPBx are difficult to quote when counselling men with 
a negative initial biopsy. There is no validated agreed protocol defining the 
need for rPBx and the European Association of Urology (EAU) guidelines 
only provide indications for the first rPBx (Mottet et al., 2017).  
 
Within the ProtecT RCT, those diagnosed with PCa on PBx were 
randomised to active surveillance, radical radiotherapy or radical 
prostatectomy. Those with initial negative PBx underwent routine care (Lane 
et al., 2010; Hamdy et al., 2016).  
 
Biomarkers such as the FDA approved PCA3 are used to help stratify men 
for rPBx, with the aim of reducing under- or over-treatment of disease. The 
primary aim of the current analysis was to report a single centre’s experience 
on the PCa detection rate on pre-MRI rPBx in a previously unscreened 
population of community-dwelling men in the UK with a negative initial PBx 
within the ProtecT study. Urinary and prostate biopsy specimens (FFPE) 
from men (Sheffield) within the ProtecT/ProMPT studies were retrieved for 
PCA3-shRNA2 evaluation (Chapter 4 and 5). 
 
The secondary aim was to identify clinical features that may predict PCa and 
aid decision to rPBx. 
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4.2 Methods 
	
4.2.1 Design and patient population 
The current study was a prospective observational cohort study within the 
ProtecT study. Within the Sheffield cohort, 16656 men were invited for PSA 
testing, 10412 men underwent testing and 920 had a TRUS-PBx. Of these, 
599 (65%, 95% CI 62-68) men had a negative PBx and were included in the 
current analysis. The interval of repeat PSA testing was left at the discretion 
of the attending Urologist. Men with inadequate or HGPIN findings on 
previous PBx and %free PSA <12% were offered a rPBx. Prostate tissue 
was obtained via TRUS-PBx, as described in Chapter 2.3.3.  
 
4.2.2 Data collection and analysis 
Data regarding age, PSA kinetics (PSA value, %free PSA, PSA velocity) and 
PBx/prostatectomy characteristics including pathology, Gleason scores, 
biopsy cores, tumour length, tumour volume and staging were gathered. 
Tumours with a Gleason 7-10 score were classified as high-grade tumours. 
Indolent tumours were classified using the Epstein criteria (Gleason score <6; 
<3cores positive; <50% positive per core) (Epstein et al., 1994). 
Characteristics between biopsy groups, and patients with and without PCa 
were compared. 
 
4.2.3 Statistical analysis 
General statistical tests used were described in Chapter 2.6. PCa diagnostic 
rates were analysed using Kaplan-Meier survival estimates and log-rank test. 
Time to PCa diagnosis was calculated from the date of first PCa clinic. 
Patients who died, who were lost to follow-up or who have not reached 
endpoint were censored. Uni- and multivariable logistic regression analysis 
was used to identify predictors of PCa on rPBx. 
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4.3 Results 
	
4.3.1 Patient population within the Sheffield cohort 
In total, 321/920 (34.9%) men (mean age (standard deviation) 62.1 (+4.9) 
years) undergoing TRUS-PBx between 30 November 2001 and 28 
November 2008 were found to have PCa on initial biopsy. Of the remaining 
599 men (mean age 61.8 (+5.0) years, median (interquartile range (IQR)) 
baseline PSA of 4.1ng/ml (3.5-4.5) and a median follow-up of 17 (10-45) 
months), 248 (41.4%) had >1 rPBx (Table 7). A total of 66/248 (26.6%) men 
who underwent a rPBx were found to have PCa. 
 
4.3.2 Outcomes of repeat prostate biopsy 
A total of 337 rPBx were performed, a single rPBx was performed on 248 
men; 2nd rPBx on 71; a 3rd on 16; and a 4th on 2 men. Clinical parameters 
and histopathology results of rPBx are demonstrated in Table 8. PCa was 
detected in 66/337 (biopsy yield, 19.6%) rPBx with 41/248 (16.5%) and 
25/89 (28.1%) PCa detected on 1st and 2nd – 4th rPBx respectively (Table 9 
and Figure 15).  
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Characteristics 
 
n= 599 
 
Baseline Age (Years) 
Mean (SD) 
 
 
61.8 (5.0) 
 
Baseline PSA (ng/ml) 
Median (IQR) 
 
 
4.1(3.5-5.5) 
 
Number of PSA tests (n) 
1 
2 
3 
>4  
 
 
8 
118 
193 
280 
 
Number of Biopsy (n) 
1 
 
2* 
3* 
4* 
5* 
 
 
351 
 
177 
55 
14 
2 
 
Follow-up (Months) 
Median (IQR) 
 
 
17.0 (10.0-45.0) 
 
Table 7. Baseline characteristics of men with an initial negative prostate 
biopsy. 
In total, 599 of the 920 men biopsied within Sheffield had an initial negative biopsy. 
At a median follow-up was 17 months, 248 men underwent at least one rPBx, of 
which two men received a 4th rPBx.  
 
2-5*, Repeat prostate biopsies. 
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Table 8. Baseline characteristics of patients and prostate biopsy outcomes in each biopsy group. 
Age, PSA details and histopathological results from prostate biopsies are detailed here. The baseline %free PSA (p=0.009), PSA (p<0.001) and 
PSA velocity (0.05) at biopsy were significantly different in the 2nd-4th rPBx group compared to the initial PBx/1st rPBx group. 
 
  
Initial PBx 
(n= 920) 
 
1st rPBx 
(n= 248) 
 
2nd rPBx 
(n= 71) 
 
3rd rPBx 
(n= 16) 
 
4th rPBx 
(n= 2) 
 
p-value 
 
Baseline Age (years) 
Mean (SD) 
 
 
62.1 (4.9) 
 
 
61.0 (5.0) 
 
 
 
 
 
60.0 (4.6) 
  
 
0.96 
Age at biopsy (years) 
Mean (SD) 
 
62.3 (4.9) 
 
62.1 (5.2) 
  
62.8 (5.0) 
  
0.34 
Baseline PSA (ng/ml) 
Median (IQR) 
4.4 (3.5-6.4) 4.5 (3.7-6.1)  5.2 (3.8-6.8)  0.25 
Baseline %free PSA 
Median (IQR) 
  
13.0 (8.7-16.9) 
  
8.9 (7.7-8.9) 
  
0.009 
PSA at biopsy (ng/ml) 
Median (IQR) 
4.2 (3.2-6.2) 5.1 (3.8-7.2)  7 (5.5-10.6)  <0.001* 
PSA velocity at biopsy (ng/ml/y) 
Median (IQR) 
 0.5 (-8.0-1.9)  0.54 (0.2-2.1)  0.05 
 
Time from 1st Biopsy (Months) 
Median (IQR) 
 
- 
 
 
4.0 (2.0-14.0) 
 
 
25.5 (9.0-37.0) 
 
 
47.0 (24.8-70.8) 
 
 
47.0 
 
 
Benign, n (%) 
 
547 (59.5) 
 
192 (77.4) 
 
47 (66.2) 
 
8 (50) 
 
1 (50) 
 
 
HGPIN/Atypia 
 
34 (3.7) 
 
5 (2.0) 
 
3 (4.2) 
 
0 
 
0 
 
 
ASAP 
 
18 (2.0) 
 
10 (4.0) 
 
4 (5.6) 
 
1 (6.3) 
 
0 
 
 
Adenocarcinoma 
 
321 (34.9) 
 
41 (16.5) 
 
17 (23.9) 
 
7 (43.8) 
 
1 (50) 
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Figure 15. Percentage of prostate cancer identified on prostate biopsy. 
A total of 321/920 (34.9%) PCa was detected on initial PBx. Prostate cancer was 
detected in 66/337 (biopsy yield, 19.6%) rPBx with 41/248 (16.5%) and 25/89 
(28.1%) PCa detected on 1st and 2nd – 4th rPBx respectively 
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4.3.3 Prostate cancer identified by prostate biopsy 
Baseline clinical features (age, PSA, time to diagnosis) and biopsy 
characteristics of positive (PCa) biopsies are shown in Table 9. The median 
(IQR) time to diagnosis on rPBx in the 2nd-4th rPBx group was 31 (11.5-57.5) 
months. The median (IQR) aggregate tumour length (mm) was 7.5 (2-26), 4 
(1.5-10), 4 (1.5-11) mm (p=0.001) in the initial PBx, 1st rPBx and 2nd-4th rPBx 
groups respectively. Out of all tumours detected on initial and rPBx, 93/387 
(24.0%) high-grade (Gleason 7-10) tumours were detected. In the first set of 
biopsies 78/321 (24.3%) were high-grade tumours compared to 15/66 
(22.7%) of tumours detected on rPBx (p=0.88). Of all high-grade tumours 
83.9% (78/93), 8.6% (8/93) and 7.5% (7/93) were detected on initial PBx, 1st 
rPBx and 2nd-4th rPBx respectively. A total of 114/321 (35.5%) tumours found 
on initial PBx and 33/66 (50%) tumours found on rPBx were classed as 
indolent (p=0.04). 
 
4.3.4 The risks of being diagnosed with cancer on repeat biopsy 
The Kaplan-Meier estimated risk of being diagnosed with any grade PCa on 
rPBx was 8.8% at 2 years, 14.3% at 3 years, 15.4% at 4 years and 17.4% at 
5 years (Figure 16a). The estimated risk of being diagnosed with high-grade 
Gleason 7-10 PCa was, 1.4% at 2 years, 3.2% at 3 years, 4.6% at 4 years 
and 5.5% at 5 years (Figure 16b). 
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Characteristics PCa Initial PBx 
(n= 321/920, 34.9%) 
1st rPBx 
(n= 41/248, 16.5%) 
2nd to 4th rPBx 
(n=25/89, 28.1%) 
p-value 
(Initial Vs all rPBx) 
Baseline Age (years) 
Mean (SD) 
61.8 (4.9) 60.2 (4.6) 58.7 (4.9)  0.57 
 
Age at diagnosis (years) 
Mean (SD) 
 
 
62.0 (4.9) 
 
 
61.3 (4.6) 
 
 
61.9 (5.4) 
 
 
0.71 
 
Baseline PSA (ng/ml) 
Median (IQR) 
 
4.4 (3.5-6.2) 
 
5.1 (4.2-7.5) 
 
5.4 (3.9-6.7) 
 
 
0.007 
Baseline %free PSA 
Median (IQR) 
 
- 
 
13.0 (10.2-15.9) 
 
8.3 (5.6-10.7) 
 
0.006a 
 
PSA at diagnosis (ng/ml) 
Median (IQR) 
 
 
4.1 (3.2-6.1) 
 
 
5.8 (4.3-7.8) 
 
 
6.2 (4.4-11.2) 
 
 
<0.001 
PSA velocity at diagnosis (ng/ml/y) 
Median (IQR) 
- 0.8 (-0.5-2.4) 0.4 (0.05-2.7) 0.91a 
 
Time to diagnosis from 1st Bx (months) 
Median (IQR) 
 
 
- 
 
 
4 (2.5-21) 
 
 
31 (11.5-57.5) 
 
 
<0.001a 
Type of Biopsy, n (%) 
TRUS 
Saturation 
Saturation + TURP 
 
321 (100) 
0 
0 
 
41 (100) 
0 
0 
 
10 (40) 
5 (20) 
10 (40) 
 
Laterality, n (%) 
Unilateral 
Bilateral 
Unknown 
 
187 (58.3) 
131 (40.8) 
3 (0.9) 
 
29 (70.7) 
10 (24.4) 
2 (4.9) 
 
15 (60) 
8 (32) 
2 (8) 
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Table 9. Patient and prostate biopsy characteristics in positive cohorts. 
Clinical parameters and detailed histopathological data of men who underwent initial and rPBx are shown. PSA is higher in men who underwent 
rPBx. Tumours found on rPBx appear to be smaller and indolent compared with tumours detected on initial PBx. 
a Comparison between 1st rPBx and 2nd-4th rPBx; *indolent PCa (Epstein): Gleason score <6; <3cores positive; <50% positive per core. 
Number Cores taken 
Median (IQR) 
 
10 (10-10) 
 
20 (10-12.5) 
 
23 (10-25) 
 
<0.001 
Number Cores Positive 
Median (IQR) 
 
3 (1-6) 
 
2 (1-3.3) 
 
2 (1-3) 
 
<0.001 
% (IQR) cores positive  
30 (10-50) 
 
 
20 (10-30) 
 
 
10 (4-20) 
 
 
<0.001 
 
Aggregate tumour length (mm)  
Median (IQR) 
7.5 (2-26) 4 (1.5-10) 4 (1.5-11) 0.001 
Max. tumour length (mm)  
Median (IQR) 
4 (2-8) 2 (1-5.3) 3 (1-5) 0.01 
% total tumour length (IQR) 6.1 (2-22) 2.5 (1.05-6.5) 2.2 (0.7-3.6) <0.001 
 
Gleason Score, n (%) 
6 
7 (3+4) 
7 (4+3) 
8-10 
HG 7-10 
 
 
243 (75.7) 
34 (10.6) 
20 (6.2) 
24 (7.5) 
78 (24.3) 
 
 
33 (80.5) 
3 (7.3) 
3 (7.3) 
2 (4.9) 
8 (19.5) 
 
 
18 (72.0) 
4 (16.0) 
0 (0) 
3 (12.0) 
7 (28) 
 
 
0.88 
1.00 
0.78 
1.00 
0.88 
Indolent PCa*, n (%) 114 (35.5) 19 (46.3) 14 (56) 0.04 
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a) 
 
Time 
(months) 
0 12 24 36 48 60 72 84 96 
Number at 
risk 
599 443 267 190 148 103 82 35 16 
% PCa-free 100 93.8 91.2 85.7 84.6 82.6 78.8 75.3 70.8 
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b) 
 
 
Figure 16. Kaplan-Meier estimate of time from date of first prostate cancer 
clinic to diagnosis of a) all cancer and b) high-grade cancer. 
a) The Kaplan-Meier estimated risk of being diagnosed with any grade PCa on rPBx 
was 8.8% at 2 years and 17.4% at 5 year; b) The estimated risk of being diagnosed 
with high-grade Gleason 7-10 PCa was 1.4% at 2 years and 5.5% at 5 years.
Time (months) 0 12 24 36 48 60 72 84 96 
Number at risk 599 469 272 207 151 104 82 42 18 
% HG PCa-
free 
100 99 98.6 96.8 95.4 94.5 93.4 91.8 91.8 
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4.3.5 Comparison between men with and without cancer 
The median (IQR) time to diagnosis was 14 (5.8-33.3) months. The mean 
(SD) baseline age in the cancer group was 60.7 (4.9) years and 61.9 (5.0) 
years in the non-PCa group (p=0.06). The median (IQR) baseline PSA and 
median (IQR) PSA velocity was 5.1 (3.9-6.4) ng/ml and 4.1 (3.4-5.4) ng/ml 
(p<0.001), and 0.76 (-0.2-2.3) and -0.1 (-1.1-0.3) ng/ml/year (p<0.001) in the 
PCa and non-PCa group respectively. The percentage of ASAP on previous 
negative PBx in the PCa and non-PCa group was 13.6% and 4.1% (p=0.001) 
respectively (Table 10).  
 
4.3.6 Uni- and Multivariable analysis of predictors 
Uni- and multivariable analyses were used to analyse dependent variables. 
Both demonstrated that baseline PSA and %free PSA (<12%), PSA velocity 
and ASAP detected on previous PBx are positive predictors of PCa (Table 
11). 
 
4.3.7 Review of the international data 
A literature review of the international data on rPBx was performed. Both 
retrospective and prospective studies reporting data on standard TRUS, 
extended and saturation PBx were included. A total of 20 studies were 
identified between 1994 and 2013. The diagnostic rate of PCa on rPBx is 
between 7.45 and 26.2% (Table 12).  
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Table 10. Clinical and pathological characteristics of patients with and 
without prostate cancer at the time of analysis. 
Of the 599 who had an initial negative PBx, 66 men were found to have PCa on 
rPBx.   Baseline PSA and PSA velocity were higher, and %free PSA was lower in 
the PCa group.  There were more ASAP detected in the no PCa group.
 
Characteristics 
 
 
PCa n=66 
 
 
No PCa n=533 
 
p-value 
 
 
Baseline Age (Years) 
Mean (SD) 
 
 
60.7 (4.9) 
 
 
61.9 (5.0) 
 
 
0.06 
 
Age at PCa diagnosis (Years) 
Mean (SD) 
 
 
62.7 (5.2) 
 
 
- 
 
   
Baseline PSA (ng/ml) 
Median (IQR) 
 
 
5.1 (3.9-6.4) 
 
 
4.1 (3.4-5.4) 
 
 
<0.001 
PSA at diagnosis 
Median (IQR) 
6.2 (4.9-10.2) -  
PSA velocity (ng/ml/year) 
Median (IQR)  
 
0.76 (-0.2-2.3) 
 
-0.1 (-1.1-0.3) 
 
<0.001 
%free PSA 
Median (IQR) 
 
10.6 (6.6-14.4) 
 
17 (13-22.7) 
 
<0.001 
 
Follow-up (Months) 
Median (IQR) 
 
 
14.5 (4.8-34.0) 
 
 
17.0 (12.0-48.0) 
 
 
0.18 
 
Number of PSA tests, n (%) 
1 
2 
3 
> 4 
 
 
0 (0) 
8 (12.1) 
24 (36.4) 
34 (51.5) 
 
 
8 (1.5) 
110 (20.6) 
169 (31.7) 
246 (46.2) 
 
 
0.61 
0.14 
0.45 
0.41 
 
Number of biopsy, n (%) 
1 
2 
3 
4 
5 
 
 
0 (0) 
41 (62.1) 
17 (25.8) 
7 (10.6) 
1 (1.5) 
 
 
351 (65.9) 
137 (25.7) 
37 (6.9) 
7 (1.3) 
1 (0.2) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.21 
HGPIN/atypia, n (%) 7 (10.6%) 35 (6.6%) 0.23 
ASAP, n (%) 9 (13.6%) 22 (4.1%) 0.001 
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Table 11. Univariable and multivariable analysis of predictors for tumours detected on repeat biopsy. 
Univariable and multivariable analyses were performed to identify predictors of PCa on rPBx. Analyses revealed that PSA, PSA velocity, %free 
PSA, ASAP were associated with PCa detected on rPBx. 
	
HR, Hazard ratio; CI, Confidence interval 
 
 
 
Characteristics 
 
 
PCa n=66 
 
 
No PCa 
n=533 
 
p-value 
Univariable  
 
HR 
 
95% CI for HR 
 
p-value 
Multivariable 
 
 
 
HR 
 
95% CI for HR 
Baseline Age (Years) 
Mean (SD) 
 
60.7 (4.9) 
 
61.9 (5.0) 
 
0.09 
 
0.96 
 
0.91-1.01 
 
0.11 
 
0.96 
 
0.91-1.01 
Baseline PSA (ng/ml) 
Median (IQR) 
 
5.1 (3.9-6.4) 
 
4.1 (3.4-5.4) 
 
0.001 
 
1.14 
 
1.05-1.24 
 
0.02 
 
1.11 
 
1.02-1.22 
PSA velocity (ng/ml/y) 
Median (IQR) 
0.76 (-0.2-2.3) -0.1 (-1.1-0.3) <0.001 1.18 1.10-1.26 0.001 1.16 1.06-1.26 
Baseline %free PSA, n (%) 
<12% 
>12% 
 
24 (61.5) 
15 (38.5) 
 
55 (18.3) 
246 (81.7) 
<0.001 5.16 2.70-9.87 0.01 2.72 1.23-6.03 
Previous HGPIN/atypia, n (%) 7 (10.6%) 35 (6.6%) 0.47 1.34 0.61-2.93 0.49 1.34 0.59-3.05 
Previous ASAP, n (%) 9 (13.6%) 22 (4.1%) 0.002 3.06 1.50-6.21 0.01 2.60 1.24-5.48 
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Author Year Country Study type Specimen Protocol rPBx (n) PCa on rPBx (n) Initial PBx 1st rPBx 2nd rPBx 3rd rPBx >4 rPBx Ref
Current 2014 England Pros (ProtecT PBx
10-core (5-
33) 337 66 (19.6%)
321/920 
(34.9%)
41/248 
(16.5%)
17/71 
(23.9%)
7/16 
(43.8%) 1/2 (50%)
Elshafei 2013 USA Retro PBx - 682
179 
(26.2%) (Elshafei et al. , 2013)
Ploussard 2013 France Pros PBx
Extended 21-
core 847
139 
(16.4%)
103/617 
(16.7%)
28/166 
(16.9%)
6/48 
(12.5%)
2/16 
(12.5%) (Ploussard et al. , 2013)
Cussenot 2013 France Retro PBx - 176 26% 52% (Cussenot et al. , 2013)
Park B 2013 Korea Retro PBx 10-12-core 1180
190 
(16.1%)
1956/7191 
(27.2%)
142/976 
(14.5%)
38/174 
(21.8%)
9/27 
(33.3%) 1/3 (33.3%) (Park et al. , 2013)
Bakardzhiev 2012
Bulgaria, 
Germany Retro PBx 166 22 (13.3%)
18/113 
(15.9%) 3/35 (8.6%) 1/18 (5.5%)
(Bakardzhiev et al. , 
2012)
Najari 2012 Germany, USA Retro PBx >10-core 764
199 
(26.1%)
3671/6729 
(54.6%)
199/764 
(26.1%) (Najari et al. , 2012)
Resnick 2011 USA Retro RP - - 456 1867 281 (Resnick et al. , 2011)
Quinlan 2009
Republic of 
Ireland Retro PBx 10-core 175 27 (15.4%) 16 4 4 3 (Quinlan et al. , 2009)
Leite 2008 Brazil Retro PBx
Sextant 
extended 9-
32
99 8 (8.1%) 524/1177 
(44.5%)
6/76 (7.9%) 1/7 (5.9%) 1/5 (20%) 0/1 (0%) (Leite et al. , 2008)
Tan 2008 USA Retro PBx
Standard <20 
and 
saturation 
>20
966
215 
(22.3%)
690/1212 
(56.9%)
142/621 
(22.9%) (Tan et al. , 2008)
175
73/345 (21.2%)
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Table 12. Published international data on repeat prostate biopsy outcomes. 
A literature review was performed on prostate biopsies. A total of 20 studies were identified between 1994 and 2013. The diagnostic rate of 
PCa on rPBx is between 7.45 and 26.2%.  
 
Pros, Prospective; Retro, Retrospective; (r)PBx, (repeat) prostate biopsy; RP, Retropubic Prostatectomy; PCa, prostate cancer 
 
Tan 2008 USA Retro PBx
Standard <20 
and 
saturation 
>20
966
215 
(22.3%)
690/1212 
(56.9%)
142/621 
(22.9%) (Tan et al. , 2008)
Pepe 2007 Italy Pros PBx Saturation 24-
37
- 18 46 (46.9%) 17 (22.6%) 1 (6.2%) (Pepe and Aragona, 
2007)
Lopez-
Corona
2007 USA Pros RP - - 315 1042 227 59 29 (Lopez-corona et al. , 
2007)
Ciatto 2004 Italy Pros PBx
Sextant 6-
core 87 13 (14.9%) (Ciatto et al. , 2004)
Lujan 2004 Spain
Pros 
(ERSPC) PBx
Sextant 6-
core 241
32/223 
(14.4%)
111/770 
(14.4%)
27/172 
(15.7%) 5/51 (9.8%) ?/16 ?/2 (Lujan et al. , 2004)
Steiner 2004 Austria Retro RP
Sextant 6-10-
core 573
105 
(18.3%) 548 73 32 (Steiner et al. , 2004)
Park SJ 2003 Japan Retro PBx
Sextant, 
extended 104 24 (21.2%) (Park et al. , 2003)
Mian 2002 USA Retro PBx 10-11-core 89 15 (16.9%) (Mian et al. , 2002)
Djavan 2000
Austria, 
Belgium, 
France, Poland
Pros PBx 8-core 1651
123 
(7.45%)
231/1051 
(22.0%)
83/820 
(10.1%)
36/737 
(4.9%) 4/94  (4.3%) (Djavan et al. , 2000)
O’Dowd 2000 USA Retro PBx - 6380
1637 
(25.7%)
50,521/132,
426 (38.2%) (O’dowd et al. , 2000)
Keetch 1994 USA Pros PBx
Sextant 6-
core 721
104 
(14.4%)
391/1136 
(34.4%)
82/427 
(19.2%)
16/203 
(7.9%) 6/91 (6.6%)
(Keetch, Catalona and 
Smith, 1994)
73/345 (21.2%)
1637/6380 (25.7%)
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4.4 Discussion  
 
4.4.1 Diagnostic rate of prostate cancer on repeat biopsies 
The rPBx outcomes in UK men within the ProtecT study in a region without a 
screening programme was analysed. A total of 66 of 599 (11.0% risk) men 
with an elevated PSA between 3 and 19.9 ng/mL and an initial negative PBx 
were found to have PCa during the study period (median 17; IQR 10-45 
months). The yield of PCa on subsequent rPBx (66/337, 19.6%) was found 
to be similar to previously reported data, 7.45-26.2% (Table 12) from the 
international literature. Population movement within South Yorkshire is 
limited and men tend to stay with the same practice. Although not all men 
were biopsied, giving a risk of verification bias, no clinical cases of PCa 
presented in the unbiopsied cohort during the study period.  
 
Over-performing rPBx increases healthcare costs, places patients at risk of 
rPBx complications, and increases the risk of diagnosing and over-treating 
insignificant disease. It is known that the majority of PCa is detected on initial 
PBx, this was also evident in the current study (321/387, 83.0%). Therefore, 
optimisation of the first PBx would be highly valuable, including the use of 
extended PBx (Roehl et al., 2002; Hong et al., 2004; Eskicorapci et al., 2007), 
taking additional anterior apical cores (Wright et al., 2006), and saturation 
PBx (sPBx). The optimal rPBx protocol is unclear, several series have shown 
that sPBx and TURP enhances PCa detection on subsequent rPBx (Scattoni 
et al., 2007, 2010; Ploussard et al., 2009; Zaytoun, Moussa, et al., 2011). In 
the current study, 60% of PCa detected on 2nd-4th rPBx were diagnosed on 
saturation rPBx +/- TURP. Transperineal template-guided biopsy (TPM-Bx) 
may detect additional PCa, but this procedure requires general/regional 
anaesthesia and can result in additional complications, such as urinary 
retention (Symons et al., 2013).  
 
A more contemporaneous approach is the use of mpMRI scanning prior to a 
decision for biopsy (Moore et al., 2013).  Whereas several centres have 
reported promising results with such an approach in terms of reducing the 
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number of negative biopsies (Lawrentschuk et al., 2009; Hoeks et al., 2012), 
prospective data on the standard diagnostic criteria, risks and benefits, as 
well as the cost-effectiveness are limited (Hamoen et al., 2014).  In the 
setting of an initial negative biopsy, mpMRI-guided rPBx (mpMRI-Bx) 
requires fewer cores and the initial PCa detection rates are similar to TRUS-
PBx (Moore et al., 2013). A recent meta-regression analysis comparing PCa 
detection using TRUS-PBx (30.0%), TPM-Bx (36.8%) and mpMRI-Bx (37.6%) 
in a re-biopsy setting could not define which strategy offers the highest 
cancer detection rate, however MRI-PBx may potentially detect more PCa 
and the authors of the meta-analysis concluded that more well-designed 
prospective comparative studies with standardised outcome measures are 
required to define an optimum rPBx strategy (Nelson et al., 2013). The 
national UK PROMIS study (PROstate MRI Imaging Study) was a 
multicentre, paired-cohort study that tested diagnostic accuracy of mpMRI 
and TRUS-PBx against TPM-Bx as the reference standard. A total of 576 
men underwent all three diagnostic tests and concluded that 27% of men 
may avoid a primary PBx and diagnosis of 5% fewer clinically insignificant 
PCa (reducing over-diagnosis of clinically insignificant PCa). If subsequent 
TRUS-PBx were indicated by mpMRI findings, up to 18% more cases of 
clinically significant PCa may be detected compared with the standard 
pathways of TRUS-PBx (PROMIS, 2012; El-Shater Bosaily et al., 2015; 
Ahmed et al., 2017). 
 
4.4.2 Grades of prostate cancer 
In keeping with other reports (Djavan et al., 2001), the majority of PCa 
identified on rPBx in this study were graded Gleason 6 (77.3% of all PCa). 
Results showed that tumours identified on rPBx tend to be smaller, similarly 
differentiated and less significant (Epstein criteria) (Epstein et al., 1994) 
when compared to tumours found on initial PBx. PSA also appeared to be 
higher in the rPBx group indicating its use in stratifying men for rPBx. 
Although the risk of having high-grade disease on rPBx is low (15/337, 4.5%), 
these poorly-differentiated tumours could result in poor outcomes if not 
detected and acted upon.  On comparing histology from RP specimens, a 
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delay in diagnosis does not appear to alter tumour stage, but a larger 
proportion are high-grade, which contrasts with the findings on biopsy. The 
reason for this paradox is not immediately apparent. 
 
Our Kaplan-Meier analyses provide evidence for the estimated risk of PCa 
being diagnosed on rPBx on a man presenting with an initial negative rPBx 
and elevated PSA- such data will be useful in counselling men considering 
biopsy for an elevated PSA, particularly in the setting of an initial negative 
biopsy.  
 
4.4.3 Predictors of prostate cancer 
In the current observation, it appears that rPBx were performed on patients 
with a higher PSA and PSA velocity, and a lower %free PSA. Patients 
appeared to be younger (baseline age) in the rPBx group, probably 
indicating an age-bias, however, this did not reach statistical significance. 
 
Positive predictors of PCa on rPBx identified on multivariable analysis 
include baseline PSA and %free PSA, PSA velocity and ASAP detected on 
previous PBx. These predictors are amongst the list reported in the literature 
(Catalona et al., 1997; Djavan et al., 2000; Gann et al., 2010). Other 
predictors described include age, family history, DRE, PSA slope, HGPIN, 
prostate volume and prostate cancer antigen-3 (PCA3) (Zaytoun and Jones, 
2011). Despite all the data available on PCa detection rates and predictors of 
PCa on subsequent rPBx, unfortunately, there is currently still no agreed 
protocol on rPBx. However, evolving data suggest that performing MRI prior 
to biopsy may avoid potentially unnecessary biopsies (Nelson et al., 2013; 
Ahmed et al., 2017). Knowing around 70% of men who undergo initial or 
rPBx have a negative result, other molecular strategies in addition to 
diagnostic imaging are needed. The clinical data collected in the current 
analysis assisted in identify men and specimens for subsequent laboratory 
analyses in Chapters 4 and 5. 
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4.4.4 Limitations  
Men with features set out in the inclusion criteria were recruited for PSA 
testing via written invitation sent out by GPs, therefore non-responders were 
not included. Data in the current study may only apply to such selected men 
and not include men seen in routine UK clinical practice with clinically 
suspected PCa (urinary symptoms, suspicious DRE). The decision for rPBx 
was based on PSA and clinicians’ interpretation of the whole scenario as 
guidelines on >1 rPBx are not available. This represents a degree of 
verification bias, and as demonstrated patients with high PSA and high PSA 
velocity were selected for rPBx. Although no further cases of clinical PCa 
were reported in the region in the unbiopsied cohort, it is unknown whether 
they may have received further rPBx or were diagnosed with PCa in a 
different trust or region. There could therefore be an underestimate of the 
rates of PCa diagnosis.  
 
4.4.5 Generalisability  
The current study included large number of UK men recruited for the ProtecT 
study. The results are likely to be generalizable to UK men aged between 50 
and 69 years undergoing TRUS-PBx for the first time as a result of a first-
time PSA level between 3.0 and 19.9ng/ml, rather than men with clinically 
suspected PCa. 
 
4.5 Conclusions 
Around 1 in 10 men with an initial negative PBx are diagnosed with PCa on 
rPBx, with 2.5% found to have high-grade disease. Biopsy characteristics of 
cancers identified on rPBx suggested smaller, similarly differentiated tumours 
compared to tumours detected on initial PBx. These data are useful to quote 
when counselling patients with a persistently elevated PSA level and 
contemplating rPBx. Recent data on mpMRI and PBx appear promising and 
this modality may soon be adopted wide-spread in the UK to better select 
men for rPBx. 
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CHAPTER 4: The Identification and Role of 
PCA3-shRNA2 In Prostate Cancer 
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3.1 Background 
As discussed in Chapter 1.3.7.3, PCA3 is a FDA approved long ncRNA 
biomarker used in conjunction with PSA (PCA3 score- PCA3/PSA mRNA 
ratio) to guide rPBx decisions (Hessels et al., 2003; Clarke et al., 2009). 
However, the limitations discussed prevent its global use including in the UK 
NHS. It is known that long ncRNAs have few exons, can be processed into 
short active RNAs (Röther et al., 2011), and are not conserved from primitive 
species. As no functional role for PCA3 has been investigated at the time of 
our study, we questioned whether PCA3 may encode a shorter active RNA 
that targets mRNA. To test this hypothesis, we searched for probable short 
ncRNAs derived from sequences from the BMCC1 transcript, which spans 
PCA3, and investigated their translational role.   
  
3.2 Methods 
 
3.2.1 Identification of hairpin RNA structures 
Together with Dr Ross Drayton (post doc in the Catto lab) I searched 
BMCC1 gene for predicted RNA hairpins using Probabilistic miRNA 
prediction (ProMir II) (Nam et al., 2006) and miRNA Predictor (MiPred) (Jiang 
et al., 2007) bioinformatic algorithms. These bioinformatic online programs 
compare random sequences within the target hairpin. A small RNA 
transcriptome generated from malignant prostatic tissue using deep 
sequencing (Martens-Uzunova et al., 2012) was searched for RNA 
sequences derived from these predicted hairpins. The expression of any 
identified short RNA hairpins was measured using custom stem loop primers 
(TaqMan small RNA assays, Applied Biosystems) with qRT-PCR in cell lines, 
human urinary and prostate tissue samples. 
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3.2.2 Cell lines and androgen regulation of RNA 
The following cell lines (purchased from ATCC) were used: 
 
• Prostate- DU145, LNCaP, LNCaP-LN3, LNCaP-pro5, PC2, PC3M, 
PC3M-LN4 
• Lung- A549, NCI-H460 
• Endometrial- AN3CA 
• Bladder- EJ/T24, RT112, RT4 
• Colorectal- HCT-116 
• Human embryonic kidney- HEK293 
• Cervical- HeLa 
• T-cell lymphoma- Jurkat 
• Breast- MCF-7, T47D 
• Lung fibroblasts- MRC5 
• Ovarian- SKOV-3 
• Melanoma- WM793 
 
*Performed by Dr Ross Drayton* 
For the androgen regulation experiment, LNCaP cells (androgen-dependent 
cells) were grown in androgen-depleted media (phenol red free RPMI-1640 + 
10% charcoal stripped fetal bovine serum (FBS) (Sigma)) with no (0nmol/L), 
1nmol/L and 10nmol/L of testosterone (Sigma). Total RNA was extracted and 
PSA, PCA3, and PCA3-shRNA2 were measured using qRT-PCR with 
appropriate primers (Clarke et al., 2009). 
 
3.2.3 Expression of PCA3-shRNA in urinary samples 
The expression of short RNAs in urinary samples was measured by qRT-
PCR. RNA from exfoliated prostatic urinary cells was collected following 
prostatic massage in men with PCa and matching controls within a pilot and 
a validation cohort from the University of Sheffield. Controls were matched 
for age and PSA, and selected if they had undergone two or more negative 
PBx. Following prostatic massage, 10-20ml of urine was collected and 
centrifuged. The cell pellet was then washed in PBS before storage at -80oC.  
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3.2.4 RNA extraction and quantification (cell lines and urine) 
Total RNA was extracted from cell lines and patient urinary samples and 
were measured using qRT-PCR (Clarke et al., 2009; Dudziec et al., 2011). 
Primers for BMCC1, PCA3 and PSA were purchased from Applied 
Biosystems, Life Technologies. PCA3-shRNA primers (Sigma) were 
designed using sequences obtained from previous bioinformatics analysis. 
 
• Sequence A: ACTGCACTCCAGCCTGGGCA  
• Sequence B: CACTGCACTCCAGCCTGGGCA  
(Ambion: assay IDs, SCSGJ090 and CSHSNF8 respectively). 
 
Expression of PCA3, PCA3-shRNA and BMCC1 was normalized to PSA and 
fold changes calculated using Delta cycle threshold (DCt) values (Catto et al., 
2009). In brief, the DCt value was calculated from subtracting the control Ct 
value (PSA) from the test Ct value (i.e PCA3-shRNA). Delta DCt (DDCt) was 
the difference between the test DCt (cancer) and control DCt (benign). Fold 
change was calculated using –log2 of DDCt (Livak et al., 2001). For RNA 
localization studies, nuclear and cytoplasmic RNA fractions were extracted 
separately (Stuart et al., 2004). The expressions of the potential mRNA 
targets were measured in cell lines and patient urinary samples using qRT-
PCR (Dudziec et al., 2011).  
 
3.2.5 Cloning primary transcripts using 3’RACE 
*Performed by Dr Ross Drayton* 
To determine the sequence and genomic origin of the primary RNA transcript 
producing short-PCA3, 3’ Rapid Amplification of cDNA ends (3’ RACE) in 
PC3 cells using the GeneRacer Kit according to the manufacturer’s 
guidelines (Life Technologies) was performed. Total RNA was extracted from 
PC3 cells and cDNA synthesized by PCR using an adapter primer (AP) that 
targets the poly(A) tail of mRNA. Amplification of cDNA by PCR was 
performed using PCA3-shRNA primers.  
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The target sequences were cloned into E.coli (Top10; Left Technologies) and 
then extracted, purified and sent for Sanger sequencing. Sequences were 
aligned (Sequencher 5.1, Gene Codes), and genomic matches were 
identified using Basic Local Alignment Search Tool (BLAST, NCBI) (Altschul 
et al., 1990). 
 
3.2.6 mRNA target analysis and knock-up 
TargetScan (v4.2) was used to identify putative target mRNAs with 
complementary sequences to the short-PCA3. Potential targets were 
analysed for PCa relevance by cross-referencing with aberrantly expressed 
genes obtained from publicly available microarray datasets (Arrayexpress ID: 
E-GEOD-8218 (Wang et al., 2010)) Cellular functions and pathway 
enrichment for these mRNAs were analysed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 (Huang et al., 2009). 
 
Primers were designed for selected targets, and expression measured using 
qRT-PCR in LNCaP cells following PCA3-shRNA knock-up. Knockup was 
performed by transfecting LNCaP cells with a custom made hairpin precursor 
designed to generate PCA3-shRNA using Lipofectamine RNAiMAX (Catto et 
al., 2009). Transfection with scrambled RNA was used as a control. Success 
of transfection was obtained by measuring PCA3-shRNA expression using 
qRT-PCR. 
	
3.3 Results 
 
3.3.1 Identification of PCA3-shRNA 
A total of 13 potential RNA hairpins (Table 13) were identified following an in-
silico analysis of the BMCC1 locus. Each hairpin was derived from sequence 
within a BMCC1 intron and most were located around the PCA3 locus. A 
search of the prostate transcriptome (Martens-Uzunova et al., 2012) 
identified five of these RNAs, including RNA2 (second in the list), which we 
termed PCA3-shRNA2 (short RNA number 2), Table 13. This RNA 
accounted for 72 of 79 (91%) of hits. PCA3-shRNA2 was identified to be 
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located within PCA3 gene intron 1, adjacent to a region of high species 
conservation (Figure 17).  
 
Alignment of the transcriptomic sequences to the genome revealed two 
potential 5’ start sequences for PCA3-shRNA2; ACUG and a minority 
member starting with CACUG (Figure 18) We designed TaqMan assays to 
each (given that the 5’ end of short RNA is vital for mRNA targeting) and 
named these assays PCA3-shRNA2a and PCA3-shRNA2b, respectively 
(Bioinformatic identification of PCA3-shRNA was performed together with Dr 
Ross Drayton). 
 
3.3.2 Determination of the genomic origin of PCA3-shRNA 
These data support our transcriptomic analysis, however, do not prove that 
our short RNA is derived from sequence within the PCA3 intron. To analyse 
this, 3’ RACE to clone the primary sequence from the PCA3-shRNA2 primer 
was performed (performed by Dr Ross Drayton). Sequenced RACE products 
aligned to the PCA3 intronic locus and supported our in-silico prediction of a 
98-bp hairpin (Figure 19). A BLAST search of the 98-bp sequence revealed 
strong homology (97%) for one locus in the genome- within PCA3 intron 1 
(Figure 20). 
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Table 13. Predicted hairpin RNAs within PCA3 and BMCC1. 
ProMir and MiPred were used to search for predicted RNA hairpins from BMCC1. A total of 13 hairpins were found, 10 were predicted to be 
real, whilst three were pseudo- hairpin sequences with similar stem-loop features. Short RNA number 2 was found within intron 6 of the 
BMCC1 gene. The short RNA accounted for 72/79 (91.1%) of hits when the sequence was searched in a prostate cancer transcriptome.  
(Drayton et al., 2015).
End$(bp) BMCC1$Region Note Free$energy GC$ratio Entropy Promir$value MiPred$Result MiPred$Confidence Freq$in$Transcriptomic$data %$of$$hits31,365 Intron$1 J25.5 0.38 1.9508 0.0489 Pseudo 68.70% 1 1.3%93,278 Intron$6$(downstream$PCA3) Repeat,$first$75$bp$is$AluSx$(SINE/Alu) J30.8 0.45 1.97326 0.0451 Real 54.00% 72 91.1%100,952 Intron$6$(downstream$PCA3) Repeat,$MER5A$(DNA/MER1_type) J36.44 0.45 1.97809 0.0617 Real 66.90% 0 0.0%105,132 Intron$6$(downstream$PCA3) Conserved$in$4$mammals J27 0.33 1.8797 0.0635 Real 74.20% 0 0.0%115,526 Intron$6$(downstream$PCA3) J49.7 0.3 1.85017 5.0776 Real 74.20% 0 0.0%163,666 Intron$6$(upstream$PCA3) J46.3 0.46 1.98194 1.5115 Real 68.60% 0 0.0%176,673 Intron$6$(upstream$PCA3) Repeat,$MER5A$(DNA/MER1_type) J37 0.46 1.99233 0.0559 Real 62.90% 0 0.0%181,993 Intron$6$(upstream$PCA3) Conserved$in$human$dog$(see$the$alignment$in$the$end$of$the$file) J28.1 0.33 1.89539 0.0742 Real 61.10% 3 3.8%215,235 Intron$9 J30.9 0.51 1.99248 0.1165 Pseudo 50.80% 1 1.3%236,277 Intron$9 Repeat,$$L1HS$(LINE/L1) J34.8 0.47 1.91696 0.0531 Real 62.30% 2 2.5%247,401 Intron$9 Repeat,$Tigger4a$(DNA/MER2_type) J39.2 0.38 1.95071 85.884 Real 75.80% 0 0.0%254,347 Intron$10 Repeat,$$Tigger4a$(DNA/MER2_type) J29.03 0.36 1.94008 0.2239 Real 80.00% 0 0.0%268,339 Intron$12 J27.85 0.39 1.9288 0.6003 Pseudo 51.20% 0 0.0%
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Figure 17. Identification of PCA3-shRNA2.  
Our potential short-PCA3 is located in exon 6 of the BMCC1 gene. PCA3-shRNA2 is situated adjacent to a region of high species conservation 
within intron 1 of PCA3 (Drayton et al., 2015). 
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Figure 18. Alignment of the transcriptomic sequences to the genome.  
The predicted short PCA3 RNA hairpin identified is shown. Prostate cancer RNA 
transcriptomic data identified a relative abundance of our predicted RNA. The bases 
in red are those identified within the prostate transcriptome. Alignment of the 
transcriptomic sequences to the genome revealed two potential 5’ start sequences. 
(Drayton et al., 2015). 
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Figure 19. The genomic origin of PCA3-shRNA2.  
To determine the origin of our short RNA, 3’ RACE was used to clone the primary sequence from the PCA3-shRNA2 primer. 3’ RACE identified 
the longer hairpin structure in LNCaP cells. The predicted 98-bp PCA3-shRNA2 is highlighted in red (Drayton et al., 2015). 
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Figure 20. BLAST results of the PCA3-shRNA2 sequence. 
BLAST results of the 98bp fragment derived from PCA3-shRNA2 using 3’RACE indicated that the sequence is found within PCA3 
intron 1 (Drayton et al., 2015).  
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3.3.3 Expression of PCA3-shRNA 
3.3.3.1 Cell lines 
The expression of PCA3-shRNA2 was measured in 22 cell lines and 
expression was detectable in all 7 prostate and 15 other cancer cell lines 
(Figure 21). PCA3 and PCA3-shRNA2 expression did not vary significantly 
with organ of origin for these cell lines. RNA expression was normalized to 
PSA mRNA since the commercial PCA3 test uses PSA as a reference gene. 
A correlation between the expression of PCA3 and PCA3-shRNA2 (PCA3-
shRNA2a assay: r=0.92; P<0.001 and PCA3- shRNA2b assay: r=0.92; 
P<0.001) was identified, which was closer than for BMCC1 (r=0.56, P=0.01) 
(Figure 22). 
 
 
 
Figure 21. Expression of PCA3 and PCA3-shRNA2 in cell lines representing 
prostate cancer and other malignancies  
The expression of PCA3 and PCA3-shRNA2 is shown (normalized to PSA mRNA 
expression) for the 22 cell lines. Prostate cell lines are coloured in blue, and other 
malignancies in red. The non-prostate cancer cell lines are not labelled for clarity. In 
order of PCA3-shRNA2 expression these are (from HCT-116 (PCA3-shRNA2, 
DCt=-15.85), HEK 293, A549, NCI-H460, WM793, RT112, T47D, MRC5, AN3CA, 
RT4, SKOV-3, EJ, MCF-7, Jurkat and HeLa (PCA3-shRNA2, DCt=5.08)) (Drayton 
et al., 2015).  
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Figure 22. The correlation between PCA3-shRNA2 and PCA3/BMCC1. 
RNA was extracted from PCa cell lines and qRT-PCR was used to measure the 
expression of BMCC1, PCA3 and PCA3-shRNA2. Expression of PCA3-shRNA2 
(r=0.92, p<0001) is closely correlated with PCA3 and less so to BMCC1 (DCt values 
normalized to PSA expression shown)  (Drayton et al., 2015).  
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3.3.3.2 Urinary samples 
The clinical use for PCA3 is to test for PCa using exfoliated prostatic urinary 
cells. To explore this function for PCA3-shRNA2, its expression in 179 post-
DRE urinary samples (Table 14) from men with (n=129) and without PCa 
(n=50) was examined. Once again, there was a close correlation between 
PCA3 and PCA3-shRNA2 expression (Figure 23; r=0.84; P<0.001).  
Overall, there was upregulation of PCA3 (86.2+53.1 fold change (mean+ 
SD)), PCA3-shRNA2 (273+0.1) and BMCC1 (2.7+0.1) in specimens from 
men with cancer, when compared with controls (all t-test P<0.003, Figure 24).  
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Table 14. Clinical and histopathological characteristics of patients and 
samples.  
A pilot (n=179) and validation (n=471) urinary cohort was used in the current 
analysis. The age and PSA are shown in both the benign and malignant groups. 
Gleason score and T-stage are shown in the malignant group (Drayton et al., 2015). 
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Figure 23. The correlation between PCA3-shRNA2 and PCA3 in urinary 
RNA. 
RNA was extracted from the pilot (n=179) cohort of urinary samples obtained from 
patients with (n=129) and without (n=50) PCa. qRT-PCR was used to measure the 
expression of PCA3 and PCA3-shRNA2. The expression of PCA3-shRNA2 was 
closely correlated with PCA3 expression (r=0.84, p<0.001) (Drayton et al., 2015). 
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Figure 24. The expression of PCA3-ShRNA2, PCA3 and BMCC1 in urinary 
RNA. 
We showed that PCA3-shRNA2 expression correlated to that of PCA3. We 
compared the expression (qRT-PCR) of BMCC1, PCA3 and PCA3-shRNA2 in 
benign (n=50) and malignant (n=129) samples and found that the expression was 
higher in urinary pellets from men with PCa than in benign controls for PCA3, 
PCA3-shRNA2 and BMCC1 (P<0.003) (Drayton et al., 2015). 
 
To explore the robustness of these findings, a separate larger validation 
cohort of 471 urinary samples was examined. Once again, PCA3-shRNA2 
expression was correlated with PCA3 (r=0.60, p<0.01) (Figure 25). qRT-PCR 
revealed that PCA3-shRNA2 expression was higher in samples from men 
with prostate cancer than controls (13.0+2.8-fold upregulation (mean+SD) in 
malignant samples; t-test P<0.001; Figure 26). However, expression of 
PCA3-shRNA2 did not vary with tumour stage (Figure 27). 
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Figure 25. The correlation between PCA3-shRNA2 and PCA3 in a large 
urinary cohort. 
The expression (qRT-PCR) of PCA3 and PCA3-shRNA2 was measured in a larger 
validation (n=471) cohort of urinary samples. Expression of PCA3-shRNA2 was 
correlated with PCA3 expression (r=0.60, P<0.01), supporting our pilot exploration 
findings (Drayton et al., 2015).  
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Figure 26. The expression of PCA3-shRNA2 in benign and cancerous 
urinary samples. 
The expression (qRT-PCR) of PCA3 and PCA3-shRNA2 in benign (n=116) and 
malignant (n=355) samples from the larger validation (n=471) urinary cohort was 
compared. PCA3-shRNA2 is overexpressed in urinary samples obtained from men 
with PCa (Drayton et al., 2015). 
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Figure 27. The expression of PCA3-shRNA2 in different stages of disease. 
The expression (qRT-PCR) of PCA3-shRNA2 was compared in different stages of 
PCa. Expression was higher in urinary pellets from men with PCa than in BPH 
controls, but did not vary with cancer stage (ANOVA, P=0.46 between stages) 
(Drayton et al., 2015). 
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3.3.4 The ability of PCA3-shRNA2 to identify disease (urine) 
PCA3-shRNA2 allowed the identification of malignancy in most men. 
Concordance indices show that PCA3 (C-index 0.78) and PCA3-shRNA2 (C-
index 0.75) had similar accuracy for PCa, and both were superior to BMCC1 
(C-index 0.66) when analysing results from our pilot study (Figure 28a). On 
analysing the ability of PCA3-shRNA2 to identify disease within a larger 
validation cohort of urinary samples, results supported our pilot exploration 
outcomes (C-index 0.81, Figure 28b).  
 
a) 
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b) 
 
 
Figure 28. Identification of disease by PCA3-shRNA2. 
Receiver Operating Characteristic (ROC) curve analysis was used to explore the 
diagnostic performance of PCA3-shRNA. a) In comparison, PCA3 and PCA3-
shRNA2 expressions were more reliable (C-indices 0.78, 0.75, respectively) than 
BMCC1 (C-index 0.66) at identify the presence of the cancer; b) PCA3-shRNA2 
expression could identifythe presence of prostate cancer in mostmen (C-index 
0.81) in a large validation (n=471) urinary cohort (Drayton et al., 2015).  
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3.3.5 Androgen regulation of PCA3-shRNA2 
It is known that many RNAs important in prostate oncogenesis are regulated 
by androgens. In LNCaP cells (chosen for their androgen dependency), both 
PCA3 (2.1+0.31 fold change (mean+SD)) and PCA3-shRNA2 (2.75+0.23 
fold change (mean+SD)) were upregulated in a dose-dependent manner 
(Figure 29) by testosterone. The changes were minimal for PSA (219.0+25.2 
fold upregulation (mean+SD)).  
 
	
 
Figure 29. Androgen regulated expression of PSA, PCA3 and PCA3-
shRNA2.  
LNCaP cells were cultured in androgen-depleted media with 0, 1 and 10nM of 
testosterone. PSA, PCA3 and PCA3-shRNA2 expression was measured using qRT-
PCR. PCA3 and PCA3-shRNA2 expression was directly related to the concentration 
of testosterone (Drayton et al., 2015). 
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3.3.6 Functional role of PCA3-shRNA2 
It is known that miRNA/short RNA function by binding to target mRNA in the 
cytoplasm. To explore this role, the localization of PCA3-shRNA2 was 
examined followed by identifying target mRNAs. The expression of target 
mRNAs was measured in PCa cell lines and patient urinary samples.  
 
3.3.6.1 Localization of PCA3-shRNA2 
qRT-PCR of total and nuclear fractions revealed a cytoplasmic enrichment 
(nuclear:cytoplasmic ratio=0.6) for PCA3-shRNA2, close to that seen for 
established miRNAs (Figure 30), and very different from PCA3 (with its 
mostly nuclear localization). This suggests a potential mRNA targeting 
capacity within the cytoplasm. 
 
3.3.6.2 Identifying potential mRNA targets 
The genome for complementary sequences was searched. Using 
TargetScan, 178 mRNAs with complementary seed sequences (Table 15) 
were identified. Gene enrichment analysis (DAVID) revealed significant 
associations (P<0.05) with pathways important in cell regulation (i.e. cell 
adhesion and growth, and cell signalling) and prostate biology (i.e. response 
to steroids, TGF-β signalling, and uro-genital development).  
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Table 15. Predicted mRNA targets for PCA3-shRNA2. 
TargetScan revealed 178 mRNA targets with complementary sequence with PCA3-
shRNA2. Gene ID and Gene name are displayed in this table. 
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Gene ID Gene name 
1 KIAA0515 KIAA0515 
2 COPS2 COP9 constitutive photomorphogenic homolog subunit 2 
3 AFF3 AF4/FMR2 family, member 3 
4 SFRS2 splicing factor, arginine/serine-rich 2 
5 TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer factor) 
6 ANKHD1-EIF4EBP3 ANKHD1-EIF4EBP3 
7 ANKRD57 ankyrin repeat domain 57 
8 BTBD3 BTB (POZ) domain containing 3 
9 C13orf36 chromosome 13 open reading frame 36 
10 C8orf33 chromosome 8 open reading frame 33 
11 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 
12 CLDN22 claudin 22 
13 DCAKD dephospho-CoA kinase domain containing 
14 EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 
15 ETV1 ets variant gene 1 
16 ETV5 ets variant gene 5 (ets-related molecule) 
17 FAM123A family with sequence similarity 123A 
18 FAM123B family with sequence similarity 123B 
19 FAM40B family with sequence similarity 40, member B 
20 FLJ20309 hypothetical protein FLJ20309 
21 HDHD2 haloacid dehalogenase-like hydrolase domain containing 2 
22 INVS inversin 
23 IRF2BP2 interferon regulatory factor 2 binding protein 2 
24 LIN9 lin-9 homolog (C. elegans) 
25 LMNB1 lamin B1 
26 LSM11 LSM11, U7 small nuclear RNA associated 
27 MAP3K1 mitogen-activated protein kinase kinase kinase 1 
28 METTL8 methyltransferase like 8 
29 MLLT6 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog); translocated to, 6 
30 NOG noggin 
31 ODZ4 odz, odd Oz/ten-m homolog 4 (Drosophila) 
32 ORMDL1 ORM1-like 1 (S. cerevisiae) 
33 P15RS cyclin-dependent kinase 2B-inhibitor-related protein 
34 PDS5A PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) 
35 PHF21A PHD finger protein 21A 
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36 PHKA2 phosphorylase kinase, alpha 2 (liver) 
37 PIGA phosphatidylinositol glycan anchor biosynthesis, class A (paroxysmal nocturnal 
hemoglobinuria) 
38 PNMA1 paraneoplastic antigen MA1 
39 PSCDBP pleckstrin homology, Sec7 and coiled-coil domains, binding protein 
40 PXMP4 peroxisomal membrane protein 4, 24kDa 
41 RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 
42 RNF169 ring finger protein 169 
43 SESN2 sestrin 2 
44 SFRS12IP1 SFRS12-interacting protein 1 
45 SFRS2B splicing factor, arginine/serine-rich 2B 
46 SFRS3 splicing factor, arginine/serine-rich 3 
47 SOX11 SRY (sex determining region Y)-box 11 
48 SSR1 signal sequence receptor, alpha (translocon-associated protein alpha) 
49 TLR4 toll-like receptor 4 
50 TYW3 tRNA-yW synthesizing protein 3 homolog (S. cerevisiae) 
51 WDR1 WD repeat domain 1 
52 WDR48 WD repeat domain 48 
53 XPO7 exportin 7 
54 ZC3H10 zinc finger CCCH-type containing 10 
55 ZFAND6 zinc finger, AN1-type domain 6 
56 HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 
57 LIN54 lin-54 homolog (C. elegans) 
58 SPTBN1 spectrin, beta, non-erythrocytic 1 
59 ABI1 abl-interactor 1 
60 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 
61 ANKH ankylosis, progressive homolog (mouse) 
62 APH1A anterior pharynx defective 1 homolog A (C. elegans) 
63 ARL5B ADP-ribosylation factor-like 5B 
64 BRPF1 bromodomain and PHD finger containing, 1 
65 CCNL2 cyclin L2 
66 CPEB2 cytoplasmic polyadenylation element binding protein 2 
67 CROP cisplatin resistance-associated overexpressed protein 
68 CTBP2 C-terminal binding protein 2 
69 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
70 EHMT1 euchromatic histone-lysine N-methyltransferase 1 
71 EIF3J eukaryotic translation initiation factor 3, subunit J 
72 EIF4G3 eukaryotic translation initiation factor 4 gamma, 3 
73 EML1 echinoderm microtubule associated protein like 1 
74 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 
75 GATAD2A GATA zinc finger domain containing 2A 
76 H3F3B H3 histone, family 3B (H3.3B) 
77 HMGB2 high-mobility group box 2 
78 HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 
79 IKZF2 IKAROS family zinc finger 2 (Helios) 
80 ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 
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81 KCMF1 potassium channel modulatory factor 1 
82 KCNA4 potassium voltage-gated channel, shaker-related subfamily, member 4 
83 LHFPL4 lipoma HMGIC fusion partner-like 4 
84 LMO7 LIM domain 7 
85 LOC399947 similar to expressed sequence AI593442 
86 MAGI2 membrane assoc'd guanylate kinase, WW and PDZ domain containing 2 
87 MAP4K4 mitogen-activated protein kinase 4 
88 MBOAT1 membrane bound O-acyltransferase domain containing 1 
89 MEIS1 Meis homeobox 1 
90 MN1 meningioma (disrupted in balanced translocation) 1 
91 MON2 MON2 homolog (S. cerevisiae) 
92 NDN necdin homolog (mouse) 
93 NLK nemo-like kinase 
94 NMNAT2 nicotinamide nucleotide adenylyltransferase 2 
95 OPCML opioid binding protein/cell adhesion molecule-like 
96 P2RY4 pyrimidinergic receptor P2Y, G-protein coupled, 4 
97 PAX3 paired box 3 
98 PBRM1 polybromo 1 
99 PKD2 polycystic kidney disease 2 (autosomal dominant) 
100 PPP1R8 protein phosphatase 1, regulatory (inhibitor) subunit 8 
101 PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) 
102 PRPF40B PRP40 pre-mRNA processing factor 40 homolog B (S. cerevisiae) 
103 PURB purine-rich element binding protein B 
104 RAP2C RAP2C, member of RAS oncogene family 
105 RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
106 RELT RELT tumor necrosis factor receptor 
107 SENP6 SUMO1/sentrin specific peptidase 6 
108 SLC25A1 solute carrier family 25 (mitochondrial citrate transporter), member 1 
109 SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 
110 SLC38A4 solute carrier family 38, member 4 
111 SNX22 sorting nexin 22 
112 SOCS5 suppressor of cytokine signalling 5 
113 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
114 THSD7A thrombospondin, type I, domain containing 7A 
115 TNNI1 troponin I type 1 (skeletal, slow) 
116 UNK unkempt homolog (Drosophila) 
117 USP7 ubiquitin specific peptidase 7 (herpes virus-associated) 
118 VEGFA vascular endothelial growth factor A 
119 VGLL4 vestigial like 4 (Drosophila) 
120 WSB2 WD repeat and SOCS box-containing 2 
121 ZFAND3 zinc finger, AN1-type domain 3 
122 ZFHX4 zinc finger homeobox 4 
123 ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) 
124 ZNF516 zinc finger protein 516 
125 ZNF740 zinc finger protein 740 
126 ZNF827 zinc finger protein 827 
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127 tcag7.1228 hypothetical protein FLJ25778 
128 ABHD13 abhydrolase domain containing 13 
129 ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 
130 ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 
131 ASB8 ankyrin repeat and SOCS box-containing 8 
132 BLID BH3-like motif containing, cell death inducer 
133 BRMS1L breast cancer metastasis-suppressor 1-like 
134 C1orf83 chromosome 1 open reading frame 83 
135 C22orf15 chromosome 22 open reading frame 15 
136 CD84 CD84 molecule 
137 CEP350 centrosomal protein 350kDa 
138 CSDE1 cold shock domain containing E1, RNA-binding 
139 DCP1A DCP1 decapping enzyme homolog A (S. cerevisiae) 
140 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 
141 DLX2 distal-less homeobox 2 
142 FAM104A family with sequence similarity 104, member A 
143 GMEB2 glucocorticoid modulatory element binding protein 2 
144 HAO1 hydroxyacid oxidase (glycolate oxidase) 1 
145 KIAA1147 KIAA1147 
146 KLHL20 kelch-like 20 (Drosophila) 
147 LIMCH1 LIM and calponin homology domains 1 
148 LPCAT3 lysophosphatidylcholine acyltransferase 3 
149 MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
150 MAPK1 mitogen-activated protein kinase 1 
151 MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog) translocated to 4 
152 MTF1 metal-regulatory transcription factor 1 
153 NAV1 neuron navigator 1 
154 PISD phosphatidylserine decarboxylase 
155 RALBP1 ralA binding protein 1 
156 RAVER1 ribonucleoprotein, PTB-binding 1 
157 RPE ribulose-5-phosphate-3-epimerase 
158 SDC4 syndecan 4 
159 SDK1 sidekick homolog 1, cell adhesion molecule (chicken) 
160 SMAD4 SMAD family member 4 
161 SOCS1 suppressor of cytokine signalling 1 
162 SOCS6 suppressor of cytokine signalling 6 
163 SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 
164 SSH2 slingshot homolog 2 (Drosophila) 
165 TARDBP TAR DNA binding protein 
166 TIAM2 T-cell lymphoma invasion and metastasis 2 
167 ZAK sterile alpha motif and leucine zipper containing kinase AZK 
168 ZNF263 zinc finger protein 263 
169 ZNF618 zinc finger protein 618 
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Figure 30. Expression of PCA3-shRNA2 and primary/mature miRNAs 
according to nuclear and cytoplasmic localization. 
The nuclear:cytoplasmic RNA expression is shown for PCA3-shRNA2 (red) 
and various primary and mature microRNAs for comparison. For each 
mature short RNA (including PCA3-shRNA2, ratio 0.60), the majority of the 
transcript is expressed within the cytoplasm, (ratio <1) in contrast to the 
primary pri-miR hairpin transcript (ratio >1). The majority of the PCA3 mRNA 
is within the nucleus (nuclear:cytoplasmic ratio 454.2) (Drayton et al., 2015).  
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3.3.6.3 The selection and expression of mRNA targets in cell lines 
The target mRNAs were annotated with their expression in human PCa 
samples (Stuart et al., 2004), and were preferentially selected if they’re 
known to be downregulated in cancer (reflecting our hypothesized targeting 
by upregulated PCA3-shRNA2: defined as fold change <1.0 and t-test 
P<0.05) or implicated in PCa biology, and having high predicted binding 
affinity (e.g. 8-mer seed). The resultant panel (Table 16) included interesting 
potential targets, such as ETS variant genes 1 and 5 (ETV1 and ETV5), 
mitogen-activated protein kinase 1 (MAPK31), noggin, N-cadherin, and TEA 
domain family member 1 (SV40 transcriptional enhancer factor).  
 
Transfection of DU145 cells (chosen as they have low endogenous PCA3-
shRNA2 expression) with the PCA3-shRNA2 plasmid and a scrambled RNA 
sequence was performed. A 1000 fold change seen with PCA3-shRNA2 
plasmid represents successful transfection (Figure 31). RNA expression of 
these 12 predicted targets (Table 17, primers) was measured in PCA3-
shRNA2 transfected DU145 cells. Reciprocal knockdown of COPS2 (COP9 
signalosome subunit 2), SOX11 (sex determining region Y HMG-box 11), 
WDR48, TEAD1, and Noggin, suggestive of targeting was identified (Table 
16).  
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Table 16. Selected potential mRNA targets of PCA3-shRNA2. 
TargetScan revealed 178 potential mRNA targets of PCA3-shRNA2. A total of 12 mRNA targets were selected for evaluation. These mRNA 
have high predicted binding affinity, are known to be downregulated in cancer (Stuart et al., 2004) or implicated in prostate oncogenesis. The 
expression of the 12 mRNAs were measured following transfection of DU145 cells with PCA3-shRNA2 plasmid. Fold change was calculated 
relative to non-transfected cells (Drayton et al., 2015). *’Mer’ suffix refers to the number of bases. 
Gene$Id Gene$Name 8$Mer 7Mer.M
8
7Mer.1
A
Microa
rray$Ex
pressio
n:$Fold
$
Chang
e$<1.0$
&$p<0.
05
Fold$ch
ange$$$
$$$$$$$$$$$$
$$$$$$$$$$$$
$
(DU14
5$&$PC
A3.shR
NA2$
(mean
$±st.$de
v.))$
Cell$Ad
hesion
Cell$Gr
owth
Cell$Su
rface$S
ignallin
g
Growt
h$Regu
lation
Negati
ve$Reg
ulation
$of$
Prolife
ration
Protein
$Signal
ling
Regula
tion$of
$Trans
criptio
n
TGFB$S
ignallin
g
Transm
embra
ne$Sign
alling
Urogen
ital$De
velopm
ent/Se
x$
Develo
pment
COPS2 COP9$constitutive$photomorphogenic$homolog$subunit$2 1 1 0 0 0.24 ±0.15 1SOX11 SRY$(sex$determining$region$Y).box$11 1 0 0 0 0.36 ±0.31 1 1WDR48 WD$repeat$domain$48 1 0 0 1 0.51 ±0.2TEAD1 TEA$domain$family$member$1$ 1 0 1 1 0.57 ±0.32 1NOG Noggin 1 0 0 0 0.72 ±0.27 1 1 1 1 1 2WDR1 WD$repeat$domain$1 1 0 0 1 0.86 ±0.32INVS Inversin 1 0 0 0 1.06 ±0.53 1 1CDH2 N.cadherin 1 0 0 1 1.37 ±1.87 1MAP3K1 Mitogen.activated$protein$kinase$kinase$kinase$1 1 0 0 0 1.54 ±0.93 1 1 1 1 1 1ETV5 Ets$variant$gene$5 1 0 0 1 1.55 ±0.39 1KIAA0515 KIAA0515 2 0 0 0 1.59 ±1.35ETV1 Ets$variant$gene$1 1 0 0 0 3.35 ±3.2 1
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Figure 31. Transfection of DU145 with PCA3-shRNA2 and controls. 
DU145 cells were transfected with PCA3-shRNA2 (red) or a scrambled RNA 
sequence (mock). Expression of PCA3-shRNA2 in cells transfected with PCA3-
shRNA2 (Red), scrambled RNA sequence and untransfected cells (control) is 
shown. Bars represent the mean of three independent repeats and standard 
deviation. A 1000 fold change seen with PCA3-shRNA2 plasmid (red) represents 
successful transfection (Drayton et al., 2015).  
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Table 17.  Primers and condition used to detect target mRNAs. 
TargetScan revealed 178 mRNA targets of PCA3-shRNA2. mRNAs (n=12) with predicted high binding affinity and implicated in prostate 
oncogenesis were selected for validation. Primers and conditions used for qRT-PCR are shown (Drayton et al., 2015).
ID	 Name	 Fwd	Primer	 Rev	Primer	 Annealing	Temp	 Amplicon	Size	KIAA0515	 KIAA0515		 TGGCTCACCTTCGTCATCTGA	 TCATCCTCGGATACTGTTGGAA	 60	°C	 215	COPS2	 COP9	constitutive	photomorphogenic	homolog	subunit	2	(Arabidopsis)	 TTTTACGCCAGTTACATCAGTCG	 CTTCCCTCAAGTGCATTTTACCA	 60	°C	 234	TEAD1	 TEA	domain	family	member	1	(SV40	transcriptional	enhancer	factor)	 GGCCGGGAATGATTCAAACAG	 CAATGGAGCGACCTTGCCA	 60	°C	 165	CDH2	 cadherin	2,	type	1,	N-cadherin	(neuronal)	 TCAGGCGTCTGTAGAGGCTT	 ATGCACATCCTTCGATAAGACTG	 60	°C	 94	ETV1	 ets	variant	gene	1	 TGGCAGTTTTTGGTAGCTCTTC	 CGGAGTGAACGGCTAAGTTTATC	 60	°C	 170	ETV5	 ets	variant	gene	5	(ets-related	molecule)	 CAGTCAACTTCAAGAGGCTTGG	 TGCTCATGGCTACAAGACGAC	 60	°C	 168	INVS	 inversin	 TGCTCTACAGAGGCTCATCGT	 ACGCAATACATAAGTGGTGTTCT	 60	°C	 84	MAP3K1	 mitogen-activated	protein	kinase	kinase	kinase	1	 TCTCACCATATAGCCCTGAGGA	 AGGAAAGAGTTAGGCCCTATCTG	 60	°C	 97	NOG	 noggin	 CCATGCCGAGCGAGATCAAA	 TCGGAAATGATGGGGTACTGG	 60	°C	 337	SOX11	 SRY	(sex	determining	region	Y)-box	11	 AGGATTTGGATTCGTTCAGCG	 AGGTCGGAGAAGTTCGCCT	 60	°C	 121	WDR1	 WD	repeat	domain	1	 TGGGATTTACGCAATTAGTTGGA	 CCAGATAGTTGATGTACCCGGAC	 60	°C	 209	WDR48	 WD	repeat	domain	48	 TGGGACAATTCGCCTTTGGTC	 TGTCAGGGTTTCTTAGGTCTGT	 60	°C	 164	
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3.3.6.4 Expression of target mRNAs in urinary samples 
The mRNA expression of the two strongest (largest reciprocal fold change 
following PCA3-shRNA2 transfection) candidates (COPS2 and SOX11) was 
measured in the larger urinary sample cohort (n=471) to look for biologic 
associations in-vivo. There was a significant inverse correlation between the 
expression of COPS2 and PCA3-shRNA2 (Figure 32, r=-0.32, P<0.001) and 
reduced expression of COPS2 in the PCa samples (Figure 33, fold change, 
0.29+0.5; t-test P<0.001) was identified when compared with controls. Non-
significant lower expression for SOX11 was also seen in cancerous samples 
(fold change, 0.74+1.5; P=0.08) when compared with controls and this 
mRNA was not significantly correlated with PCA3-shRNA2 expression (r=-
0.1; P=0.48).  
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Figure 32. The correlation between COPS2 and PCA3-shRNA2 in urinary 
samples. 
COPS2 had the lowest fold change when DU145 cells were transfected with PCA3-
shRNA2 and was further validated in the larger urinary cohort (n=471). The 
expression (qRT-PCR) of COPS2 was inversely correlated to that of PCA3-shRNA2 
(Drayton et al., 2015). 
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Figure 33. The expression of COPS2 in urinary samples. 
COPS2 expression (qRT-PCR) was measured in urinary samples (n=471). 
Expression of COPS2 was lower in the urinary cells of patients with prostate cancer 
(n=355) when compared to BPH (n=116) controls (Drayton et al., 2015). 
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3.4 Discussion  
Many transcribed RNAs do not encode proteins and these RNAs are termed 
non-coding RNAs. They are classified according to size and cellular location. 
Although short RNAs/miRNAs (~20-22-bp in size) have been extensively 
studied (Catto et al., 2011), little is known about the function of most long 
ncRNAs. Long ncRNAs may have direct involvement in chromatin 
remodeling and androgen receptor regulation (Yang et al., 2013), and may 
be processed into shorter more active ncRNAs. Many miRNAs are clustered 
together and are derived from single primary transcripts (i.e. miRs-24-
2/27a/23a) (Drayton et al., 2014). Rogler et al showed that RNase MRP (a 
268-bp ncRNA component of mitochondrial RNA processing 
endoribonuclease) was the source for two shorter (~20-bp) RNAs involved in 
the biology of cartilage-hair hypoplasia (Rogler et al., 2014). Therefore, we 
hypothesized that PCA3 could be a source for short biologically active RNAs. 
 
3.4.1 Identification of PCA3-shRNA2 and expression in urinary samples 
We present in-silico and in-vitro data suggesting that a short RNA hairpin is 
produced during processing of the PCA3 transcript. This short RNA is 
located within intron 1 of PCA3, close to a region of high species 
conservation, suggesting biologic protection. Our short ncRNA expression 
appeared closely correlated with that for PCA3 in both cell lines and urinary 
samples. This was expected as our data suggested that the short RNA is 
derived from the PCA3 transcript. In post-prostate massage (DRE) urinary 
cell pellets from two large patient cohorts, we found that PCA3-shRNA2 
detected PCa with a similar accuracy to PCA3.  
 
Unlike long ncRNAs, short ncRNAs are stable molecules and do not decay 
with repeated freeze-thawing or prolonged storage at room temperature. We 
previously showed that short RNAs do not dramatically degrade with freeze-
thawing  and prolonged storage at room temperature (in plain clean universal 
containers without RNase inhibitors)  (Miah et al., 2012). As such, PCA3-
shRNA2 may be a more stable biomarker for PCa than the current PCA3 test. 
Assays to detect our PCA3-shRNA2 would not be as vulnerable to delays in 
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handling or variations in stringency in collection, and so should be more 
reproducible.  
 
3.4.2 The biological role of PCA3-shRNA2 
Nuclear and cytoplasmic RNA ratios suggested that PCA3-shRNA2 is 
abundant in the cytoplasm. In contrast, PCA3 is more abundant in the 
nucleus. This finding is not entirely clear but may suggest a potential 
functional mRNA targeting role in the cytoplasm for PCA3-shRNA2. Another 
method to investigate RNA localization include RNA fluorescence in-situ 
hybridization (FISH) (Coassin et al., 2014). An unbiased genome-wide 
computational search through the use of TargetScan (potential mRNA 
targets), annotation from PCa microarray (genes implicated in PCa) and 
DAVID (oncogenic significance) identified genes and pathways implicated in 
the biology of PCa. 
 
Our targeting analysis identified expression changes in COPS2, SOX11, 
WDR48, TEAD1, and Noggin when PCA3-shRNA2 upregulation was 
induced. These mRNAs are involved in the regulation of gene transcription, 
uro-genital tract development, and in cell growth and signalling. Therefore, 
they appear ideal oncogenic gene candidates. We explored the expression 
of COPS2 and SOX11 in exfoliated urinary cell pellets. We found that 
COPS2 expression was inversely correlated to PCA3-shRNA2 and 
significantly reduced in cancerous urinary samples (p<0.001), suggesting 
biological validation. Although, SOX11 expression was also inversely 
correlated to PCA3-shRNA2 and its expression was lower in cancerous 
urinary samples, this did not reach statistical significance.  
 
COPS2 is a transcription corepressor that underwent a decreased 
expression in cells with PCA3-shRNA2 upregulation. COPS2 is a component 
of the COP9 signalosome complex that regulates the ubiquitin conjugation 
pathway during various cellular and developmental processes, including 
phosphorylation of p53. COPS2 is abundantly expressed in most human 
tissues, suggesting an important role in cellular homeostasis, but has not 
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been studied in depth with respect to human malignancies. SOX11 is a 
transcription factor belonging to the SRY-related HMG-box (SOX) family. 
These regulate many biological processes, including haematopoiesis, 
vasculogenesis, and cardiogenesis during embryonic development (Stovall 
et al., 2014), and some members are negative regulators of the WNT-beta-
catenin-TCF pathway (Katoh, 2002) which is associated with prostate biology. 
Although Katoh et al reported reduced expression of SOX7 in PCa cells, 
SOX11 function and expression has not been reported in PCa at the time of 
our analysis.  
 
Of the other predicted targets, noggin appears particularly interesting 
because of its association with bone metastasis. Noggin is an antagonist of 
bone morphogenetic proteins (BMP) (Haudenschild et al., 2004), which has 
been reported to be downregulated in PCa cells (Schwaninger et al., 2007; 
Secondini et al., 2011). Noggin loss leads to the development of bone 
metastases. Therefore, reversal of noggin loss may be used to palliate or 
reduce the activity of osteolytic malignant disease.  
 
3.5 Conclusions 
We found a short RNA (PCA3-shRNA2) that is derived from the PCA3 gene 
that is probably co-expressed with PCA3. We identified a potential role for 
this ncRNA in PCa biology. The short RNA may be a more suitable target of 
the PCA3 biomarker assay.  
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CHAPTER 5: PCA3-shRNA2 Expression and Eventual 
Diagnosis of Prostate Cancer 
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5.1 Background 
In Chapter 3 we reported retrospectively our initial and repeat PBx data from 
the Sheffield cohort of the ProtecT study. Patients with an initial negative 
biopsy and persistently elevated PSA levels are difficult to manage. Our data 
showed that 321/920 (34.9%) men were diagnosed with PCa on initial biopsy 
and 66/248 (26.6%) were diagnosed with PCa on rPBx. These data were 
consistent with the international data presented in Table 12. Whilst MRI now 
appears a promising tool in this context, there is an urgent need to identify 
biomarkers that may inform rPBx decisions. 
 
In Chapter 4 we identified a short RNA within PCA3, which we termed PCA3-
shRNA2. We showed that PCA3-shRNA2 was expressed in PCa cell lines 
and overexpressed in urinary samples obtained from patients with PCa. In 
addition, we explored the functional roles of this short RNA and found that it 
targets mRNAs involved in PCa biology (including COPS2 and SOX11).  
 
Our initial analysis of PCA3-shRNA2 used urine samples from men with and 
without PCa. All specimens were taken at first presentation or diagnosis 
(Drayton et al., 2015). Although PCA3-shRNA2 appeared to be a promising 
option as a urinary biomarker, its expression in PBx tissues warranted 
exploration, since the PROGENSA PCA3 assay is clinically advocated for 
guiding rPBx in men with an elevated PSA. We aimed to investigate whether 
PCA3-shRNA obtained from the negative initial PBx has a predictive role in 
PCa detection on rPBx.  
 
5.2 Methods 
 
5.2.1 Expression of PCA3-shRNA2 in FFPE samples 
The pathology database for men with an initial PBx between 1994 and 2010 
(to allow follow-up) was searched. An annotation with clinical details, the 
number and timing of rPBx, and the eventual diagnosis of PCa was 
performed. Men whose initial PBx did not show cancer were identified, and a 
matched cohort whose rPBx did or did not find PCa was made.  
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5.2.2 RNA extraction from prostate biopsies (FFPE) 
The formalin fixed paraffin embedded (FFPE) blocks from the initial PBx 
were retrieved, and cut sections at 10µm thickness were obtained 
(Sectioning from FFPE blocks was performed by Maggie Glover). One 
section was stained with H&E to confirm diagnosis and extraction of RNA 
was performed from the remaining. Paraffin (deparaffinization solution, 
Qiagen, UK) was removed before lysis with Proteinase K. Samples were 
treated with DNase to eliminate all genomic DNA, before washing and elution 
in RNase-free water. Total and miRNA were extracted using miRNeasy 
FFPE kit (Qiagen, UK) as per manufacturer’s protocol and measured using a 
2100 Bioanalyzer (Agilent).  
	
As detailed (Drayton et al., 2015) extracted RNA was subject to real-time 
quantitative RT-PCR (HT7900 PCR system) using the High-capacity reverse 
transcription cDNA kit (Applied Biosystems) and the TaqMan microRNA 
Reverse Transcription kit (Applied Biosystems). RNA expression was 
determined using qPCR with TaqMan primers for PSA (Assay ID: 
Hs03063374_m1), PCA3 (Assay ID: Hs03309852_g1) and two custom 
designed TaqMan assays, PCA3-shRNA2A and PCA3-shRNA2B. 
 
PCA3-shRNA2A 
ACTGCACTCCAGCCTGGGCA (Ambion: assay IDs, CSGJ090) 
 
PCA3-shRNA2B 
CACTGCACTCCAGCCTGGGCA (Ambion: assay IDs, CSHSNF8) 
 
Expression of PCA3, and PCA3-shRNA2 was normalized to PSA  (Clarke et 
al., 2009) calculated using DCt values (Miah et al., 2012). 
 
PSA forward  
5-GCATCAGGAACAAAAGCGTG-3 
PSA reverse 
5-CCTGAGGAATCGATTCTTCA-3 
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5.3 Results  
	
5.3.1 Patients and FFPE samples 
Residual tissue from the first PBx (between 2002 and 2008) of 116 men with 
an eventual diagnosis of PCa (rPBx between 2002 and 2013) and 94 men 
without PCa were obtained (Table 18). The two populations were broadly 
comparable for clinical features. The mean (±SD) age at referral within our 
cohort was 63.5 (±7.1) for men with cancer and 62.5 (±6.5) years for those 
with benign PBx. The mean initial PSA was 9.5 (±1.8) and 13.2 (±61.4) in the 
cancer and benign group respectively. A total of 17/23 (73.4%) men with 
suspicious findings and 4/7 (57.1%) men with HGPIN on initial PBx were 
found to have cancer on rPBx.  The majority of cancers (n=74, 64%) were 
detected on the second PBx and Gleason score 3+3=6 was the most 
common grade amongst these tumours (n= 78, 67.2%). The mean (SD) time 
to diagnosis of PCa from the initial negative PBx was 29.8 (±36.6) months. 
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Table 18. Patients and FFPE samples analysed in this report. 
A total of 210 men had a negative initial PBx. All men underwent at least one rPBx 
and 116 men were found to have PCa. The age and PSA in the malignant and 
matched benign groups, and the Gleason score for PCa detected on rPBx are 
shown. (Pang et al., 2017). 
5.3.2 Expression of PCA3-shRNA2 in prostate biopsies (FFPE) 
PSA and PCA3-shRNA2 RNA was detected in all samples, and PCA3 mRNA 
in 190 (90%) biopsies. Expression of PCA3 and PCA3-shRNA2 was 
normalized to PSA mRNA, as for the PROGENSA assay. As seen previously, 
expression of PCA3 and PCA3-shRNA2 were correlated (Pearson’s r=0.69, 
p<0.01, Figure 34) suggesting co-expression. Interestingly, there appeared 
no deterioration in RNA yield across the time period that the samples were 
stored (Figure 35). 
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Figure 34. Scatterplot of PCA3 and PCA3-shRNA2 RNA expression 
normalized to PSA mRNA in FFPE benign prostate biopsies. 
 
RNA was extracted from FFPE samples and PCA3 and PCA3-shRNA2 expression 
was measured with qRT-PCR. PCA3-shRNA2 was correlated to PCA3 expression 
in FFPE benign prostate sample (Pang et al., 2017). 
 
*Red: prostate cancer detected on repeat biopsies; Black: benign 
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Figure 35. PSA, PCA3 and PCA3-shRNA2 expression in FFPE prostate biopsies stratified by year of collection. 
FFPE initial PBx specimens were retrieved and categorized into years they were obtained. PSA, PCA3 and PCA3-shRNA2 expression (qRT-
PCR) was measured. The level of PCA3-shRNA2 (also PSA and PCA3) expression did not vary in PBx obtained between 2002 and 2008 
(Pang et al., 2017). 
* Line in the box represents the median and whiskers represent the highest and lowest DCt value.
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5.3.3 PCA3-shRNA2 expression and eventual diagnosis 
RNA expression with the eventual diagnosis in each man was compared. We 
saw upregulation of PCA3 (average 2.1-fold) and PCA3-shRNA2 (average 
1.5-fold) in men with an eventual diagnosis of cancer, when compared to 
those with only benign histology (Table 19). For PCA3, this difference 
reached statistical difference (t-test p=0.02), but this was not the case for 
PCA3-shRNA2 (p=0.2, Figure 36). When evaluating PCA3 and PCA3-
shRNA2 expression with respect to Gleason scores, PCA3 expression was 
significantly higher in low Gleason Scores. No differences were observed 
with PCA3-shRNA2 (Figure 37). 
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  Eventual diagnosis 
  Cancer Benign Fold change** t-test 
  Mean DCt* ± St. Dev Mean DCt* ± St. Dev   p-value 
PCA3-shRNA2  -16.53 3.24 -15.99 3.61 1.45 0.20 
PCA3  6.40 3.03 7.48 2.86 2.12 0.02 
 
Table 19. RNA expression stratified by eventual diagnosis. 
PCA3 and PCA3-shRNA2 expression was measured in the initial PBx FFPE specimens obtained from men with or without PCa detected on 
rPBx. There was a significant elevated PCA3 RNA level (fold change 2.12, p=0.02) from men who were diagnosed with PCa on rPBx (Pang et 
al., 2017). 
	
* Delta Ct (DCt) normalized to PSA mRNA 
**Fold change in patients with cancer versus. those with BPH 
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Figure 36. Box plot of PCA3 and PCA3-shRNA2 expression stratified for 
eventual diagnosis. 
PCA3 and PCA3-shRNA3 expression (qRT-PCT) was measured in FFPE. PCA3 
and PCA3-shRNA2 DCt levels were normalized to PSA mRNA. The expression of 
PCA3 in FFPE of initial PBx were significantly higher in men who were diagnosed 
with PCa on rPBx compared to benign pathology (Pang et al., 2017). 
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Figure 37. PSA, PCA3 and PCA3-shRNA2 expression in tissues with 
respect to Gleason grade. 
 
The expression of PCA3 and PCA3-shRNA2 (normalized to PSA) in FFPE initial 
PBx specimens was compared across Gleason scores. PCA3 expression is higher 
in low-grade disease (Gleason 6). No differences in PCA3-shRNA2 expression was 
seen with respect to Gleason scores (Pang et al., 2017). 
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5.3.4 The ability of PCA3-shRNA2 to identify disease (PBx FFPE) 
To determine predictive role, we calculated the concordance index for each 
RNA (Figure 38). Whilst, PCA3 was associated with the detection of PCa (C-
index 0.61, p=0.01), this was not the case for PCA3-shRNA2 (C-index 0.55, 
p=0.22). 
 
 
	
	
	
Figure 38. Predictive ability of PCA3 and PCA3-shRNA2 expression for the 
eventual diagnosis of prostate cancer. 
Receiver operating characteristic curve analysis was used to assess the diagnostic 
role of PCA3-shRNA2 in FFPE. The concordance index for PCA3 and PCA3-
shRNA2 was 0.61 and 0.55 respectively (Pang et al., 2017).  
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5.4 Discussion	
The clinical context of the PCA3 assay is to guide further investigation in 
men with an elevated serum PSA, whose PBx do not reveal cancer. With this 
in mind, we undertook a further analysis of PCA3 in rPBx specimens. Whilst 
the PCA3 assay uses urine samples to measure PCA3, this resource was 
not available, and others have found that urine PCA3 expression reflects that 
within tissues (Hessels et al., 2003). Both RNAs and proteins are considered 
good candidates for biomarkers in FFPE tissues, due to their stability over 
long periods of time (Sequeiros et al., 2013). 
 
We selected men with and without PCa, matched for age, PSA and duration 
of rPBx, and extracted RNA from stored FFPE tissue not used during 
pathological reporting. We identified several key findings. Despite storage at 
room temperature for 8-14 years, we detected robust expression of PSA and 
PCA3 and PCA3-shRNA2. The latter was most abundant, in keeping with its 
stability and ease of detection. We identified correlated expression of the two 
RNAs expressed from the PCA3 gene confirming our previous observations 
and suggesting that the short ncRNA is a product of PCA3 transcription 
(Drayton et al., 2015). These two observations suggest that PCA3-shRNA2 
may be incorporated into the PCA3 assay to facilitate easier handling of the 
biological samples prior to laboratory measurement. 
 
However, our experiments failed to support our primary hypothesis, namely 
that PCA3-shRNA2 expression was associated with a subsequent diagnosis 
of PCa. This is in contrast to expression of PCA3 mRNA within our 
population, and may reflect that this ncRNA is not expressed by PCa, that 
ncRNAs have a dynamic expression that is less stable than mRNAs over 
time, or that our experimental design was wrong. With regards to the former, 
we previously found high malignant expression of PCA3-shRNA2 in three 
separate cohorts (i.e. PCa cell lines, fresh frozen microdissected prostatic 
tissues and prostate massage fluids) suggesting this may not be the 
explanation. With regards to dynamic expression, it is known that one 
function of short ncRNAs is to epigenetically regulate mRNA expression. 
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This regulation is dynamic, with ncRNA expression fluctuating depending 
upon the cellular needs and stress. For example, individual ncRNAs have 
been found to have both oncogenic and tumour suppressive roles, 
depending upon the context (Svoronos et al., 2016). Thus, it is plausible that 
2-3 years before the diagnosis of cancer, PCA3-shRNA2 expression is not 
elevated, as the target mRNAs (such as COPS2 and SOX11) do not have, 
as yet, altered function in the prostate. With regards to experimental design, 
we powered the study using expression estimates and used FFPE tissues (to 
replace urine samples). We did find a trend towards upregulation of PCA3-
shRNA2 in cancer, suggesting under-powering of the sample size. It may 
also be that FFPE tissues do not preserve differential expression of all RNAs. 
Of note, previous analyses of PCA3 expression in PBx tissues have reported 
inconsistencies, with upregulation in PCa and no difference between 
malignant and normal prostate (Klecka et al., 2010; Paziewska et al., 2014; 
Alinezhad et al., 2016). 
 
Extracting good quality RNA from stored FFPE can be difficult as quality is 
affected by paraffin, and often FFPE specimens become brittle due to age 
which makes sectioning difficult resulting in lower yields of useable tissue. 
The yield and molecular weight of recovered RNA are often low as evident in 
our current analysis. Although we detected PCA3-shRNA2 in the historic 
FFPE specimens, we should have used RNA integrity number (RIN) to 
measure RNA integrity prior to qRT-PCR and also sequencing of the PCR 
product in order to confirm detection (Schroeder et al., 2006; Bustin et al., 
2009). The positive controls used for the urinary/FFPE experiments were 
PSA (used to normalize PCA3 and PCA3-shRNA2) and U1/GAPDH. 
Negative control was non-template control (NTC) using NF-water. In addition, 
the use of controls without reverse transcription enzymes and appropriate 
primer design (e.g. intron-spanning) are important to exclude the possibility 
of genomic DNA amplification. Other positive controls that could have been 
used include RNU 44/48 and hsa-miR-26b/92 as these control RNAs have 
been shown the least variability.  
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5.5 Conclusion	
We showed stable expression of PSA, PCA3 and PCA3-shRNA2 in historic 
PBx samples. Whilst PCA3 and PCA3-shRNA2 expression were correlated, 
only the former was significantly associated with the presence of occult PCa.  
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CHAPTER 6: N6-Adenosine Methylation and Cancer 
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6.1 Background 
Although PCA3-shRNA2 is expressed in urinary and PBx (FFPE) samples 
obtained from patients with PCa (Chapter 4 and 5), and overexpressed in the 
former when compared with benign samples, we found no correlation 
between localised and advanced disease. In addition, the mechanistic drive 
for the aberrant RNA expression was unknown. To explore mechanisms of 
altered RNA expression in PCa, we focused upon RNA methylation as a 
newly identified epigenetic trait. Whilst it has been known for many years that 
methylation of N6-adenosine base (m6A) is the most common epigenetic 
modification of RNA (Wei et al., 1976), technological limitations have 
prevented in-depth analysis (Pollex et al., 2010). Recent molecular advances 
have now overcome these limitations and the epigenome wide distribution of 
m6A has been reported in a human (hepatocellular carcinoma cell line 
(HepG2)) and mouse (normal liver) cells (Dominissini et al., 2012). The 
authors identified over 12,000 m6A sites on mRNAs of >7,000 human genes, 
these sites were highly conserved between human and mouse, and 
preferentially located within stop codons and long internal exons. They also 
identified that m6A is a dynamic mark, associated with cell stimuli and cell 
phenotypes. N6-methyladenosine is known to be regulated by ‘writers’ 
(METTL3/4/14, WTAP), ‘erasers’ (FTO, ALKBH5) and ‘readers’ 
(YTHDF1/2/3), and is associated with RNA splicing, export, decay and 
translation (Jia et al., 2011; Fu et al., 2014). In addition, it has been shown 
that m6A is associated with a wide range of disease processes including 
obesity, inflammation and cancer (Leukaemia, prostate, breast, colorectal, 
gastric cancers) (Maity et al., 2015). 
 
The importance of the m6A in malignancy is reported, but the extent and 
relative distribution of this event in common cancers is currently unknown (Fu 
et al., 2014). In addition, to date, mammalian m6A sites have been mapped 
and characterized in only a small number of mammalian cell lines/tissues. 
Whether m6A is abundant across common human tumours is unknown. 
 
We hypothesised that the conservation of m6A sites would allow an in-silico 
analysis to determine the likely extent of m6A within common cancers, and 
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the potential biological implications of this. Using an in-silico approach, we 
aimed to explore whether m6A was abundant in a range of tumours and 
compared the expression of mRNAs reported to undergo methylation of N6-
adenosine in a sample of common human cancers including prostate, 
bladder, renal, lung, breast, ovarian, colorectal and gastric cancer. Part two 
of this project involved identifying m6A within androgen-sensitive (LNCaP) 
and its metastatic (LNCaP-LN3) sibling cell lines through methylated RNA 
immunoprecipitation and next generation sequencing (MeRIP-seq).	
 
6.2 Methods 
	
5.2.1 In-silico analysis of m6A 
5.2.1.1 Selection and annotation of RNA transcriptomic datasets  
Array Express (http://www.ebi.ac.uk/arrayexpress/ 2014) was searched for 
publically deposited RNA expression microarray datasets reporting 
transcriptomes within prostate, bladder, renal, lung, breast, ovarian, 
colorectal and gastric cancer. Commercially manufactured, non-custom 
platforms were filtered (preferentially selecting the Affymetrix HG-
U133A/B/plus 2 platforms) to reduce experimental variation between 
experiments. Processed data in tab-delimited text (*.txt) files were extracted, 
annotated for RNA locus, sample details and m6A susceptibility. m6A 
susceptibility was defined using topology by Dominissini et al. (Dominissini et 
al. 2012); specifically, susceptible loci were RNAs whose N6-adenosine 
methylation peaked under all experimental conditions (untreated, exposure 
to ultraviolet-radiation, heat shock, hepatocyte growth factor and interferon-γ) 
in HepG2 hepatic cell carcinoma and normal human brain cells.  
 
6.2.1.2 RNA Selection 
Differential mRNA expression was calculated within each microarray dataset 
using the Significance Analysis of Microarrays (SAM) method, Student’s t-
test p<0.001 and FDR <0.05 (Tusher et al., 2001). Fold change (FC) was 
calculated using median values across each sample type. Comparisons were 
between malignant and non-malignant tissues within each cancer, between 
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cancer types and within cancer phenotypes when available (e.g. androgen-
sensitive prostate cancer (AS-PCa) and castration-resistant prostate cancer 
(CRPC)). Differentially expressed mRNAs were ranked according to m6A 
susceptibility (m6A susceptible, m6A(+); m6A not susceptible, m6A(-)) and 
the frequency of their aberrant expression (across and within cancer types). 
To predict oncogenic processes that involve m6A, the DAVID bioinformatics 
database (http://david.abcc.ncifcrf.gov/ 2014) (Huang et al. 2009) was used 
to identify the gene ontology (GO) terms that are enriched for m6A predicted 
transcripts. Coding genes were functionally clustered at ‘high’ stringency, 
and clusters with an enrichment score of >1.5 were selected for analysis.  
 
6.2.1.3 Statistical analysis 
Data were plotted using GraphPad Prism 6 and Microsoft Excel 2016. 
Parametric continuous data were compared using Student’s t-test and a 
threshold of p>0.05 was considered significant. Differential mRNA 
expression was calculated using SAM method (Student’s t-test p<0.001 and 
FDR <0.05). 
 
6.2.2 Immunoprecipitation and sequencing of m6A 
To test our in-silico findings in cultured cells, RNA extraction followed by 
m6A immunoprecipitation and RNA sequencing was performed. RNA 
extraction and fragmentation using Prime 5 PerfectPure RNA cultured cell kit 
(Scientific Laboratory Supplies) was described in Chapter 2.4.1. A total of 
2mg of total RNA was extracted from each LNCaP and LNCaP-LN3 cell lines. 
Fragmentation was performed using Zinc Chloride and fragmented RNA was 
subject to IP using anti-m6A rabbit polyclonal antibody (Synaptic Systems). 
Immunoprecipitation with the same amount of input RNA (1mg total RNA) 
without anti-m6A antibody served as a negative control. RNA-sequencing on 
the IP libraries was performed using an Illumina Hi-Seq 2500 (Performed by 
Emilie Jarratt from the Sheffield diagnostic genetic services, Sheffield 
children’s hospital). Bioinformatic analyses were performed with colleagues 
(Dr Ian Sudbery and Dr James Bradford) from the University of Sheffield 
Bioinformatic Hub (Chapter 2.5.1). 
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6.3 Results 
 
6.3.1 Microarray datasets and sample population 
At total of 47 microarray datasets (Tables 20 and 21) reporting mRNA 
profiles in 2,405 (range: 172-998) cancer and 1,434 (83-616) control samples 
were identified and extracted (Lenburg et al., 2003; Dyrskjøt et al., 2004; 
Jones et al., 2005; Hendrix et al., 2006; Liu et al., 2006; Richardson et al., 
2006; Gumz et al., 2007; Moreno et al., 2007; Chandran et al., 2007; Galamb 
et al., 2008, 2010; Bahrani-Mostafavi et al., 2008; Landi et al., 2008; 
Arredouani et al., 2009; Gyorffy et al., 2009; Mok et al., 2009; Casey et al., 
2009; Yusenko et al., 2009; D’Errico et al., 2009; Hou et al., 2010; Kim et al., 
2010; Pau Ni et al., 2010; Shiraishi et al., 2010; Skrzypczak et al., 2010; 
Wang et al., 2010, 2012, 2013; Zhang et al., 2010; Holbrook et al., 2011; 
King et al., 2011; Sanchez-Palencia et al., 2011; Chen et al., 2011; Cho et al., 
2011; Alhopuro et al., 2012; Jia et al., 2012; Lopez et al., 2012; Okayama et 
al., 2012; Urquidi et al., 2012; Eftang et al., 2013; Kuner et al., 2013; Clarke 
et al., 2013; Ryan et al., 2014). These datasets included multiple 
comparisons between malignant and non-malignant (benign/normal) tissues 
and two datasets comparing AS-PCa with CRPC (Best et al., 2005; Cai et al., 
2013). The average mean (SD) experiment size was 84.6 (±63.7) samples.  
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Table 20. Total number of cancer and control samples within each cancer 
type. 
 
A total of 47 datasets were extracted from Array express and analysed. 
Percentages of m6A susceptible (m6A+) and non-susceptible (m6A-) mRNAs of 
those with significant aberrant expression (Student’s t-test p<0.001) in cancer are 
shown. 
 
CRPC, castration-resistant prostate cancer; ca, cancer	
	
	
Cancer Number 
Datasets 
Total samples  
(n, range) 
% m6A (+) 
Mean (range) 
% m6A (-) 
Mean (range) 
Prostate 7 Ca: 292 (11-68) 
Control: 294 (8-71) 
47.8 (37.6-55.1) 52.2 (45.0-62.4) 
CRPC 2 CRPC: 39 (10-29) 
AS-PCa: 32 (10-22) 
57.2 (56.2-58.2) 42.8 (41.8-43.8) 
Bladder 4 Ca: 291 (10-188) 
Control: 129 (7-68) 
49.9 (42.5-59.4) 50.1(40.6-57.6) 
Renal 6 Ca: 175 (10-69) 
Control: 56 (4-23) 
40.1 (26.3-54.1) 59.9 (46.0-73.7) 
Breast 6 Ca: 342 (42-104) 
Control: 232 (7-143) 
45.2 (39.0-54.8) 54.8 (45.2-61.1) 
Lung 6 Ca: 481 (30-226) 
Control: 219 (20-65) 
41.7 (27.3-55.4) 58.3 (44.6-72.7) 
Colorectal 5 Ca: 213 (15-81) 
Control: 140 (8-55) 
52.9 (47.8-59.2) 47.1 (40.8-52.2) 
Ovarian 5 Ca: 252 (32-99) 
Control: 65 (4-35) 
48.6 (36.2-56.8) 51.4 (43.2-63.8) 
Gastric 6 Ca: 320 (12-134) 
Control: 267 (15-134) 
45.8 (39.7-53.9) 54.2 (46.1-60.3) 
Total 47 Ca: 2405 (172-998) 
Control: 1434 (83-616) 
46.7 (26.3-59.4) 53.3 (40.6- 73.7) 
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Table 21. Summary of the 47 microarray datasets extracted from Array Express. 
The number (%) and mean fold changes (FC) of aberrantly (t-test p<0.001) expressed transcripts that are susceptible (m6A+) and not susceptible 
(m6A-) to m6A-methylation are shown. mRNAs were also subcategorised into upregulation (FC within top 10% percentile) and downregulation (FC 
within bottom 10% percentile). 
 
Author Cancer 
Cancer 
(n) 
Benign/Norma
l (n) Array m6A+ n % 
Mean (SD) 
FC m6A- n % 
Mean (SD) 
FC Reference 
Wang Y Prostate 53 71 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.04 Total 11643 
52.4
% 
 
Wang Y 2010 
     
p<0.001 3077 
29.1
% 1.00 + 0.06 p<0.001 2555 
21.9
% 1.01 + 0.07 Jia Z 2011 
     
p<0.001 
FC>90% 927 8.8% 1.07 + 0.04 
p<0.001 
FC>90% 986 8.5% 1.08 + 0.05 
 
     
p<0.001 
FC<10% 1074 
10.2
% 0.94 + 0.03 
p<0.001 
FC<10% 730 6.3% 0.94 + 0.04 
 
              
Wang Y Prostate 68 69 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 0.05 Total 35660 
65.3
% 
  
     
p<0.001 5464 
28.8
% 1.01 + 0.08 p<0.001 7394 
20.7
% 0.99 + 0.10 
 
     
p<0.001 
FC>90% 1471 7.8% 1.09 + 0.07 
p<0.001 
FC>90% 2176 6.1% 1.11 + 0.07 
 
     
p<0.001 
FC<10% 1222 6.4% 0.92 + 0.03 
p<0.001 
FC<10% 2999 8.4% 0.90 + 0.04 
 
              
Liu P Prostate 44 13 HG-U133A Total 
1046
4 
47.3
% 1.03 + 0.37 Total 11669 
52.7
% 
 
Liu P 2006 
     
p<0.001 409 3.9% 1.08 + 0.63 p<0.001 334 2.9% 1.07 + 0.81 
 
     
p<0.001 
FC>90% 134 1.3% 1.81 + 0.56 
p<0.001 
FC>90% 95 0.8% 2.12 + 0.81 
 
     
p<0.001 
FC<10% 124 1.2% 0.56 + 0.12 
p<0.001 
FC<10% 156 1.3% 0.54 + 0.15 
 
              
 
Prostate 44 13 HG-U133B Total 6691 29.6 1.02 + 0.32 Total 15886 70.4
 
Liu P 2006 
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% % 
     
p<0.001 111 1.7% 1.48 + 0.66 p<0.001 184 1.2% 1.60 + 0.89 
 
     
p<0.001 
FC>90% 58 0.9% 1.82 + 0.74 
p<0.001 
FC>90% 118 0.7% 2.00 + 0.87 
 
     
p<0.001 
FC<10% 9 0.1% 0.63 + 0.05 
p<0.001 
FC<10% 31 0.2% 0.61 + 0.01 
 
              
Chandran R Prostate 11 81 HG-U95Av2,B,C Total 
1346
7 
35.7
% 1.04 + 0.22 Total 24223 
64.3
% 
 
Chandran R 2007 
     
p<0.001 959 7.1% 0.97 + 0.35 p<0.001 889 3.7% 1.00 + 0.46 
 
     
p<0.001 
FC>90% 164 1.2% 1.52 + 0.31 
p<0.001 
FC>90% 230 0.9% 1.59 + 0.43 
 
     
p<0.001 
FC<10% 485 3.6% 0.70 + 0.11 
p<0.001 
FC<10% 446 1.8% 0.65 + 0.13 
 
              
Kuner R Prostate 59 39 
Illumina HumanHT-12 
v3.0 Total 
1275
0 
26.2
% 1.00 + 0.02 Total 35902 
73.8
% 
 
Kuner R 2012 
     
p<0.001 2692 
21.1
% 1.00 + 0.06 p<0.001 3073 8.6% 0.99 + 0.60 
 
     
p<0.001 
FC>90% 1320 
10.4
% 1.05 + 0.04 
p<0.001 
FC>90% 1179 3.3% 1.05 + 0.04 
 
     
p<0.001 
FC<10% 1290 
10.1
% 0.95 + 0.03 
p<0.001 
FC<10% 1754 4.9% 0.94 + 0.03 
 
              
Arredouani M Prostate 13 8 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.02 + 0.37 Total 35660 
65.3
% 
 
Arredouani M 2009 
     
p<0.001 337 1.8% 1.25 + 1.83 p<0.001 397 1.1% 1.33 + 1.09 
 
     
p<0.001 
FC>90% 138 0.7% 2.14 + 2.62 
p<0.001 
FC>90% 194 0.5% 2.02 + 1.18 
 
     
p<0.001 
FC<10% 154 0.8% 0.58 + 0.12 
p<0.001 
FC<10% 151 0.4% 0.54 + 0.12 
 
              
Best CJ CRPC 10 10 HG-U133A Total 
1054
6 
47.5
% 
 
Total 11669 
52.5
% 
 
Best CJ 2005 
   
AS-PCa 
 
p<0.001 32 0.3% 0.74 + 0.72 p<0.001 23 0.2% 1.23 + 1.16 
 
     
p<0.001 
FC>90% 3 0.0% 2.77 + 0.91 
p<0.001 
FC>90% 9 0.1% 2.49 + 0.83 
 
     
p<0.001 
FC<10% 20 0.2% 0.46 + 0.17 
p<0.001 
FC<10% 14 0.1% 0.41 + 0.12 
 
              
Cai C CRPC 29 22 HG-U133A Total 8942 
49.2
% 
 
Total 9244 
50.8
% 
 
Cai C 2013 
   
AS-PCa 
 
p<0.001 1628 18.2 1.68 + 2.51 p<0.001 1268 13.7 1.85 + 2.24 
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% % 
     
p<0.001 
FC>90% 631 7.1% 2.59 + 3.81 
p<0.001 
FC>90% 585 6.3% 2.80 + 2.98 
 
     
p<0.001 
FC<10% 340 3.8% 0.50 + 0.16 
p<0.001 
FC<10% 271 2.9% 0.45 + 0.17 
 
              
Kim WJ Bladder 188 68 Illumina Human- v2 Total 7846 
31.4
% 1.00 + 0.04 Total 17150 
68.6
% 
 
Kim WJ 2010 
     
p<0.001 3780 
48.2
% 1.00 + 0.06 p<0.001 5116 
29.8
% 0.99 + 0.06 
 
     
p<0.001 
FC>90% 1361 
17.3
% 1.06 + 0.03 
p<0.001 
FC>90% 905 5.3% 1.05 + 0.03 
 
     
p<0.001 
FC<10% 827 
21.9
% 0.92 + 0.04 
p<0.001 
FC<10% 1416 8.3% 0.91 + 0.05 
 
              
Dyrskjøt L Bladder 41 14 HG-U133A Total 
1057
2 
47.6
% 1.08 + 0.48 Total 11643 
52.4
% 
 
Dyrskjøt L 2004 
     
p<0.001 3512 
33.2
% 1.51 + 0.69 p<0.001 3526 
30.3
% 1.00 + 0.63 
 
     
p<0.001 
FC>90% 1273 
12.0
% 2.16 + 0.59 
p<0.001 
FC>90% 536 4.6% 2.17 + 0.54 
 
     
p<0.001 
FC<10% 356 3.4% 0.54 + 0.09 
p<0.001 
FC<10% 1316 
11.3
% 0.54 + 0.08 
 
              
Urquidi V Bladder 52 40 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.03 + 0.29 Total 35660 
65.3
% 
 
Urquidi V 2012 
 
 (urine) 
   
p<0.001 11 0.1% 1.54 + 0.77 p<0.001 12 0.0% 1.24 + 0.79 
 
     
p<0.001 
FC>90% 6 0.0% 2.03 + 0.68 
p<0.001 
FC>90% 5 0.0% 1.99 + 0.45 
 
     
p<0.001 
FC<10% 2 0.0% 0.66 + 0.07 
p<0.001 
FC<10% 5 0.0% 0.44 + 0.14 
 
              
Zhang Z  Bladder 10 7 HG-U133 Plus 2.0 Total 7790 
44.4
% 1.00 + 0.09 Total 9737 
55.6
% 
 
Zhang Z 2010 
     
p<0.001 41 0.5% 0.95 + 0.12 p<0.001 28 0.3% 1.13 + 0.30 
 
     
p<0.001 
FC>90% 6 0.1% 1.19 + 0.07 
p<0.001 
FC>90% 13 0.1% 1.40 + 0.24 
 
     
p<0.001 
FC<10% 22 0.3% 0.88 + 0.04 
p<0.001 
FC<10% 11 0.1% 0.89 + 0.02 
 
              
              
Gumz M Renal 10 10 HG-U133A Total 
1057
2 
47.6
% 1.22 + 2.54 Total 11643 
52.4
% 
 
Gumz M 2007 
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p<0.001 1603 
15.2
% 1.06 + 2.63 p<0.001 1583 
13.6
% 1.60 + 2.68 
 
     
p<0.001 
FC>90% 452 4.3% 3.99 + 4.07 
p<0.001 
FC>90% 418 3.6% 4.52 + 3.88 
 
     
p<0.001 
FC<10% 379 3.6% 0.34 + 0.12 
p<0.001 
FC<10% 655 5.6% 0.28 + 0.15 
 
              
 
Renal 10 10 HG-U133B Total 6691 
29.6
% 1.11 + 1.83 Total 15886 
70.4
% 
  
     
p<0.001 758 
11.3
% 1.81 + 3.15 p<0.001 1302 8.2% 1.53 + 6.55 
 
     
p<0.001 
FC>90% 273 4.1% 3.68 + 4.66 
p<0.001 
FC>90% 343 2.2% 
4.35 + 
12.34 
 
     
p<0.001 
FC<10% 181 2.7% 0.34 + 0.13 
p<0.001 
FC<10% 548 3.4% 0.30 + 0.15 
 
              
Yusenko M Renal 62 5 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.07 + 0.97 Total 35660 
65.3
% 
 
Yusenko M 2009 
     
p<0.001 1212 6.4% 1.97 + 1.61 p<0.001 1729 4.8% 2.63 + 3.45 
 
     
p<0.001 
FC>90% 559 2.9% 2.81 + 2.04 
p<0.001 
FC>90% 1060 3.0% 3.58 + 4.11 
 
     
p<0.001 
FC<10% 51 0.3% 0.28 + 0.14 
p<0.001 
FC<10% 106 0.3% 0.25 + 0.13 
 
              
Jones J Renal 69 23 HG-U133A Total 
1057
2 
47.6
% 1.25 + 0.74 Total 11643 
52.4
% 
 
Jones J 2005 
     
p<0.001 6659 
63.0
% 1.42 + 0.65 p<0.001 5662 
48.6
% 1.39 + 1.22 
 
     
p<0.001 
FC>90% 1164 
11.0
% 2.21 + 2.17 
p<0.001 
FC>90% 1024 8.8% 2.55 + 2.46 
 
     
p<0.001 
FC<10% 411 3.9% 0.51 + 0.19 
p<0.001 
FC<10% 834 7.2% 0.47 + 0.20 
 
              
Lenburg M Renal 12 4 HG-U133A Total 
1057
2 
47.6
% 1.24 + 1.55 Total 11643 
52.4
% 
 
Lenburg M 2003 
     
p<0.001 5 0.0% 1.06 + 0.59 p<0.001 14 0.1% 2.25 + 1.41 
 
     
p<0.001 
FC>90% 1 0.0% 1.95 
p<0.001 
FC>90% 7 0.1% 3.42 + 0.91 
 
     
p<0.001 
FC<10% 2 0.0% 0.62 + 0.06 
p<0.001 
FC<10% 3 0.0% 0.58 + 0.08 
 
              
 
Renal 12 4 HG-U133B Total 6691 29.6 1.09 + 0.85 Total 15886 70.4
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% % 
     
p<0.001 32 0.5% 1.60 + 1.34 p<0.001 69 0.4% 1.91 + 2.22 
 
     
p<0.001 
FC>90% 14 0.2% 2.86 + 0.99 
p<0.001 
FC>90% 27 0.2% 4.05 + 2.24 
 
     
p<0.001 
FC<10% 11 0.2% 0.33 + 0.17 
p<0.001 
FC<10% 26 0.2% 0.42 + 0.10 
 
              
Bong I Breast 43 43 HG-U133A Total 
1057
2 
47.6
% 0.96 + 0.56 Total 11643 
52.4
% 
 
Bong I 2009 
     
p<0.001 605 5.7% 1.17 + 1.60 p<0.001 500 4.3% 1.14 + 2.94 
 
     
p<0.001 
FC>90% 220 2.1% 2.27 + 2.26 
p<0.001 
FC>90% 131 1.1% 2.99 + 5.34 
 
     
p<0.001 
FC<10% 352 3.3% 0.52 + 0.15 
p<0.001 
FC<10% 346 3.0% 0.48 + 0.18 
 
              
Casey T Breast 56 10 HG-U133A 2.0 Total 
1057
7 
47.5
% 1.00 + 0.10 Total 11700 
52.5
% 
 
Casey T 2009 
     
p<0.001 300 2.8% 0.99 + 0.23 p<0.001 369 3.2% 1.02 + 0.28 
 
     
p<0.001 
FC>90% 116 1.1% 1.19 + 0.16 
p<0.001 
FC>90% 168 1.4% 1.22 + 0.23 
 
     
p<0.001 
FC<10% 99 0.9% 0.75 + 0.12 
p<0.001 
FC<10% 98 0.8% 0.72 + 0.16 
 
              
Clarke C Breast 104 17 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 0.16 Total 35660 
65.3
% 
 
Clarke C 2013 
     
p<0.001 5279 
27.9
% 1.06 + 0.29 p<0.001 6679 
18.7
% 1.04 + 0.32 
 
     
p<0.001 
FC>90% 2098 
11.1
% 1.31+ 0.25 
p<0.001 
FC>90% 2505 7.0% 1.34 + 0.24 
 
     
p<0.001 
FC<10% 1264 6.7% 0.71+ 0.13 
p<0.001 
FC<10% 1769 5.0% 0.65+ 0.16 
 
              
Lopez FJ Breast 54 12 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 0.10 Total 35660 
65.3
% 
 
Lopez FJ 2012 
     
p<0.001 3874 
20.4
% 0.97+ 0.17 p<0.001 6072 
17.0
% 0.99+ 0.18 
 
     
p<0.001 
FC>90% 907 4.8% 1.19+ 0.11 
p<0.001 
FC>90% 1521 4.3% 1.19+ 0.12 
 
     
p<0.001 
FC<10% 1466 7.7% 0.81+ 0.08 
p<0.001 
FC<10% 1812 5.1% 0.77+ 0.11 
 
              
Richardson  Breast 43 7 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 
1.20 + 
19.08 Total 35660 
65.3
% 
 
Richardson AL 2006 
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p<0.001 3941 
20.8
% 
1.88+ 
15.43 p<0.001 5376 
15.1
% 
1.10+ 
30.07 
 
     
p<0.001 
FC>90% 1095 5.8% 
4.62+ 
28.83 
p<0.001 
FC>90% 1625 4.6% 
3.57+ 
16.15 
 
     
p<0.001 
FC<10% 841 
21.3
% -0.05+ 4.65  
p<0.001 
FC<10% 841 
15.6
% 
-4.39+ 
72.38    
 
              
Chen DT Breast 42 143 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 0.06 Total 35660 
65.3
% 
 
Chen DT 2010 
     
p<0.001 6799 
35.9
% 1.01+ 0.10 p<0.001 7901 
22.2
% 0.98+ 0.10 
 
     
p<0.001 
FC>90% 2681 
14.1
% 1.10+ 0.06 
p<0.001 
FC>90% 1878 5.3% 1.10+ 0.08 
 
     
p<0.001 
FC<10% 1745 9.2% 0.90+ 0.05 
p<0.001 
FC<10% 2981 8.4% 0.88+ 0.06 
 
              
Landi M Lung 58 49 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.02 Total 11643 
52.4
% 
 
Landi M 2008 
     
p<0.001 3 0.0% 0.98 + 0.05 p<0.001 8 0.1% 1.08 + 0.01 Shiraishi T 2010 
     
p<0.001 
FC>90% 1 0.0% 1.04 
p<0.001 
FC>90% 4 0.0% 1.08 + 0.04 
 
     
p<0.001 
FC<10% 2 0.0% 0.95 + 0.00 
p<0.001 
FC<10% 4 0.0% 0.94 + 0.04 
 
              
GirardA Lung 30 20 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.05 Total 11643 
52.4
% 
  
     
p<0.001 2996 
28.3
% 1.00 + 0.09 p<0.001 2412 
20.7
% 0.97 + 0.11 
 
     
p<0.001 
FC>90% 1064 
10.1
% 1.08 + 0.04 
p<0.001 
FC>90% 676 5.8% 1.09 + 0.06 
 
     
p<0.001 
FC<10% 851 8.0% 0.89 + 0.05 
p<0.001 
FC<10% 989 8.5% 0.88 + 0.07 
 
              
GirardB Lung 30 20 HG-U133B Total 6691 
29.6
% 1.00 + 0.04 Total 15886 
70.4
% 
  
     
p<0.001 1613 
24.1
% 1.00 + 0.08 p<0.001 2707 
17.0
% 0.99 + 0.09 
 
     
p<0.001 
FC>90% 644 9.6% 1.07 + 0.04 
p<0.001 
FC>90% 948 6.0% 1.08 + 0.05 
 
     
p<0.001 
FC<10% 545 8.1% 0.91 + 0.05 
p<0.001 
FC<10% 1018 6.4% 0.91 + 0.06 
 
              Hou J Lung 91 65 HG-U133 Plus 2.0 Total 1895 34.7  -0.24 + Total 35660 65.3
 
Hou J 2010 
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3 % 42.93 % 
     
p<0.001 
1040
8 
54.9
%  -0.60 + 2.9 p<0.001 15809 
44.3
% 
 -0.63 + 
2.66 
 
     
p<0.001 
FC>90% 18 0.1% 
16.41 + 
67.73 
p<0.001 
FC>90% 106 0.3% 
6.81 + 
16.42 
 
     
p<0.001 
FC<10% 359 1.9% 
 -2.01+ 
1.43 
p<0.001 
FC<10% 1108 3.1% 
 -3.06+ 
7.55 
 
              Sanchez-
Palencia  Lung 46 45 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 0.11 Total 35660 
65.3
% 
 
Sanchez-Palencia A 
2010 
     
p<0.001 8903 
47.0
% 1.02 + 0.16 p<0.001 10652 
29.9
% 0.97 + 0.18 
 
     
p<0.001 
FC>90% 2922 
15.4
% 1.17 + 0.15 
p<0.001 
FC>90% 2301 6.5% 1.21 + 0.22 
 
     
p<0.001 
FC<10% 1718 9.1% 0.84 + 0.07 
p<0.001 
FC<10% 3452 9.7% 0.81 + 0.09 
 
              
Okayama H Lung 226 20 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.11 + 1.73 Total 35660 
65.3
% 
 
Okayama H 2012 
     
p<0.001 8134 
42.9
% 1.23 + 0.80 p<0.001 9884 
27.7
% 1.33 + 3.20 
 
     
p<0.001 
FC>90% 1491 7.9% 2.19 + 1.39 
p<0.001 
FC>90% 2456 6.9% 2.52 + 6.22 
 
     
p<0.001 
FC<10% 1140 6.0% 0.48 + 0.13 
p<0.001 
FC<10% 2321 6.5% 0.44 + 0.15 
 
              
Galamb O 
Colorecta
l 15 8 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.00 + 1.10 Total 35660 
65.3
% 
 
Galamb 2008 
     
p<0.001 672 3.5% 1.54 + 1.17 p<0.001 657 1.8% 1.66 + 5.01 Gyorffy B 2009 
     
p<0.001 
FC>90% 366 1.9% 2.20 + 1.22 
p<0.001 
FC>90% 208 0.6% 4.02 + 8.44 
 
     
p<0.001 
FC<10% 83 0.4% 0.48 + 0.09 
p<0.001 
FC<10% 254 0.7% 0.43 + 0.12 
 
              
Alhopuro P 
Colorecta
l 34 15 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.07 Total 11643 
52.4
% 
 
Alhopuro P 2011 
     
p<0.001 2471 
23.4
% 1.06+ 0.11 p<0.001 1705 
14.6
% 1.00+ 0.15 
 
     
p<0.001 
FC>90% 1207 
11.4
% 1.14+ 0.07 
p<0.001 
FC>90% 539 4.6% 1.15+ 0.09 
 
     
p<0.001 
FC<10% 423 4.0% 0.87+ 0.07 
p<0.001 
FC<10% 602 5.2% 0.85+ 0.10 
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Galamb O 
Colorecta
l 27 38 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.11 + 2.62 Total 35660 
65.3
% 
 
Galamb O 2012 
     
p<0.001 6026 
31.8
% 1.43+ 3.18 p<0.001 6571 
18.4
% 1.34+ 6.42 
 
     
p<0.001 
FC>90% 1842 9.7% 2.65+ 5.53 
p<0.001 
FC>90% 1390 3.9% 
3.93+ 
13.63 
 
     
p<0.001 
FC<10% 871 4.6% 0.42+ 0.13 
p<0.001 
FC<10% 2458 6.9% 0.37+ 0.15 
 
              
Skrzypczak  
Colorecta
l 81 24 HG-U133 Plus 2.0 Total 
1301
2 
51.2
% 1.01 + 0.13 Total 12398 
48.8
% 
 
Skrzypczak M 2010 
     
p<0.001 5138 
39.5
% 1.05+ 0.16 p<0.001 4476 
36.1
% 1.01+ 0.23 
 
     
p<0.001 
FC>90% 1317 
10.1
% 1.22+ 0.16 
p<0.001 
FC>90% 999 8.1% 1.27+ 0.26 
 
     
p<0.001 
FC<10% 679 5.2% 0.81+ 0.09 
p<0.001 
FC<10% 1212 9.8% 0.75+ 0.13 
 
              
Ryan BM 
Colorecta
l 56 55 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.05 Total 11643 
52.4
% 
 
Ryan BM 2014 
     
p<0.001 1880 
17.8
% 1.01+ 0.08 p<0.001 1626 
14.0
% 0.98+ 0.11 
 
     
p<0.001 
FC>90% 836 7.9% 1.08 + 0.04 
p<0.001 
FC>90% 575 4.9% 1.10 + 0.06 
 
     
p<0.001 
FC<10% 627 5.9% 0.92 + 0.04 
p<0.001 
FC<10% 766 6.6% 0.88 + 0.07 
 
              
Moreno CS Ovarian 33 10 HG-U95Av2 Total 6010 
91.8
% 1.00 + 0.04 Total 6548 
52.1
% 
 
Moreno CS 2007 
     
p<0.001 1 0.0% 1.11 p<0.001 1 0.0% 1.05 
 
     
p<0.001 
FC>90% 1 0.0% 1.11 
p<0.001 
FC>90% 1 0.0% 1.05 
 
     
p<0.001 
FC<10% 0 0.0% 0 
p<0.001 
FC<10% 0 0.0% 0 
 
              
Hendrix ND Ovarian 99 4 HG-U133A Total 
1057
2 
90.8
% 1.00 + 0.10 Total 11643 
52.4
% 
 
Hendrix ND 2006 
     
p<0.001 2498 
23.6
% 0.99 + 0.14 p<0.001 2210 
19.0
% 0.99 + 0.16 
 
     
p<0.001 
FC>90% 439 4.2% 1.20 + 0.14 
p<0.001 
FC>90% 428 3.7% 1.21 + 0.15 
 
     
p<0.001 
FC<10% 615 5.8% 0.84 + 0.06 
p<0.001 
FC<10% 675 5.8% 0.83 + 0.06 
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Mok SC Ovarian 53 10 HG-U133 Plus 2.0 Total 
1895
3 
53.1
% 1.49 + 2.11 Total 35660 
65.3
% 
 
Mok SC 2009 
     
p<0.001 4702 
24.8
% 1.86 + 3.40 p<0.001 8273 
23.2
% 1.89 + 4.04 
 
     
p<0.001 
FC>90% 543 2.9% 6.06 + 8.83 
p<0.001 
FC>90% 1130 3.2% 6.28 + 9.74 
 
     
p<0.001 
FC<10% 663 3.5% 0.34 + 0.13 
p<0.001 
FC<10% 1753 4.9% 0.32 + 0.13 
 
              
King ER Ovarian 35 6 HG-U133 Plus 2.0 Total 
1895
3 
53.1
% 1.22 + 1.79 Total 35660 
65.3
% 
 
King ER 2011 
     
p<0.001 3794 
20.0
% 2.79 + 5.17 p<0.001 4263 
12.0
% 2.21 + 2.87 
 
     
p<0.001 
FC>90% 1758 9.3% 4.24 + 7.32 
p<0.001 
FC>90% 1122 3.1% 4.41 + 4.94 
 
     
p<0.001 
FC<10% 11 0.1% 0.29 + 0.07 
p<0.001 
FC<10% 28 0.1% 0.26 + 0.08 
 
              
Mostavi ZB Ovarian 32 35 HG-Focus Total 3933 
81.7
% 1.21 + 2.88 Total 4813 
55.0
% 
 
Mostavi ZB 2008 
     
p<0.001 765 
19.5
% 2.16 + 7.68 p<0.001 582 
12.1
% 1.42 + 3.00 
 
     
p<0.001 
FC>90% 247 6.3% 
5.10 + 
13.04 
p<0.001 
FC>90% 138 2.9% 4.11 + 5.31 
 
     
p<0.001 
FC<10% 223 5.7% 0.44 + 0.15 
p<0.001 
FC<10% 285 5.9% 0.39 + 0.17 
 
              
Wang Q Gastric 12 15 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 1.04 + 1.06 Total 35660 
65.3
% 
 
Wang Q 2012 
     
p<0.001 479 2.5% 1.03 + 1.27 p<0.001 727 2.0% 0.75 + 0.96 
 
     
p<0.001 
FC>90% 110 0.6% 2.57 + 1.91 
p<0.001 
FC>90% 99 0.3% 2.67 + 1.46 
 
     
p<0.001 
FC<10% 166 0.9% 0.36 + 0.12 
p<0.001 
FC<10% 423 1.2% 0.32 + 0.14 
 
              
Eftang LL Gastric 20 20 Illumina Human-12 v3 Total 
1290
9 
35.7
% 1.00 + 0.03 Total 23248 
64.3
% 
 
Eftang LL 2013 
     
p<0.001 589 4.6% 1.00 + 0.08 p<0.001 690 3.0% 0.94 + 0.13 
 
     
p<0.001 
FC>90% 306 2.4% 1.07 + 0.04 
p<0.001 
FC>90% 209 0.9% 1.09 + 0.07 
 
     
p<0.001 
FC<10% 255 2.0% 0.92 + 0.05 
p<0.001 
FC<10% 450 1.9% 0.87 + 0.09 
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Wang G Gastric 134 134 HG-U133A Total 
1057
2 
47.6
% 1.00 + 0.05 Total 11643 
52.4
% 
 
Wang G 2013 
     
p<0.001 4645 
43.9
% 1.02 + 0.06 p<0.001 4951 
42.5
% 0.99 + 0.07 
 
     
p<0.001 
FC>90% 1357 
12.8
% 1.08 + 0.04 
p<0.001 
FC>90% 783 6.7% 1.09 + 0.06 
 
     
p<0.001 
FC<10% 721 6.8% 0.93 + 0.04 
p<0.001 
FC<10% 1263 
10.8
% 0.92 + 0.06 
 
              
Holbrook JD Gastric 50 49 Illumina Human-12 v3 Total 
1291
3 
35.7
% 
1.32 + 
43.89 Total 23244 
64.3
% 
 
Holbrook JD 2011 
     
p<0.001 2352 
18.2
% 
1.68 + 
13.08 p<0.001 2015 8.7% 
4.08 + 
110.14 
 
     
p<0.001 
FC>90% 442 3.4% 
5.20 + 
27.25 
p<0.001 
FC>90% 460 2.0% 
13.67 + 
229.93 
 
     
p<0.001 
FC<10% 54 0.4% 
 -7.07 + 
34.73 
p<0.001 
FC<10% 298 1.3% 
 -2.32 
+15.42 
 
              
Cho JY Gastric 65 19 
Illumina HumanWG-6 
v3 Total 
1179
7 
32.8
% 1.00 + 0.05 Total 24169 
67.2
% 
 
Cho JY 2011 
     
p<0.001 2033 
17.2
% 1.03 + 0.09 p<0.001 2873 
11.9
% 0.99 + 0.13 
 
     
p<0.001 
FC>90% 1127 9.6% 1.09 + 0.06 
p<0.001 
FC>90% 1053 4.4% 1.10 + 0.07 
 
     
p<0.001 
FC<10% 430 3.6% 0.90 + 0.06 
p<0.001 
FC<10% 1055 4.4% 0.85 + 0.10 
 
              
D'Errico M Gastric 39 30 HG-U133 Plus 2.0 Total 
1895
3 
34.7
% 0.95 + 0.61 Total 35660 
65.3
% 
 
D'Errico M 2009 
     
p<0.001 4086 
21.6
% 1.37 + 1.15 p<0.001 4918 
13.8
% 0.95 + 1.24 
 
     
p<0.001 
FC>90% 1806 9.5% 2.03 + 1.43 
p<0.001 
FC>90% 1032 2.9% 2.34 + 2.14 
 
     
p<0.001 
FC<10% 475 2.5% 0.40 + 0.11 
p<0.001 
FC<10% 1792 5.0% 0.37 + 0.13 
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6.3.2 The proportion of N6-adenosine methylated RNAs 
Dominissini et al.  found that up to 12,769 mRNAs were susceptible to the 
m6A modification (Dominissini et al. 2012). Annotation of our mRNA 
datasets using these loci found that m6A(+) mRNAs represented between 
26.3% (renal) and 59.4% (bladder) of those with significant aberrant 
expression (p<0.001 between cancer and controls) in cancer (Table 20, and 
presented as m6A:non-m6A ratios in Figure 39). Colorectal, bladder and 
prostate cancers have more predicted m6A(+) (ratio >1), whilst ovarian, 
gastric (p=0.02), breast (p=0.01), lung (p=0.01), renal (p=0.009) cancers 
have significantly more m6A(-) mRNAs (ratio <1). 
 
6.3.3 Fold changes of m6A susceptible RNAs 
All m6A(+) and m6A(-) fold change (FC) and p-value (Malignant Vs Benign) 
were plotted and visualised through volcano plots (Figures 40 (prostate) and 
41 (other cancers)). Only mRNAs shared in all datasets within each 
individual cancer were included. Little difference was seen between m6A(+) 
and m6A(-) within each cancer type or across all eight cancers.  
 
The expression of m6A(+) and m6A(-)  were upregulated (FC>1), except for 
lung cancer, which had a mean FC of 0.77 in both m6A(+) and m6A(-). Little 
difference was seen across the cancer types and the overall mean FC was 
not significant between aberrantly expressed m6A(+) and m6A(-) (Figure 42). 
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Cancer Colorectal Bladder Prostate Ovarian Gastric Breast Lung Renal All 
%m6A:%non-m6A 
Mean (SD)  
1.14 + 0.20  1.03 + 0.31 1.03 + 0.27 0.98 + 0.28 0.86 + 0.18 0.84 + 0.20 0.76 + 0.29 0.72 + 0.32 0.92+0.28 
*P-value 0.06 0.97 0.93 0.60 0.02 0.01 0.01 0.009 <0.001 
Figure 39. Proportion of differentially expressed RNA susceptible to 
N6-adenosine methylation.  
For each cancer, the number of differentially expressed mRNAs is presented as a 
ratio of those susceptible to m6A divided by those not susceptible to this 
modification. Within PCa (blue), there is slightly more m6A(+) compared to m6a(-). 
*p-value= %m6A Vs %non-m6A (Student’s t-test) 
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a) 
 
 
b) 
 
Figure 40. Volcano plots of a) all mRNAs and b) m6A susceptible mRNAs 
within prostate cancer. 
mRNAs shared in all seven prostate cancer and two castration-resistant prostate 
cancer datasets (n=9) were analysed. Genes with aberrant expressions (p<0.01) 
are shown.    a) all mRNAs, n=  3097; b) m6A(+)    only, n=  1993.   
	
	
206	
Figure 41. Volcano plots of expression of all mRNAs and m6A(+) within a) 
all cancers, b) bladder, c) kidney, d) breast, e) lung, f) ovarian, g) colorectal, 
h) gastric cancer. 
 
a) 
 
 
*All 571 genes were m6A+
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Cancer Fold change Prostate Bladder Renal Lung Breast Ovarian Colorectal Gastric All 
*P-Value  0.50 0.39 0.24 0.99 0.40 0.48 0.92 0.65 0.83 
m6A(+) Mean (SD) 1.13 + 0.29 1.25 + 0.32 1.59 + 0.32 0.77 + 0.68 1.18 + 0.35 1.81 + 0.72 1.22 + 0.25 1.19 + 0.28 1.25 + 0.49 
m6A(-) Mean (SD) 1.23 + 0.31 1.09 + 0.12 1.89 + 0.48 0.77 + 0.70 1.05 + 0.06 1.51 + 0.53 1.20 + 0.30 1.45 + 1.29 1.28 + 0.64 
Figure 42. Average fold change of aberrantly expressed RNAs within 
each cancer and across all cancer types.  
 
The mean (SD, Standard Deviation) fold changes between m6A(+) and 
m6A(-) within each cancer and across all 8 cancers was not significant. 
*p-value= m6A Vs non-m6A (Student’s t-test); m6A(+), N6-methyladenosine 
susceptible; m6A(-), N6-methyladenosine non-susceptible  
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6.3.4 Fold changes of the most differentially expressed RNAs 
In an attempt to identify potentially the most important differentially 
expressed m6A susceptible RNAs, those with the highest or lowest (>90% or 
<10% thresholds) FC in each cancer were selected. The mean percentage of 
differentially expressed up- and downregulated m6A(+) mRNAs ranged 
between 12.5-70.4% and 0-66.7% respectively (Figure 43, presented as 
m6A:non-m6A ratios). With regards to upregulated RNAs, colorectal 
(p<0.001) and gastric cancer (p=0.004) had significantly more m6A(+) 
upregulated mRNAs, and prostate (p=0.02) and renal (p=0.002) cancers had 
significantly more m6A(-) RNAs (Figure 43a). In contrast, when analysing 
downregulated mRNAs, all cancers, specifically breast (p=0.02), colorectal 
(p<0.001), lung (p<0.001), renal (p<0.001) and gastric (p<0.001) cancers 
had significantly more m6A(-) mRNAs (Figure 43b). However, the mean up- 
or downregulated FC did not differ between the m6A susceptible and non-
susceptible groups (Figure 44). 
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Cancer Colorectal Bladder Gastric Breast Ovarian Prostate Lung Renal All 
%m6A:%non-m6A 
Mean (SD)  
1.62+0.39 1.39+0.79 1.34+0.35 0.99+0.46 0.98+0.39 0.83+0.34 0.76+0.56 0.70+0.38 1.04+0.52 
p-value <0.001 0.50 0.004 0.45 0.54 0.02 0.06 0.002 0.10 
Figure 43. Proportion of differentially expressed RNA susceptible 
to N6-adenosine methylation within a) top and b) bottom 10%-fold 
change percentile. 
For each cancer, the number of differentially expressed mRNAs is 
presented as a ratio of those susceptible to m6A divided by those not 
susceptible to this modification. There were more upregulated (a) and 
downregulated m6A(-) RNAs compared to m6A(+) in PCa (blue).  
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%m6A:%non-m6A 
Mean (SD)  
0.94+0.42 0.85+0.18 0.81+0.80 0.69+0.69 0.55+0.21 0.53+0.18 0.50+0.12 0.40+0.16 0.67+0.41 
p-value 0.22 0.02 0.15 0.47 <0.001 <0.001 <0.001 <0.001 <0.001 
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a) 
	
	
Upregulated Fold change Prostate Bladder Renal Lung Breast Ovarian Colorectal Gastric All 
P-Value m6a(+) V m6A(-) 0.89 0.92 0.09 0.59 0.95 0.93 0.44 0.51 0.74 
m6A(+) Mean (SD) 1.76 +0.65 1.61 +0.57 2.91 +0.80 3.82 +6.18 1.94 +1.38 3.54 +2.27 1.66 +0.72 2.17 +1.61 2.42 +2.55 
m6A(-) Mean (SD) 1.81 +0.64 1.65 +0.52 3.75 +0.72 2.30 +2.28 1.90 +1.09 3.41 +2.24 2.29 +1.54 3.66 +4.95 2.58 +2.20 
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b) 
	
	
Downregulated Fold change Prostate Bladder Renal Lung Breast Ovarian Colorectal Gastric All 
P-Value m6a(+) V m6A(-) 0.77 0.73 0.80 0.82 0.42 0.91 0.78 0.60 0.85 
m6A(+) Mean (SD) 0.69 +0.20 0.75 +0.18 0.40 +0.13 0.34 +1.17 0.61 +0.35 0.38 +0.30 0.70 +0.23 -0.59 +3.18 0.41 +1.21 
m6A(-) Mean (SD) 0.66 +0.21 0.70 +0.24 0.38 +0.13 0.15 +1.59 -0.15 +2.08 0.36 +0.30 0.66 +0.24 0.17 +1.25 0.37 +1.01 
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Figure 44. The mean fold changes in a) up and b) 
downregulated N6-methyladenosine susceptible 
RNAs in each cancer type. 
The mean fold change (up- or downregulated FC) did not 
vary between m6A(+) and m6A(-) in the 8 common 
cancers (p>0.05).	
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6.3.5 Functional annotation of m6A susceptible RNAs 
6.3.5.1 Individual cancers 
To determine the impact of m6A in each cancer we selected differentially 
expressed mRNAs, susceptible to m6A and common to >50% of the 
datasets within each individual cancer (number of predicted m6A transcripts: 
PCa/CRPC, n=733; bladder, n=1,239; renal, n=1,708; breast, n=2,505; lung, 
n=4,281; colorectal, n=1,759; ovarian, n=2,859; gastric, n=1,588 (Figures 45 
(Prostate) and 46 (other cancers)). We analysed their functional roles using 
gene set enrichment analysis (GSEA) within DAVID 
(https://david.ncifcrf.gov/). DAVID (enrichment score (ES) >1.5) identified 
tumour specific and shared pathways between the individual cancers. Within 
PCa, predicted m6A(+) candidates are involved in a range of oncogenic 
pathways including regulation of transcription and apoptosis, and nuclear 
division (Figure 47). Common clusters that are shared in >50% of datasets 
from each cancer type include regulation of apoptosis, nucleotide-binding, 
regulation of transcription, and protein transport/localization (Figure 48).  
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Figure 45. Functional annotation of aberrantly expressed genes shared in prostate cancer. 
Genes shared in at least 50% of the nine PCa/CRPC datasets were clustered (DAVID). The number of genes (m6A(+) 
and m6A(-)) and significance within each cluster is shown. m6A(+) in PCa appear to have oncogenic roles including 
regulation of apoptosis, nuclear division and regulation of transcription.  
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Figure 46. Functional annotation of aberrantly expressed m6A(+) and m6A(-) in a) bladder, b) kidney, c) breast, d) lung, e) ovarian, 
f) colorectal, g) gastric cancer. 
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Figure 47. Annotation clusters common in each cancer type. 
Clusters common in all cancers were searched. A total of four clusters were found 
to be shared in all of the eight common cancers. These are all important pathways 
in oncogenesis. 
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6.3.5.2 Between cancers  
To look at features common to cancer, we then selected aberrantly 
expressed mRNAs susceptible to m6A that were shared in at least one 
dataset from each cancer. In total, 689 mRNAs were selected, and GSEA 
identified key roles in oncogenic pathways such as cell cycle regulation (78 
genes, ES= 27.5, p=6.3E-29), mRNA processing (30 genes, ES= 3.8, 
p=1.2E-04) and apoptosis (52 genes, ES= 2.5, p=0.003). Again, when 
analysing m6A(-) transcripts, functional clusters were less oncogenic and 
none were related to RNA activity (Figure 48). A total of 3 clusters were 
shared in both the m6A(+) and m6A(-) groups and there were significantly 
more m6A(+) RNAs involved in two of the processes; cell cycle process, 
p=0.002 and organelle lumen activity p<0.001 (Figure 49 and Table 22).  
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Figure 48. Functional annotation of aberrantly expressed genes shared in all cancer. 
Genes shared in at least one dataset from each cancer were clustered. The number of genes and significance within 
each cluster is shown. m6A(+) common in all right cancers appear to function in mechanism associated with 
oncogenesis including apoptosis, mRNA processing/transport, nuclear division and cell cycle regulation. 
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Figure 49. Functional activities common in both m6A susceptible and non-
susceptible transcripts. 
Functional activities common in both m6A(+) and m6A(-) transcripts were searched. 
A total of three processes were found. There were significantly more m6A 
susceptible transcripts involved in cell cycle process (p=0.002) and organelle lumen 
activity (p=0.0006). 
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Cancer Clusters m6A(+) m6A(-) p-value 
 
Prostate Extracellular matrix 27 32 0.05 
m6A(+), n=733 LIM domain 9 9 0.582 
m6A(-), n=507 Vesicle 49 32 0.02 
 
Myofibril 16 9 0.767 
Bladder - - - - 
m6A(+), n=1239 
    m6A(-), n=734 
    Renal Vacuole 42 15 0.05 
m6A(+), n=1708 SH2 domain 23 9 0.09 
m6A(-), n=337 Membrane organization 65 17 0.288 
 
Cell fraction 148 32 0.6 
 
Positive regulation apoptosis 88 16 0.892 
Breast Nucleotide-binding 430 230 0.0001 
m6A(+), n=2504 Regulation cell migration 39 23 0.201 
m6A(-), n=2079 Vasculature development 51 33 0.271 
Lung Cell fraction 169 119 0.0001 
m6A(+), n=4281 SH3 domain 40 29 0.035 
m6A(-), n=1854 Nucleotide-binding 430 160 0.09 
 
Protein kinase activity 120 67 0.105 
 
Regulation cell migration 39 24 0.17 
 
Vasculature development 51 33 0.073 
 
Protein transport 140 80 0.052 
 
Phosphorylation 156 78 0.31 
Colorectal Organelle lumen 384 147 0.0001 
m6A(+), n=1759 Nucleotide process 34 22 0.782 
m6A(-), n=1273 RNA polymerase activity 11 8 0.992 
Ovarian Protein kinase activity 159 86 0.0003 
m6A(+), n=2859 Serine/theorine kinase activity 117 56 0.0002 
m6A(-), n=2501 
    Gastric Vasculature development 45 20 0.08 
m6A(+), n=1588 Nucleotide process 29 11 0.437 
m6A(-), n=429 Regulation cell migration 28 11 0.384 
All Cancers Vesicle 44 23 0.819 
m6A(+), n=689 Cell cycle process 88 20 0.002 
m6A(-), n=329 Organelle lumen 169 49 0.0006 
	
 
Table 22. Functional clusters common in both m6A(+) and m6A(-). 
The number of m6A(+) and m6A(-) involved in each shared activity and the 
associated significance is shown (p-value). 
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6.3.6 Immunoprecipitation of m6A 
Our in-silico analysis revealed that m6A is abundant in both PCa and CRPC. 
Although m6A has been profiled in several cell lines including hepatic cell 
carcinoma (HepG2) (Dominissini et al., 2012) and human embryonic kidney 
cells (HEK293T) (Meyer et al., 2012), its distribution in PCa cell lines is 
unknown. We profiled m6A in LNCaP and LNCaP-LN3 cells through MeRIP-
seq. 
 
6.3.6.1 Validation of post-fragmentation RNA size 
Validation of RNA size was performed by running fragmented 0.5µg RNA on 
an agarose gel for 30 mins (Figure 50).  
 
 
 
Figure 50. Validation of RNA size.  
Total RNA extracted from LNCaP and LNCaP-LN3 was fragmented with ZnCl2 for 4 
mins at 94oC. The desired RNA size of ~100nt (white arrows) was confirmed on a 
1.5% (wt/vol) agarose gel. 
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6.3.6.2 Immunoprecipitation quality control 
Before generating IP libraries and performing RNA-seq on the samples, the 
success of IP was confirmed by performing qRT-PCR on methylated 
transcripts identified from Dominissini et al’s analysis (Dominissini et al., 
2012). Methylated transcripts present in the m6A-antibody IP samples 
relative to the bead-only (null) IP sample was evidence for successful IP. 
 
A total of 100µg RNA extracted from each cell line LNCaP and LNCaP-LN3 
was fragmented to ~100nt and immunoprecipitated with m6A-antibody. 
cDNA was synthesized through RT-PCR and m6A susceptible genes 
(CALM3 and DDX39) were measured with qPCR in relation to controls 
(GAPDH and U1- not m6A susceptible). Results demonstrated a 1.16 and 
1.43-fold enrichment for m6A susceptible CALM3 and DDX39 compared to 
control (GAPDH/U1) respectively (Figure 51). 
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Figure 51. Concentration of Genes whose transcripts are known to undergo 
N6-adenosine methylation. 
A low scale immunoprecipitation (IP) was performed to test for success prior to 
performing a IP with RNA sequencing. Total RNA was extracted from PCa cell lines 
and fragmented to ~100nt using ZnCl2. Transcripts known to undergo N6-adenosine 
methylation according to the list published by Dominissini et al was screened 
(Dominissini et al., 2012). The expression (qRT-PCR) of CALM3 and DDX39 was 
measured and was higher in the m6A-antibody samples (Blue) compared to bead-
only (null) control (Grey), suggesting successful IP. 
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6.3.7 RNA-sequencing of m6A-IP libraries 
Following validation, cDNA libraries were prepared and RNA-sequencing 
was performed. The bioinformatics analyses were performed with Dr. Ian 
Sudbery and Dr. James Bradford (Bioinformatic Hub, University of Sheffield). 
 
6.3.7.1 MeRIP-seq read quality control 
MeRIP-seq on the IP samples obtained 65 million reads from the two cell 
lines LNCaP and LNCaP-LN3 (Table 23 and Figure 52). For each cell line, 
there were three samples, 1) input control (Fragmented and untreated RNA), 
2) IP with m6A-antibody and 3) IP without m6A-antibody (negative control). 
The %GC is slightly lower on m6a-seq sample than on RNA-seq samples 
and that %GC for LN3-input isn’t particularly higher than for m6A pulldown as 
would be expected if m6a was enriched for A-bases compared to input. In 
addition, m6A samples had more reads than input samples. This is similar to 
how data generally appear with ChIP-seq.  
 
 
 
Table 23. LNCaP and LNCaP-LN3 MeRIP-seq read quality control. 
 A total of 65 million reads were obtained from LNCaP and LNCaP-LN3. Each 
sample were split into two lanes (duplicates). The samples included, input RNA 
(fragmented and untreated), m6A (IP with m6a-antibody), ‘RNA’ control (IP without 
m6a-antibody). 
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a) 
 
b) 
 
Figure 52. Plot of base qualities for LNCaP-LN3-input. 
This plot shows the base qualities for LNCaP-LN3 input. a) Reads were of a 
relatively good quality, with only a small drop off in quality towards the end of the 
read. b) A large number of uncalled bases at the end of reads and a highly unusual 
peak in uncalled bases at position four was seen. Therefore, the first and last four 
bases from each read were trimmed to make reads of 100bp long. 
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6.3.7.2 MeRIP-seq read mapping 
Reads were mapped using HISAT (Hierarchical Indexing for Spliced 
Alignment of Transcripts) splice aware short read mapper. Samples were 
mapped in paired-end mode and data from separate lanes was merged after 
mapping. The mapping rate for LNCaP and LNCaP-LN3 was 66% and 68% 
respectively (Table 24).  
 
 
 
Table 24. LNCaP and LNCaP-LN3 reads mapping rate. 
The pairs mapped and percentage mapped for each sample are shown. For LNCaP 
and LNCaP-LN3, 66% and 68% were mapped to unique loci.  
 
6.3.7.3 Identification of m6A sites 
N6-methyladenosine sites (peak calling) were identified at a 5% FDR 
threshold using MACS2 (Model-based Analysis of ChIP-Seq) software. 
There were 132 and 218 peaks for LNCaP and LNCaP-LN3 respectively 
(Table 25). Peaks were centered on a strong ‘A’ base motif (Figure 53). 
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Table 25. m6A peak calling. 
The lengths and number of peaks for the two PCa cell lines are shown. We found 
218 and 132 peaks in the LNCaP-LN3 and LNCaP samples respectively.  
 
 
	
Figure 53. Sequence logo. 
MEME was used to identify the top motifs for each sample. These motifs have 
strong, central ‘A’ residues. 
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6.3.8 Expression of m6A transcripts in prostate cancer cell lines 
A total of 85 genes were significantly enriched within the m6A fraction and 
differentially expressed across cell type. Forty-four percent were specific to 
LNCaP-LN3 and included interesting candidates involved in NOTCH 
signalling (DTX2), regulation of the androgen (and oestrogen) receptor 
expression (CDK11), G protein signalling (Opsin-1), DNA repair (PARG) and 
Y Chromosome located genes implicated in testis/prostate carcinogenesis 
(TSPY1/3) (Figure 54). Gene-set-enrichment analysis identified significant 
alterations of pathways specific to the detection of external stimuli and RNA 
splicing in LNCaP-LN3 cells (p<0.003), suggesting a role in bypassing 
androgen-dependent signalling. 
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Figure 54. Methylated transcripts that are differentially expressed in prostate 
cancer cell lines. 
MeRIP-seq was performed in LNCaP and LNCaP-LN3 cell lines. Following 
bioinformatic analysis, a total of 37 m6A-susceptible transcripts were aberrantly 
expressed in LNCaP-LN3. These included candidates (red) involved in oncogenic 
pathways, such as PARG. 
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Poly (ADP-ribose) glycohydrolase (PARG) has previously been investigated 
within the Sheffield Department of Oncology and has been shown to be 
involved in DNA repair (Fathers et al., 2012). One response to DNA damage 
is the synthesis of poly (ADP-ribose) (PAR) through poly ADP-ribosylation of 
numerous target proteins, including proteins involved in the RNA 
transcription export complex (TREX) (Jungmichel et al., 2013; Zhang et al., 
2013). PAR is transient, once other repair proteins have localised to the site 
of damage, PAR must be removed before repair can take place. The PAR 
polymerase (PARP) enzymes responsible have been implicated in the repair 
of both single and double-strand breaks. PARG is the endo-
exoglycohydrolase that cleaves glycosidic bonds, reversing the action of 
PARP enzymes and returning proteins to their native site. Therefore, the 
balanced level of PAR is driven by PARP and PARG enzymes (Figure 55). 
Recently, a phase 2 trial has shown that treatment with the addition of PARP 
inhibitor Olaparib in mCRPC who had defects in DNA-repair genes led a to 
higher response rate (Mateo et al., 2015). 
 
The levels of the product of PARP, PAR (Western blot performed by Dr 
Helen Bryant, Figure 56a), and PARP1 (Figure 56b) and PARG enzymes 
(qRT-PCR) in LNCaP and LNCaP-LN3 were measured (Figure 56c). The 
levels of PAR were reduced in LNCaP-LN3 and the levels of PARP1 and 
PARG increased in LNCaP-LN3.  
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Figure 55. The role of PARG and PARP in DNA repair. 
In response to stress or DNA damage PARP enzyme mediates PAR synthesis 
which recruits DNA repair proteins. PARP adds one or many ribose moieties onto 
target proteins synthesising long branches PAR chains from nicotinamide adenine 
dinucleotide (NAD+). In order for repair proteins to function at full potential, PAR 
needs to be removed by PARG enzyme through cleavage of the glucosidic bonds.  
 
PAR, poly (ADP-ribose); PARP, PAR polymerase; PARG, PAR Glycohydrolase 
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Figure 56. Levels of PARP activity and mRNA in LNCaP and LNCaP-LN3.  
The expression of PAR protein and PARG mRNA was measured. a) western blot 
showed reduced levels of PAR seen in LNCaP-LN3 compared to LNCaP with a 
tubulin loading control (Performed by Dr Helen Bryant); b) qRT-PCR for PARP1 
enzyme mRNA indicated increased fold change in LNCaP-LN3; c) qRT-PCR for 
PARG enzyme indicated increased fold change in LNCaP-LN3.  
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6.4 Discussion 
 
6.4.1 In-silico analysis of N6-methyladenosine  
The methylation of N6-adenosine base has been known since the 1970s, 
however, new technological advances now allow in-depth analyses of this 
modification (N. Liu et al., 2014). The recent discovery of the reversibility of 
m6A has revived its interest in the field of cancer epigenetics (Jia et al., 
2011). Dominissini at al (Dominissini et al., 2012) revealed the abundance of 
m6A in mRNAs at a transcriptome-wide level and provided reference for the 
current analysis.  
 
A cohort of aberrantly (Student’s t-test p<0.001) expressed mRNAs in 
common eight solid tumours that are susceptible to N6-adenosine 
methylation has been derived. These mRNAs were subcategorized into up- 
(top 10% percentile) and downregulatory (bottom 10% percentile) forms. The 
numbers of predicted m6A appear to vary amongst cancer types, with the 
highest seen in bladder and colorectal cancer, and lowest seen in lung and 
renal cancer. When comparing the ratio of m6A against non-m6A susceptible 
RNAs within and across cancers, colorectal, bladder and prostate cancers 
have a ratio of >1 suggesting that they have a higher proportion of m6A 
susceptible RNAs compared to non-susceptible RNAs. However, the mean 
fold changes (cancer/control) between m6A and non-m6A susceptible RNAs 
did not differ within each cancer or across all cancers.  
 
To identify the most important m6A susceptible mRNAs, we selected ones 
within the highest and lowest fold changes and found that colorectal, bladder 
and gastric cancers had the highest percentage of upregulatory m6A 
susceptible mRNAs, in contrast all the cancers had more downregulatory 
m6a non-susceptible mRNAs. On analysing mean fold changes of predicted 
m6As, lung had the highest and bladder the lowest upregulatory FC, and 
bladder the highest and gastric the lowest downregulatory FC. These 
findings of varying percentages of m6A susceptible RNAs, percentages of 
up- and downregulatory RNAs and varying ranges of FC are interesting, but 
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the explanation for these differences are currently unclear and warrant 
further evaluation. Although, there are common oncogenic mechanisms 
across cancers such as apoptosis and cell cycle regulation, some individual 
cancers possess unique oncogenic mechanisms such as androgen 
regulation in PCa (Jerónimo et al., 2011). The uniqueness of individual 
cancers may explain the variations seen in the current analysis.  
Nonetheless, it is clear that the distribution of m6A is abundant within the 
cancer transcriptome and can be as high as 59% (bladder).  
 
Shared genes that encode m6A susceptible transcripts within each cancer 
type and across cancers were analysed using gene enrichment software 
(DAVID). These shared genes appear to be involved in oncogenic 
mechanisms such as regulation of apoptosis, cell cycle, transcription, mRNA 
processing and transport of proteins.  
 
At the time of analysis, around five independent studies reporting m6A 
MeRIP-seq data have been described (Dominissini et al., 2012; Meyer et al., 
2012; Fustin et al., 2013; Hess et al., 2013; X. Wang et al., 2014).The origin 
of RNAs came from HCC, mouse liver, human brain, HEK293T, mouse brain, 
U2OS and HeLa cells. Studies focused on identifying the distribution of m6A 
and regulators of this modification at a molecular level. With the increasing 
interest in evaluating the roles of m6A in disease processes, Lui et al 
combined data from the five independent studies and created an integrated 
methyltranscriptome database (MeT-DB, 
http://compgenomics.utsa.edu/methylation). This database comprises a 
collection of m6A predicted sites and a genome browser to enable 
visualization and comparison of m6a in different contexts (Liu et al. 2015). 
Our focus was different in the sense that we predicted m6A sites within eight 
common cancers by annotating RNA-seq data obtained from human benign 
and malignant tissues, with the aim to identify predicted m6a sites specific to 
cancers and unravelling associated oncogenic mechanisms. 
 
The exact role of m6A is unclear, but involves a complex machinery 
regulated by ‘writers’’ ‘erasers’ and ‘readers’ which affects RNA splicing, 
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export, stability/decay and translation. The outcomes are associated with 
diseases ranging from benign such as obesity, diabetes and epilepsy, to 
malignant such as breast, prostate and colorectal cancer (Niu et al., 2013; N. 
Liu et al., 2014; Maity et al., 2015). With regards to cancer, FTO (Fat mass 
and obesity-associated protein) is a m6A ‘eraser’ (demethylase) (Jia et al., 
2011) and allelic variants/mutation of FTO has been shown to be associated 
with high incidences of prostate cancer risk (Machiela et al., 2012), breast 
(Kaklamani et al., 2011), colorectal and stomach cancer (Linnebacher et al., 
2010). In contrast, increasing levels of m6A through increasing the methyl 
donor SAM (S-adenosylmethionine), results in growth inhibition of breast 
(Pakneshan et al., 2004), colon (Guruswamy et al., 2008) and gastric cancer 
(Zhao et al., 2010).  
 
Although our understanding of m6A biology is increasing, its distribution in 
common cancers are unknown. The current in-silico analysis describes the 
variation in levels of suspected N6-adenosine methylated RNAs within and 
across eight common solid tumours. In addition, the functional analysis 
provides information on the roles of these RNAs in oncogenesis. Knowing 
that m6A is reversible and its evolving role in cancer, tackling this 
modification in our identified list of susceptible RNAs may alter important 
oncogenic pathways. The m6A machinery is diverse and methylated 
transcripts may directly or indirectly affect oncogenesis through its regulators.  
 
6.4.2 N6-methyladenosine profiling in prostate cancer cell lines 
The m6A profiling studies discussed above included a range of cell lines, 
however, these do not include PCa cell lines. To the best of our knowledge, 
at the time of evaluation, the current analysis was the first to map out the 
distribution of m6A in PCa cell lines. Due to time constraint and funding 
availability, the MeRIP-seq experiment was performed once. Triplicates 
would be performed in the near future by members from the Catto laboratory. 
However, interesting findings were observed and are worth discussing.  
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LNCaP-LN3 are metastatic siblings of the same cell line LNCaP. We 
attempted to profile m6A in PCa cell lines and identify differentially 
expressed RNAs that may explain castration-resistant or metastatic 
potentials. Validation of the IP protocol was performed on a low-scale 
experiment using 300µg of total RNA before proceeding to using 1mg. IP 
peaks/motifs were centred around ‘A’ residues and ‘GC’ depleted. Several 
oncogenic candidates were confined to LNCaP-LN3 (i.e. DTX2, CDK11, 
Opsin-1, PARG, TSPY). 
 
DTX2 is expressed in PCa and is involved in activating the NOTCH signalling 
pathway which has recently been shown to promote CRPC (Stoyanova et al., 
2016). CDK11 is related to cell cycle arrest and apoptosis in a kinase-
dependent manner. In addition, it has been shown that abnormal expression 
of CDK11 in PCa tissue led to the dysfunction of apoptosis and inhibition of 
metastasis of AR-positive PCa cells (Chi et al., 2014).  
 
PARG is susceptible to N6-adenosine methylation in LNCaP-LN3 according 
to our profiling results. We showed that PARG was overexpressed in 
LNCaP-LN3 compared to LNCaP, which may be a response to the 
overexpressed PARP1 activity in LNCaP-LN3 (Figure 52). As discussed PAR, 
PARG and PARP are involved in a complex DNA damage/repair mechanism. 
These candidates are of interest in PCa, as Mateo et al conducted a phase 2 
trial in which men (n=50) with mCRPC were treated with PARP inhibitor, 
Olaparib. All men received prior treatment with Docetaxel. The study showed 
that men who had defects in DNA repair genes had a higher response rate 
(reduction in PSA and tumour cells) to Olaparib (Mateo et al., 2015). 
Olaparib is already approved for treating ovarian cancers with BRCA1/2 
mutations, and appears to be a potential PCa treatment agent (Ledermann et 
al., 2014). 
 
TSPY has been shown to be expressed in prostate tissue, regulated by 
androgens and be involved in testicular cancer and PCa (Lau, 1999). TSPY 
is one of >250 cancer testes antigens (CTA) encoding a protein found in 
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testicular tissue that maybe involved in spermatogenesis (Almeida et al., 
2009). CTAs are proteins that are normally only expressed in human testes 
but are aberrantly expressed in some cancers. They have tumour-restricted 
expression characteristics with a strong immunogenicity, which together, 
have made CTAs an attractive target for a possible diagnostic and/or 
prognostic biomarker (Maxfield et al., 2015).  
 
6.4.3 N6-methyladenosine machinery 
The discoveries of m6A mediators (writers, erasers, readers) and the 
profiling of m6A on the transcriptome enabled further evaluation of the role of 
m6A in human diseases from different angles including, biological processes 
(oncogenic, immunological, metabolic processes), pathway levels (p53-
mediated pathways), signalling and machinery pathways (spliceosome, 
nuclear export) and molecular levels (interactions with proteins, mRNAs and 
subsequent gene expression).  
 
The stability of mRNAs is affected by m6A methylation, and a negative 
correlation exists between m6A and mRNA abundance (shorter half-life). The 
presence of readers affects mRNA transport, storage, stability, splicing and 
translation. Our in-silico and in-vitro analyses have shown abundance of 
m6A within PCa (including PARG, CDK, TSPY), and these methylated RNAs 
may directly or indirectly affect the signalling pathways and mRNA 
processing activities mentioned. Epigenetic DNA and histone modifications 
affect mostly transcriptional processes, however, it is the end product of 
proteins that determines biological phenotype and therefore, the post-
transcriptional regulation of protein synthesis may prove to be significant. 
  
Several processes have been linked to m6A, for example, reduced m6A 
levels leads to prolonged nuclear retention of circadian RNAs (period 
circadian clock 2, Per2 and aryl hydrocarbon receptor nuclear translocator-
like, Arntl). The circadian clock is linked to many physiological processes in 
the human body and it has been shown that DNA methylation is associated 
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with the circadian clock influencing clock gene expression and oncogenesis. 
This may also be the case for RNA methylation (Joska et al., 2014). 
  
6.5 Conclusion 
Our in-silico analysis identified RNAs in eight common solid tumours that are 
potentially susceptible to N6-adenosine methylation. These RNAs appear to 
be involved in important oncogenic and signalling pathways. MeRIP-seq 
confirmed the presence of m6A in PCa cell lines and revealed differentially 
expressed candidates involved in prostate oncogenesis. m6A modification 
has been shown to be reversible and implicated in oncogenesis, therefore 
are attractive as potential targets for investigating biomarkers and 
therapeutic agents. 
 
   
 
 
 
 
 
 
 
 
	
	
	
	
	
	
	
252	
	
	
	
	
CHAPTER 7: Discussion 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
253	
Prostate cancer is the most common cancer in men, with a rising incidence 
in the UK. Over, 40,000 new cases are diagnosed, and over 10,000 deaths 
occur every year in the UK (CRUK, 2016). Many PCa detected are clinically 
insignificant, hence screening may represent over-diagnosis and subsequent 
over-treatment of insignificant disease (Ilic et al., 2013). The Prostate, Lung, 
Colon and Ovaries (PLCO) screening trial failed to show any evidence of 
survival benefit (Andriole et al., 2009) and although the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) showed a 
reduction in PCa mortality over 14 years, the risk of over-diagnosis was 
substantial (Hugosson et al., 2010). The Scandinavian Prostate Cancer 
Group-4 (SPCG-4) and the Prostate Cancer Intervention Versus Observation 
Trial (PIVOT) RCTs of radical prostatectomy versus watchful waiting have 
shown that the improved overall survival was restricted to high-risk, clinically 
significant PCa (Wilt, 2012; Bill-Axelson et al., 2014). 
 
Prostate cancer is a heterogeneous disease and in order to minimise over-
diagnosis and over-treatment, the optimal diagnostic pathway should be able 
to reliably differentiate between men with and without clinically significant 
disease. Diagnostic strategies include a combination of PBx techniques and 
a selection criteria for (r)PBx through imaging (i.e. mpMRI) and biomarkers 
(i.e PCA3). In addition, once PCa is diagnosed, it is important to be able to 
predict progression to advanced disease, such as CRPC or metastatic PCa, 
and also to monitor for recurrence following radical treatment.   
 
7.1 Repeat prostate biopsy outcomes 
We reported unpublished data on rPBx outcomes in a cohort of Sheffield 
men within the national ProtecT study. To the best of our knowledge, this is 
the largest UK based rPBx set of data at the time of analysis. A literature 
review was conducted on rPBx outcomes and our results (19.6%) are 
consistent with the international data (7.5-26.2%). It is important to 
emphasise that the relatively low PCa detection rate on rPBx in men with 
suspicious risk (raised PSA) results in high costs attributed to healthcare 
resources, and most importantly leave potential high-risk disease undetected. 
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In addition, performing unnecessary rPBx put men at risk of PBx 
complications (Rosario et al., 2012; Loeb et al., 2013a). Many thoughts have 
been put into better selecting men for rPBx or increasing the accuracy of 
diagnostic tests (Kirby et al., 2012). Saturation biopsy or TPM-Bx are PBx 
techniques discussed before that can increase the detection of anterior 
tumours (Ekwueme et al., 2013; Li et al., 2014). However, the latter requires 
general anaesthesia and is more invasive than the traditional TRUS-PBx. 
With the addition of mpMRI guidance, this may (PROMIS study) further 
improve outcomes. The PROMIS study showed that using mpMRI a quarter 
of men may avoid a primary PBx and performing mpMRI prior to TRUS-Bx 
up to 18% more clinically significant PCa may be  diagnosed compared with 
TRUS-PBx alone (El-Shater Bosaily et al., 2015; Ahmed et al., 2017).  
 
Majority of PCa detected on rPBx within our cohort were low-grade Gleason 
6, with ~4.5% being high-grade. This confirms our existing knowledge on 
detecting high volumes of insignificant disease on rPBx. Which again, 
indicates that we need better selection criteria for rPBx. With regards to 
predictors, our analysis is consistent with the literature in the sense that, PSA, 
PSA velocity, lower %free PSA and ASAP are positive predictors of PCa. 
 
7.2 PCA3-shRNA2 and prostate cancer 
Knowing the issues associated with identifying PCa on rPBx, apart from 
radiological alternatives, urgent biomarkers are also needed. Prostate cancer 
is a heterogeneous disease, the roles of biomarkers are not just to diagnose 
PCa, but also used to predict/detect disease progression (CRPC, metastasis) 
and monitor for recurrence (BCR) following radical treatment (Haese et al., 
2008). The current PCA3 test is promising, and now new predictive tests are 
available such as, 4K and PHI. Since PCA3 is a ncRNA and these RNAs are 
implicated in many biological processes by targeting mRNAs, and that long 
ncRNA are processed into smaller more active RNAs, we hypothesised that 
PCA3 may encode a shorter segment. Indeed, we identified PCA3-shRNA2, 
which is embedded in intron 1 of PCA3. PCA3-shRNA2 was upregulated in a 
testosterone manner and appeared to be overexpressed in urinary samples 
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obtained from men with PCa, although this was not the case for FFPE initial 
PBx specimens. PCA3 function was unclear when this work was conducted 
and we identified a list of mRNA targets of our short-PCA3 including COPS2, 
SOX11, Noggin, WDR48, TEAD1, which all have roles in oncogenesis. On 
validation, the expression of COPS2 and SOX11 was negatively correlated 
to PCA3-shRNA2 in urinary samples from men with PCa, and that the former 
was significantly underexpressed in PCa urinary samples  (Drayton et al., 
2015). This piece of work identified a new RNA within PCA3 that has similar 
predictive role and function in part by targeting mRNAs involved in PCa 
oncogenesis. However, urinary PCA3-shRNA2 failed to differentiate localised 
disease from advanced disease.  We also showed that PCA3-shRNA2 was 
detectable in historic FFPE specimens stored for up to eight years, 
representing high stability of micro/short RNAs (Pang et al., 2017). Knowing 
the stability of short RNAs, PCA3-shRNA2 may be a more suitable target of 
the current PROGENSA PCA3 assay. 
 
7.3 N6-adenosine methylation and prostate cancer 
Over a hundred post-transcriptional modifications of RNAs have been 
described. The most common being methylation of the N6-adenosine residue. 
The finding of the reversible nature of m6A revived its interest in biological 
research. Since this finding, m6A has been mapped throughout the RNA 
transcriptome (Dominissini et al., 2012). It has also been shown that m6A is 
regulated by ‘writers’, ‘erasers’ and ‘readers’ which affects RNA exportation, 
storage, processing, degradation and translation (Niu et al., 2013; Fu et al., 
2014; Cao et al., 2016). In addition, m6A appears to be associated with a 
number of biological processes including apidogenesis, stem cells renewal, 
spermatogenesis, development, immune responses and oncogenesis (Niu et 
al., 2013; Maity et al., 2015).  
 
Since our PCA3-shRNA2 failed to differentiate advanced/metastatic PCa 
from localised disease, we focused upon this new trait of epigenetics, RNA 
methylation of N6-adenosine. No association has been documented at the 
time of analysis between m6A and PCa. Hence, we performed a preliminary 
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in-silico analysis to predict the distribution of m6A in PCa. We showed 
abundance of m6A in PCa and across seven other common solid tumours, 
and identified ones that were upregulated and downregulated. In addition, 
methylated RNAs common across PCa microarray datasets analysed were 
subject to functional annotation. Many of these methylated RNAs were found 
to be involved in oncogenic pathways including regulation of transcription, 
angiogenesis and nuclear division. 
 
Following our in-silico analysis, we profiled m6A in PCa cell line through 
MeRIP-seq. We identified differentially expressed m6A transcripts in 
metastatic LNCaP cell lines, including PARG, CDK and TSPY. PARG 
inhibitors have recently been show to improve outcomes in men with 
mCRPC with known defects in DNA repair genes (Mateo et al., 2015), hence 
we focused on evaluating PARG along with PAR and PARP which are all 
involved in the DNA repair mechanism. We found differences in the 
expression of these three products (increased PARP and PARG, and 
decreased PAR in LNCaP-LN3) in metastatic PCa cell lines, which may 
suggest a mechanism for PARG-m6A in castration-resistance and 
metastasis.  
 
Due to time constraint, the MeRIP-seq was not repeated. Ideally, this needs 
to be performed in triplicates. Differentially expressed methylated mRNAs 
common in triplicate experiments should be validated in LNCaP and LNCaP-
LN3 cell lines, followed by validation in our patient urinary and PBx samples. 
RNAs found to undergo N6-adenosine methylation could then be explored 
functionally by performing apoptosis and cell proliferation assays.  
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7.4 Conclusions 
Repeat PBx are over-performed resulting in over-treatment of insignificant 
disease. PCA3-shRNA2 is a small RNA expressed by PCA3 and is detected 
in urinary and PBx samples obtained from men with PCa. This short-RNA is 
overexpressed in both urinary and initial PBx samples, although the latter did 
not reach statistical significance. PCA3-shRNA targets numerous mRNAs 
involved in prostate oncogenesis. Knowing the stability, ease of detection 
and high activity of short-RNAs, PCA3-shRNA2 may be a more suitable 
biomarker than the current PCA3 assay. MeRIP-seq revealed abundance of 
m6A in PCa cell lines, and differentially expressed candidates are involved in 
PCa biology. m6A is reversible, dynamic and is involved in oncogenesis. 
These features make m6A potential biomarkers and therapeutic targets.  
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